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Abstract  
Nonmelanoma skin cancer (NMSC) is the commonest cancer worldwide and is a 
significant and increasing burden on health care resources. NMSC aetiology is 
fundamentally linked to sun exposure although infection with oncogenic viruses 
including Human Papillomaviruses (HPV) is thought to be a cofactor. Fair skinned 
populations residing in geographical areas with high sun exposure have an 
increased incidence of NMSC and an excess of NMSC is also observed in certain 
patient groups including immunosuppressed organ transplant recipients.  
This thesis describes the epidemiology of NMSC in the immunosuppressed renal 
transplant population in the West of Scotland. Clinical samples from this 
population were investigated for the presence of HPV utilising a PCR reverse 
hybridisation technique. This assay specifically examined for HPV of the genus 
Beta that have been previously linked to NMSC.  
The effect of presence of HPV in these samples was evaluated through an 
investigation of the expression of cellular biomarkers. A biomarker expression 
pattern specific to HPV infected lesions would add further support to the link 
between HPV and NMSC. Samples were probed for Ki67, p16, p53, MCM2 and 
MCM5 antigens in addition to novel antigen, Topoisomerase II Beta Binding 
Protein 1 (TopBP1). TopBP1 is a host cellular protein that is involved in the DNA 
damage response and is an interacting partner for HPV thus making it a likely 
candidate for involvement in cutaneous carcinogenesis. A biomarker expression 
pattern specific to HPV infected NMSC was not identified although aberrant 
expression of TopBP1 was identified in a subset of skin cancers.   
To investigate this novel observation, a molecular investigation of the 
interaction between TopBP1 and the viral replication factor E2 was carried out, 
firstly in HPV-16 before extending the work to the cutaneous virus HPV-8. A 
mutant of HPV-16E2 that failed to bind TopBP1 was generated. Failure to bind 
TopBP1 resulted in a phenotype exhibiting compromised viral replication. The 
equivalent mutation generated in HPV-8E2 resulted in an even more 
compromised replicative phenotype. In addition to this work, gene targets of 
TopBP1 were also identified by a microarray analysis. This was carried out using 
MCF7 cells untreated or damaged by ultraviolet radiation (UVR) with endogenous 
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TopBP1 depleted by SiRNA treatment. These studies showed that TopBP1 is 
involved in a number of cellular processes and is likely to be involved in 
controlling DNA damage targets following UVR induced DNA damage.   
The work described in this thesis provides further evidence supporting the role 
of HPV in the aetiology of nonmelanoma skin cancer. Generation of an E2 mutant 
that fails to bind TopBP1 and exhibits a compromised replication phenotype 
provides further evidence to support the hypothesis that the E2-TopBP1 
interaction is essential for viral replication and therefore the viral life cycle. 
This work may facilitate the development of anti-viral therapies for HPV-
associated disease by targeting HPV DNA replication through disruption of the 
E2/TopBP1 interaction. 
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Definitions 
AK Actinic Keratosis 
A (Ala) Alanine 
aa Amino Acid 
N (Asn) Asparagine 
D (Asp) Aspartic Acid 
ATM Ataxia Telangiectasia Mutated 
ATR ATM Rad3-related 
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Aza Azathioprine 
BCC Basal Cell Carcinoma 
bp Base Pair 
BCA Bicinchoninic acid 
BSA Bovine serum albumin 
BRCT Breast Cancer susceptibility gene 1 (BRCA1) Carboxyl Terminus 
CO2 Carbon dioxide 
Cic Ciclosporin 
CR1 Conserved Region 1 
CR2 Conserved Region 2 
CMV Cytomegalovirus 
°C Degree centigrade 
DNA Deoxyribonucleic Acid 
DMSO Dimethyl sulphoxide 
DBD DNA Binding Domain 
ddH2O Double distilled water 
EV Epidermodysplasia Verruciformis 
FT Full thickness 
alphaPV Genus Alpha Papillomaviruses 
betaPV Genus Beta Papillomaviruses 
E (Glu) Glutamic Acid 
GST Glutathione-S-Transferase 
g  Gram 
H&E Haematoxylin and Eosin 
HHV-8 Human Herpes Virus 8 
HLA Human Leucocyte Antigen 
HPV Human Papillomaviruses 
hTERT Human Telomerase Reverse Transcriptase 
IC Immunocompetent 
IS Immunosuppressed 
IPA Ingenuity Pathway Analysis 
IEC Intra-epidermal Carcinoma 
J/cm2 Joules per centimetre squared 
KS Kaposi's sarcoma 
KC Keratinocyte Cancers 
Kb Kilobase pairs 
KDa Kilodaltons 
LM Lentigo maligna 
LMM Lentigo maligna melanoma 
LCR Long control region 
MHC Major Histocompatibilty Complexes 
MM Malignant Melanoma 
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mTORi Mammalian target of Rapamycin inhibitors 
MIS Melanoma in situ 
mRNA Messenger RNA 
l Microlitre 
Mg Milligram 
Ml Millilitre 
Mm Millimetre 
mM Millimolar 
MCM Minichromosome maintenance protein 
M Molar 
MMF Mycophenolate Mofetil 
nM  Nanometres 
NMSC Nonmelanoma skin cancer 
PM-PCR/RHA One step polymerase chain reaction - reverse hybridisation assay 
OTRs Organ transplant recipients 
PV Papillomavirus 
PBS Phosphate buffered saline 
pmol Picomole 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase Chain Reaction 
Pred Prednisolone 
PDZ PSD-95/discs large/ZO-1  
qPCR Quantitative polymerase chain reaction 
RTRs Renal transplant recipients 
pRb Retinoblastoma protein p105Rb 
RNA Ribonucleic Acid 
Ser Serine 
siRNA Small interfering RNA 
SCC Squamous Cell Carcinoma 
SBCC Superficial Basal Cell Carcinoma 
TopBP1 Topoisomerase II Beta Binding Protein 1 
p53 Tumour suppressor protein, p53 
Y (Tyr) Tyrosine 
UV Ultraviolet 
UVR Ultraviolet Radiation 
UVA Ultraviolet wave length A 
UVB  Ultraviolet wave length B 
UK United Kingdom 
V (Val) Valine 
Ori Viral origin of replication 
VLPs Virus Like Particles 
V  Volts 
v/v Volume per unit volume 
VIN III Vulval intraepithelial neoplasia III 
w/v Weight per unit volume 
XP Xeroderma Pigmentosum 
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1.1 Nonmelanoma skin cancer 
The incidence of skin cancer in the UK has risen steadily over the last decade 
and this is largely attributed to changes in the pattern of sun exposure of the 
population(1).  Skin cancer is subdivided into cutaneous Malignant Melanoma 
(MM) and nonmelanoma skin cancer (NMSC). Nonmelanoma skin cancer accounts 
for approximately 85% of all skin cancers and of these, the keratinocyte derived 
cancers, basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) account 
for at least 80%. The remainder are made up of rarer tumours such as 
appendageal tumours, cutaneous lymphomas, sarcomas and neuroendocrine 
tumours.  
Skin cancer is very common and accounts for over 20% of all cancer registrations. 
It is difficult to obtain accurate skin cancer incidence figures, particularly for 
NMSC, due to underreporting of these cancers. In England and Wales in 2001, the 
age-standardised incidence rates for NMSC were 65 for females and 96 for males 
per 100,000 population(1). Although skin cancers are the most common cancers, 
they account for only 2% of all cancer deaths and of those MM is responsible for 
over 80%. While NMSC results in few cancer deaths overall, the management of 
NMSC is a significant and increasing burden on health care resources and is the 
focus of this thesis.  
1.1.1 Aetiology and pathogenesis of NMSC 
Exposure to ultraviolet radiation (UVR) results in damage to the DNA of the 
keratinocytes and is the principal contributing factor to NMSC. Evidence for this 
is clinical, with the majority of NMSC appearing on photo-exposed skin(2); 
epidemiological with studies demonstrating an excess of NMSC in areas of high 
UVR exposure(2) and molecular as demonstrated by the finding of UVR signature 
mutations in skin cancers(3).  
Host susceptibility to NMSC plays a major role in its aetiology. NMSC is 
associated with increasing age and male sex. Those who are exposed to high 
levels of UVR through outdoor occupations or through recreational sun exposure 
are at increased risk. Those with fair skin and poor tanning ability, fair or red 
hair and light coloured eyes are at greater risk than darker skinned populations. 
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Migration of populations with these characteristics to geographical areas with 
high UVR exposure such as Australia has led to elevated skin cancer incidence 
rates in these patient groups (2). Individuals with certain inherited conditions 
have specific host genetic mutations associated with an excess of skin cancer. 
Xeroderma Pigmentosum (XP) is an autosomal recessive condition characterised 
by defects in DNA repair resulting in severe photosensitivity and increased risk of 
MM, SCC and BCC (reviewed in (4)).Gorlins syndrome is an autosomal dominant 
condition characterised by mutations in the tumour suppressor gene PTCH1 and 
results in the development of multiple basal cell carcinomas (BCC) in childhood 
and early adulthood with associated skeletal deformities (reviewed in(5)).  
There is an interplay between these host determined factors and UVR as well as 
other environmental factors such as exposure to chemical carcinogens, ionizing 
radiation, immunosuppression and Human Papillomaviruses (HPV).  
The role of both immunosuppression and HPV will be discussed in further detail 
later. 
1.1.1.1 Actinic Keratoses, Intra-epidermal Carcinoma and Squamous Cell 
Carcinoma 
SCC originate from the suprabasal epidermal keratinocytes and the epidermal 
appendages. SCC may arise de novo or from precursor lesions. Actinic Keratoses 
(AK) are epidermal dysplastic lesions, pre-malignancies that may progress to 
invasive SCC. Intra-epidermal carcinoma (IEC), also known as Bowen’s disease or 
Bowenoid AK on photo-protected/exposed sites respectively, are considered by 
most to be a more advanced precursor lesion, again with the ability to progress 
to invasive SCC. 
SCC usually occur on sun-exposed sites in fair-skinned patients and are 
associated with a chronic UVR exposure pattern, therefore appearing most 
commonly in the elderly and those with outdoor occupations. SCC typically 
appear as crusted or keratinising nodules or ulcers on sun exposed skin and may 
develop in isolation or on a background of actinic keratoses and Bowen’s 
disease. The multiplicity of lesions at differing stages of development reflects 
field damage to the skin from UVR. SCC may grow rapidly and have the potential 
to metastasise. 
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SCC may be associated with germline mutations in patients with XP as discussed 
above. Somatic mutations may be found in tumour tissue and such mutations are 
typically UVR signature mutations comprising C-T and CC-TT substitutions. Such 
mutations have been found in several key genes; tumour suppressor genes 
p53(6), p16INK4a(7;8) and the oncogene, Ha-ras (9).  
1.1.1.2 Basal Cell Carcinoma 
BCC are thought to arise from the hair follicles. BCC are slow growing tumours 
which arise de novo and metastasise rarely; they cause morbidity as a result of 
local tissue invasion and destruction. There are a number of clinical subtypes of 
BCC including nodular, superficial, pigmented and morphoeic /sclerosing. The 
nodular subtype are the most common, accounting for approximately 80% of 
BCC, 80-90% of which occur on the head and neck and typically appear as pearly 
nodules with prominent telangiectasia, rolled edges and central ulceration. 
Superficial BCC (SBCC) account for approximately 15% of all BCC, they appear as 
scaly, indurated plaques and occur on the trunk in approximately 50% of cases 
and are seen with increasing frequency in younger patients (10). The 
morphoeic/sclerosing subtype typically arises on the head and neck and is the 
most destructive to local tissue due to invasion of the sub-cutis.  BCC appear to 
be related to a different pattern of UVR exposure than SCC with exposure in 
childhood and intermittent burning exposure thought to be most significant. 
XP patients who have defective DNA repair have an increased rate of BCC as well 
as other skin cancers. Patients with Gorlins syndrome have a specific increase in 
BCC as well as associated deformities of the skeleton such as bone cysts. In 
Gorlins syndrome there is a mutation in the PTCH gene, part of the Sonic 
Hedgehog pathway, a pathway crucial for normal embryonic development. A 
variety of mutations in this pathway have been found in up to 70% of sporadic 
BCC (11).The next most common mutations found in BCC are mutations of the 
tumour suppressor gene p53 (p53) and these are predominantly UVR signature 
mutations (12). A mutation at codon 177 has been identified as specific to BCC 
whereas in SCC there is a specific p53 mutation at codon 278 (13).  
Nonmelanoma skin cancers are illustrated in Figure 1. 
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Figure 1 Nonmelanoma skin cancers.  
Upper panels demonstrate different types of basal cell carcinomas; (a) nodular, (b) 
morphoeic and (c) superficial. 
Middle panels illustrate premalignant lesions (d) diffuse actinic keratosis on a male scalp (e) 
close up of actinic keratosis (f) intra-epidermal carcinoma. 
Lower panels show a spectrum of invasive squamous cell carcinomas at different stages of 
development; early keratinising lesion on the (g) dorsum of hand (h) pinna and (i) advanced 
ulcerated lesion behind the ear. 
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1.2 Skin cancer and organ transplantation 
Patients who are immunosuppressed are at increased risk of skin cancer and one 
patient group in whom skin cancer is a major clinical problem are organ 
transplant recipients (OTRs).  
There are over one million OTRs worldwide and that number is increasing (14). 
Patients are now transplanted at an older age and are surviving longer, resulting 
in an ageing transplant population. Improvements in immunosuppressive 
regimens and transplant techniques have led to better graft survival both in the 
short and long term (15) hence the number of patients on long term 
immunosuppression is increasing. It is now well established that a consequence 
of long term immunosuppression is an increased risk of cancer.  
1.2.1 Epidemiology of skin cancer in organ transplant recipients. 
Transplant recipients are reported to have a two to six fold overall increased risk 
of cancer and the highest risks are for skin cancers, predominantly the 
keratinocyte cancers (KC) SCC and BCC, Kaposi’s sarcoma (KS), anogenital 
cancers and post transplant lymphoproliferative disorders (16-18). There is also 
an increased risk of MM and rarer tumours such as Merkel Cell Carcinoma 
(19;20), sarcomas and appendageal tumours.  
This section will focus on the epidemiology of NMSC in OTRs with brief mention 
of KS and MM.  
1.2.1.1 Nonmelanoma skin cancer 
SCC and BCC are the most common malignancies occurring in Caucasian 
transplant recipients(21). In immunocompetent populations, BCC outnumber SCC 
four fold. The incidence of both SCC and BCC is increased post transplant. The 
risk is increased two to ten fold for BCC (22-25) and 65-250 fold for SCC 
(22;26;27). There appears to be an exponential rise in the incidence of SCC post 
transplantation but a linear rise in BCC (28;29). This has resulted in a reversal of 
the BCC: SCC ratio in the transplant population. In a study from the Netherlands, 
the ratio was reversed to 3.6 SCC: 1 BCC (22).  Some studies from Southern 
Europe however report lower SCC: BCC ratios (30-33).  
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There is variability of risk across reported studies and this appears to reflect 
differences in ethnicity and skin type of the study population and the climate 
within which they reside. The highest post transplant KC incidences have been 
reported from Australia (28;34;35) with cumulative incidence of 75% for patients 
transplanted for over 20 years (28). Studies from Europe with a similar length of 
follow up report lower cumulative incidence rates of 30% and 35% in the UK(29) 
and the Netherlands(22).  The incidence of KC increases with the duration of 
time since transplantation – the cumulative incidence rising from 7% at one year 
post transplant to 82% after 20 years in one Australian study (36). Following the 
development of a first SCC, subsequent lesions are common; the cumulative 
incidence of a second skin cancer being approximately 60-70% in studies from 
France and the Netherlands (37;38). A Scandinavian study reported that 50% of 
OTRs will have a second lesion within 3.5 years (27) whilst Liddington et al 
reported a mean interval of 15 months between first and second  cancers in 
British OTRs and 11 months between second and third lesions (39). 
Approximately 30-50% of patients with SCC will also have BCC(28;40), many 
patients have multiple tumours and the number of tumours per patient can be 
very high; a study from Scandinavia reported two patients with over 100 lesions 
(41). Whilst the majority of NMSC are curable, in transplant patients, cancers 
may behave more aggressively and recur more frequently than in 
immunocompetent patients. SCC recur locally in 13% of OTRs and the risk of 
metastasis is increased from approximately 3.6 % at three years in the 
immunocompetent population (42) to 7% in OTRs (43).  
1.2.1.2 Cutaneous Melanoma 
Most but not all studies report an increased risk for MM in OTRs although the 
increase is of lower magnitude than that seen for KC. The relative risk of MM is 
increased by approximately 2-3 fold (17;25;26) although a study in 2006 by Le 
Mire et al reported an eight fold increased risk of MM in a UK transplant 
population, the highest reported increased risk in the literature (44).  
 
1.2.1.3 Kaposi’s sarcoma 
KS are cutaneous and extra-cutaneous tumours associated with Human Herpes 
Virus-8 (HHV-8) (45) which occur sporadically in populations where HHV-8 
25 
infection is prevalent and with increased frequency in immunosuppressed 
patients. The incidence of KS in OTRs is highest in areas where HHV-8 infection 
is prevalent. Data published by Penn from the Cincinnati Transplant Tumour 
Registry found a KS prevalence of 4.3% (46). Further single country studies have 
found variable prevalence ranging from 0.02 % in the USA(47) to 1.4% in Italy(48) 
and 5.3% in Saudi Arabia (49). Although the numbers of KS affected OTRs are low 
in absolute terms the risk is significantly elevated when compared to the 
immunocompetent population: for example the risk was estimated to be 54 fold 
higher in the USA and 100 fold higher in Italian OTRs (47;48). 
 
1.2.2 The aetiology of post-transplant skin cancer 
The aetiology of post transplant skin cancer is multi factorial and includes host 
factors such as skin type and environmental factors including sun exposure, 
immunosuppression and infection with oncogenic viruses.  
1.2.2.1 Immunosuppression 
Immunosuppressive regimens are highly effective in the prevention of allograft 
rejection following solid organ transplantation; however potent 
immunosuppression is associated with an increased risk of malignancy. 
Immunosuppression contributes to carcinogenesis through a number of 
mechanisms.  
Immunosuppressants prevent allograft rejection by suppressing host immune 
recognition of allograft antigens but they also cause global dysfunction of 
cellular and humoral immunity leading to reduced immune surveillance. This 
may alter the immune systems ability to recognise altered proteins in/on cells 
that are the consequence of DNA damage and mutation. 
Immunosuppressants also have a direct carcinogenic effect. Ciclosporin aids 
growth of tumours and metastases via increased expression of transforming 
growth factor β (50). Azathioprine increases the frequency of tumours in UVR 
treated mice (51) while its metabolites act as photosensitisers by absorbing light 
in the UVA spectrum and generating mutations (52). In contrast, the mammalian 
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Target of Rapamycin inhibitors (mTORi), sirolimus and everolimus exhibit both 
anti-neoplastic and immunosuppressive properties and regimens incorporating 
these agents may confer a reduced risk of skin cancer. Sirolimus has been shown 
to reduce growth and proliferation of cancer cells in vitro and inhibit 
angiogenesis via vascular endothelial growth factor pathways (53). Furthermore 
sirolimus reduces the pro-carcinogenic effects of ciclosporin when the two 
agents are combined (54). Everolimus has similar antineoplastic properties to 
sirolimus however currently available data on mTORi and post transplant 
malignancy pertain to sirolimus. 
1.2.2.2 Oncogenic viruses 
Immunosuppressants render the immunosuppressed host vulnerable to infection 
with oncogenic viruses. OTRs have and increased prevalence of virus- associated 
cancers including Kaposi’s sarcoma (HHV-8) (45), post-transplant 
lymphoproliferative disorder (Epstein Barr Virus), Merkel’s cell carcinoma 
(Merkel cell polyomavirus) (55) and anogenital cancers (mucosal HPV). NMSC has 
been associated with genus beta HPV (betaPV) and further discussion on the role 
of viruses in the aetiology of NMSC will focus on HPV. 
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1.3 Human papillomaviruses  
Papillomaviruses are small, circular, epitheliotropic double-stranded DNA viruses 
which selectively infect the cutaneous or mucosal epithelia of humans and 
animals. There are over 100 types of papillomaviruses known to infect humans, 
HPV.  
1.3.1 HPV and Disease 
HPV are causative or implicated in a wide variety of benign and malignant 
diseases. In general, the disease state is closely linked to the virus type and 
relates to the target epithelia of each virus and its ability to transform infected 
cells. Over half of the known HPV types infect the genital mucosa and certain 
types are associated most commonly with disease. HPV may be termed high or 
low risk in accordance with their prevalence in cancers (56). 
1.3.1.1 Benign disease and HPV 
A variety of benign conditions have been associated with HPV. The genital HPV 
types are the cause of condyloma acuminata or genital warts and the most 
commonly associated types are HPV-6 and -11 (57). These low-risk genital HPV 
types also cause benign papillomas on other mucosal surfaces. HPV-11 is the 
most common type found in the childhood condition recurrent respiratory 
papillomatosis (58) and HPV-6 and -11 are also found in conjunctival papillomas 
(59).  
Infection with low risk cutaneous HPV results in cutaneous warts of which there 
are a number of clinical types. Certain HPV-types are most closely associated 
with each disease. Common cutaneous warts are associated with HPV-2, -4, -7, -
26, -27, -28 and -29. Butchers warts, occurring on the hands of workers dealing 
with raw meat and poultry are usually associated with HPV-1, -2, -3, -4 and -7 
(60). Filiform warts are associated with HPV-1, -2 or -7 (61) whereas plane warts 
with HPV-2, -3, -10, -26, -27, -28, -29, -41 (62). On the foot, plantar warts are 
associated with HPV-1, -2, -60, -63 and -65 (63;64).   
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1.3.1.2 Cancers and HPV 
The high-risk mucosal types HPV-16 and HPV-18 are established causative agents 
of cervical and other ano-genital cancers. Other high risk types such as HPV-31, 
HPV-33, HPV-45, HPV-52 and HPV-58 are also found in cervical cancers. These 
high-risk types have also been isolated from other cancers of the anogenital 
tract. HPV-16 and -18 have been associated with cancers of the oral cavity, 
oropharynx and tonsil (64).  
On the skin, periungal tumours have been associated with high risk-mucosal 
types HPV-16 and -18 and it is suggested that these may represent cross-
infections from the genital tract (65). Cutaneous HPV types have been found in 
skin cancers and this will be discussed in greater detail below. 
1.3.2 Classification of HPV 
HPV belong to the family Papillomaviridae and are further classified into genera, 
species and types(66). The phylogenetic tree of 118 known HPV is illustrated in 
Figure 2. HPV infecting the genital mucosa, including HPV-16, belong to the 
genus alpha. HPV implicated in NMSC belong to the genus beta and are known as 
the betaPV types.  
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Figure 2 Phylogenetic tree of 118 papillomavirus (PV) types.  
The outermost semicircular symbols identify the genera, the inner one the PV species and 
the PV types are numerical. Abbreviations including letters refer to animal PV types.  
From “Classification of papillomaviruses” by de Villiers E.M., Fauquet, C., Broker T.R., 
Bernard H.U. and zur Hausen H. Virology, 324, 17-27(2004).  
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1.4 BetaPV and nonmelanoma skin cancer 
The main HPV types studied in this project were genus beta papillomaviruses. 
There are 25 betaPV types (HPV-5, -8, -9, -12, -14, -15, -17, 19, -20, -21, -22, -
23, -24, -25, -36, -37, -38, -47, -49, -75, -76, -80 and candidate types -92, -93, -
96). 
1.4.1 BetaPV were first isolated from patients with 
Epidermodysplasia Verruciformis  
Epidermodysplasia Verruciformis (EV) is a rare inherited skin disease; patients 
have a defect in cell-mediated immunity which renders them susceptible to 
infection with HPV. Recently, EV patients have been found to have mutations in 
two genes – EVER1 and EVER2 (67). EV patients develop multiple flat-topped 
warts which, on sun-exposed sites, progress to cutaneous SCC in 30% of patients 
by the third decade (68;69). Specific HPV types have been isolated from both 
warts and SCC from EV patients. Originally known as the EV-types these HPV are 
now known as betaPV following the 2004 taxonomic classification of 
papillomaviruses (66). The clinical features coupled with isolation of betaPV 
from lesions suggested that betaPV might act as a co-carcinogen in combination 
with UVR. It is well recognised that transplant recipients have an increased risk 
of skin cancer and these cancers, similar to EV patients, often develop on a 
background of numerous warts and keratoses(70) typically on sun-exposed skin. 
This patient group was therefore of particular interest when a link was sought 
between betaPV and NMSC not just in EV patients but in the wider population.  
1.4.2 Epidemiology of BetaPV infections and nonmelanoma skin 
cancer 
1.4.2.1 BetaPV DNA is found in NMSC from both immunosuppressed and 
immunocompetent patients.  
BetaPV DNA has been isolated extensively in premalignant and malignant skin 
biopsies from both Immunocompetent (IC) and immunosuppressed (IS) patients. 
In published studies, there is much variability in the number and type of samples 
examined, their collection method and the method utilised to detect HPV DNA. 
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Some methods detect HPV from all genera, others detect only betaPV whilst 
others detect only specific HPV types and these methods vary in sensitivity. Lack 
of a consistent method of betaPV DNA detection renders comparison between 
studies difficult.  
There are a number of studies comparing HPV prevalence within SCC biopsies 
from renal transplant recipients (RTRs) and IC controls within the same study 
hence using the same detection methods. In these studies, the prevalence of 
HPV has been consistently higher in RTRs (43%-75%) (71-75) than in IC controls 
(22-47%) (71-75). Many of these studies have also examined HPV prevalence in 
IEC, AK, BCC, warts and normal skin; a summary of the results is shown in Table 
1. 
Similarly, there are a number of studies examining HPV prevalence in SCC 
biopsies from either RTRs or IC patients and whilst direct comparison between 
studies is difficult for the reasons discussed above, in RTRs, HPV was detected in 
20.8%-91% of SCC (76-82) whilst in IC controls, HPV prevalence appeared lower, 
ranging from 13%-59.7% (83-88). A summary of the results of these studies is 
shown in Table 2.  
Newer methods for detection of betaPV however such as the broad spectrum, 
one step, polymerase chain reaction (PCR) reverse hybridisation assay (PM-PCR-
RHA) method for detecting all 25 known betaPV types as described by de Koning 
et al have been used in more recent studies (89). The use of such highly 
sensitive techniques for detection of betaPV has resulted in detection of betaPV 
in 81% and 83.7% of SCC samples from IC patients (90;91). 
1.4.2.2 BetaPV DNA is isolated in plucked hair and healthy skin samples 
from both immunosuppressed and immunocompetent patients.  
The high prevalence of betaPV in SCC samples lends support to the hypothesis 
that betaPV is involved in cutaneous carcinogenesis; however betaPV DNA is also 
detected in normal skin samples. 
There are several studies of plucked hair samples, swabs or biopsies of normal 
skin, where direct comparison is made between RTRs and IC patients. In these 
studies HPV prevalence is 71%- 94% in RTRs with the highest prevalence in 
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plucked hair samples (92-95) and is lower in samples from IC patients (35%-80%) 
with the highest prevalence in normal skin swabs (92-95).  
Studies examining HPV prevalence in skin swabs and eyebrow hairs of IC patients 
only have detected HPV in 35-66% of samples (96-100), again rising to 89%-96% of 
samples when highly sensitive detection methods are employed (101;102)(Table 
3). 
These studies demonstrate that HPV is ubiquitous in both immunocompetent and 
immunosuppressed populations. 
1.4.2.3 Serological studies 
The link between betaPV and NMSC is also supported by evidence from 
serological studies of antibodies against betaPV.  Most of these studies detect 
antibodies to the L1 capsid protein of betaPV types. The results of studies until 
2006 are reviewed by Casabonne et al (103). These studies looked at the 
prevalence of antibodies to betaPV types in cases (immunocompetent patients 
with SCC) and controls (no SCC). Briefly, positive associations were found 
between SCC cases and seroreactivity to HPV-5(104-106), HPV-8(87;103;105-
110), HPV-9(106), HPV-15(87;105;106;108), HPV-20(87;105;106), HPV-23(108), 
HPV-24(87;105;106), HPV-36(106;108) and HPV-38 (87;105;106).  
Recently it has been shown that positive betaPV serology is common in IC 
patients both with and without SCC. A study across the Netherlands, Italy and 
Australia of IC patients demonstrated positive betaPV serology in 68% of patients 
with SCC and 57% in controls, seropositivity was significantly associated with SCC 
in the Australian cohort. A serological response to HPV-8 was the most frequent 
and seropositivity to multiple betaPV types was common but the risk of SCC was 
not significantly associated with the number of positive serotypes(102). 
Conversely, Struijk et al previously demonstrated that the highest risk of SCC 
was in those patients with seroreactivity to multiple betaPV types (106).  
Similarly positive HPV serology is also common in OTRs. A study of HPV serology 
in OTRs without skin cancer in two UK centres demonstrated that seropositivity 
to HPV was common in these patients with 86% of OTRs seropositive for at least 
one HPV(111). This study detected antibodies to 34 HPV types including alpha 
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mucosal, alpha cutaneous, beta, gamma and other types; 56% of patients were 
seropositive to betaPV types, the commonest being HPV-8, HPV-15, HPV-17, 
HPV-38 and HPV-49(111). 
There are two studies in which reactivity to the viral proteins E6 and E7 
(discussed in detail later) are reported (87;112). Struijk et al demonstrated that 
antibodies to both E6 and L1 proteins rarely co-exist and that while L1 positivity 
was associated with the presence of AK and SCC, E6 positivity inversely 
correlated to the presence of AK perhaps suggesting that E6 antibodies might 
protect against SCC or that SCC patients had difficulty in mounting an antibody 
response to E6 proteins (87). Dang et al examined multiple skin biopsies from 
four immunosuppressed OTRs comparing tissue betaPV DNA with serological 
antibodies to the L1, E6 and E7 proteins of betaPV types but found no 
correlation between the two(112). 
1.4.2.4 Summary of the epidemiology of betaPV infections and link to NMSC. 
There is a high prevalence of betaPV in SCC from RTRs and IC controls. The 
seemingly higher prevalence in RTRs may reflect higher infection rates in 
immunosuppressed patients however use of more sensitive detection methods 
has led to similarly high levels of betaPV detection in IC patients. It may be that 
both groups have equally high levels of betaPV infection, it is also possible that 
viral loads are lower in IC patients and low levels of infection may have been 
missed by older less sensitive assays.  
While these findings might suggest a role for betaPV in NMSC, the high 
prevalence of betaPV DNA in normal skin suggests that these viruses are 
ubiquitous. It has been suggested that the hair follicles act as a reservoir for 
infection and betaPV could be viewed as merely a commensal on the skin. The 
presence of viral DNA in skin biopsies does not indicate active infection – viral 
messenger ribonucleic acid (mRNA) would be required for this and if skin 
samples are stripped to remove the surface layers prior to sampling, reduced 
HPV DNA is detected in biopsy samples compared to skin swabs again suggesting 
that HPV may be a contaminant (113).  
However it has been shown that the presence of betaPV is significantly 
associated with NMSC. Prevalence of betaPV DNA in plucked eyebrow hairs is 
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higher in patients with actinic keratoses than controls (93;97;98)  and patients 
with SCC (99;102) than controls. Additionally, persistence of betaPV infection in 
eyebrow hairs is associated with an increased risk for the future development of 
actinic keratoses (114). A comparative study of betaPV DNA prevalence in 
healthy skin in patients with or without NMSC demonstrated that NMSC is 
significantly associated with the presence of betaPV types (94).   
While HPV-5 and -8 predominate in SCC from EV patients (115), in non-EV 
patients no high risk betaPV types have yet been identified although there is a 
suggestion that HPV-5, HPV-8 and HPV-38 are found more commonly in SCC. This 
is in distinct contrast to alpha mucosal HPV associated with cervical cancer 
where several high risk types have been identified including HPV-16 and HPV-18.  
Clearly the epidemiology of betaPV infection in relation to NMSC differs greatly 
to the relationship between the high risk mucosal HPV types and cervical cancer. 
Furthermore, in cervical cancer, high risk mucosal HPV DNA is frequently found 
integrated into the host genome whereas in cutaneous SCC, betaPV DNA is found 
in only 1 in 14,000 cells (116). As the major aetiological factor for NMSC is 
undoubtedly UVR, it may be that betaPV plays a role in potentiating the effects 
of UVR early in carcinogenesis but is not required for maintenance of the 
malignant phenotype. This might be supported by the finding of higher betaPV 
prevalence and viral DNA loads in AK than in SCC (86;116).  
HPV is ubiquitous and detection of DNA in normal skin and skin cancers in both 
immunocompetent and immunosuppressed populations has failed to establish a 
hierarchy of risk for different betaPV types and their relationship to cutaneous 
SCC. Furthermore, detection of antibodies to betaPV has also failed to reliably 
identify high risk betaPV types across studies. Serological responses to betaPV 
may suggest a clinically significant past or present infection whereas detection 
of betaPV DNA may be a reflection of the ubiquitous nature of betaPV DNA and 
not represent active infection. However, the factors which predict a serological 
response to betaPV are not known. It is possible that development of an SCC may 
lead to a positive serological response as could a cancer related event such as 
severe sunburn, a concept known as reverse causality. Recently a study 
combined both approaches; DNA detection, utilising the skin beta HPV prototype 
research assay (Diassay BV, Rijswijk, The Netherlands) to detect betaPV DNA in 
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eyebrow hairs and multiplex serology to detect antibody responses. Using 
concordant DNA detection and antibodies, this study identified a significant 
association HPV-36 infection and cutaneous SCC in OTRs and a trend towards 
positive associations for HPV-5, -9 and -24(117). Future large epidemiological 
studies utilising this combined approach may be helpful in determining the 
association between betaPV and SCC.
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Author  
Year/REF 
Patients Method Predominant HPV genera/ 
types present 
Lesions Prevalence 
Stark  
1994(74) 
RTR Southern Blot 
and type specific PCR, 
HPV-1,-2,-5,-6,-11,-16,-18 
 SCC 
IEC/AK/Warts/NS 
43% 
33%/42%/79%/16% 
IC SCC 
IEC/AK/Warts/NS 
22% 
23%/25%/100%/8% 
      
Shamanin 
1996(73) 
RTR Degenerate PCR  SCC, n=20 
IEC/BCC 
65% 
50%/60% 
IC SCC, n=26 
KA/BCC 
31% 
50%/36% 
      
Harwood 
2000(71) 
RTR Degenerate PCR betaPV SCC, n=44 
AK+IEC/BCC 
84.1% 
88.2%/75% 
IC SCC, n=22 
AK+IEC/BCC 
27.2% 
54.4%/36.7% 
      
Meyer 
2003(72) 
RTR Degenerate PCR betaPV, HPV-1, -2, -4 SCC, n=16 
AK+ IEC/NS/Warts 
75% 
38%/17%/91% 
IC SCC, n=15 
AK+ IEC/NS/Warts 
47% 
36%/16%/88% 
      
Stockfleth 
2004(75) 
RTR Degenerate PCR betaPV, mucosal PV,  
(HPV-8 and -18  
predominate in SCC from RTR) 
 
SCC, n=16 
BCC 
75% 
50% 
IC SCC, n=19 
BCC 
37% 
48% 
      
Table 1 List of studies of prevalence of Human Papillomavirus in benign, premalignant and malignant skin lesions. 
Inter-study comparison of RTR and IC patients. 
Abbreviations:, RTR, renal transplant recipient; IC, immunocompetent; HPV, Human Papillomavirus; SCC, squamous cell carcinoma; IEC, intraepidermal 
carcinoma; AK, actinic keratoses; NS, normal skin; BCC, basal cell carcinoma; PCR, polymerase chain reaction. 
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Author  
Year/REF 
Patients Method Predominant HPV genera 
/types present 
Lesions Prevalence 
Barr 
1989(76) 
RTR Southern Blot   HPV-5, -8   SCC, n=25 60% 
Tieben 
1994(81) 
RTR Consensus PCR betaPV SCC, n=24 
IEC/AK/BCC 
20.8% 
33.3%/28.6%/0% 
deJong Tieben 
1995(78) 
RTR Broad spectrum PCR betaPV  SCC 
AK/BCC 
80% 
93%/50% 
de Villiers 
1997(80) 
RTR Nested PCR betaPV  
+ HPV-1, -2, -4, -10, -27, -57, -63 
SCC, n=22 
IEC/Keratoses/Warts 
91% 
91%/65%/100% 
Berkhout 
2000(77) 
RTR MaHa PCR  betaPV  
+  HPV-2, -3, -10, -27, -28, -29, -57 
SCC, n=81 
AK/BCC/ 
Papillomas/Benign/N/S 
77.8% 
67.9%/35.7% 
77.5%/38.5%/32.3% 
deJong Tieben 
2000(79) 
RTR Nested PCR betaPV Keratoses/NS 
(with vs. without NMSC) 
55%/13% vs 53%/0% 
Forslund 
2007(82) 
RTR Nested PCR betaPV, species 2 predominate 
(HPV-15, -23, -38, -80, -17) 
SCC, n=82 
AK/BCC/Benign/NS 
25.6% 
22.5%/17.5%/26.1%/12% 
Biliris 
2000(83) 
IC Degenerate PCR HPV-8, -18 SCC, n=23 
AK/IEC/BCC 
13% 
25%/40%/31% 
Iftner 
2003(85) 
IC Degenerate PCR mucosal, betaPV  
and cutaneous PV 
SCC, n=72 
AK+IEC/BCC/Warts/NS 
59.7% 
60.4%/27.8%/90.9%/4.7% 
Pfister 
2003(86) 
IC Nested PCR betaPV SCC, n=20 
IEC/AK, n=114 
45% 
33%/75% 
Caldeira 
2003(84) 
IC Type-specific PCR  
(HPV-38) 
HPV-38 SCC, n=26 
BCC/AK/NS 
46% 
55%/32%/10% 
Struijk 
2006(87) 
IC Type-specific PCR HPV-5, -8, -15, -20, -24, -38 SCC, n=64 
AK/NS 
44% 
54%/40% 
Asgari 
2008 (88) 
IC Nested PCR betaPV SCC, n=85 
Perilesional/NS 
54% 
53% 
Patel  
2008(90) 
IC PM-PCR/RHA betaPV SCC, n=98 
BCC 
83.7% 
77.6% 
Plasmeijer  
2010 (91) 
IC PM-PCR/RHA betaPV SCC, n=21 
Eyebrow hairs/Perilesional/NS 
81% 
86%/95%/81% 
Table 2 List of studies of prevalence of Human Papillomavirus in benign, premalignant and malignant lesions. 
Separate studies of RTR and IC patients. Abbreviations: PM-PCR/RHA, one step polymerase chain reaction/reverse hybridisation assay (other abbreviations as 
for Table 1). 
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Author  
Year/REF 
Patients Method Predominant HPV genera 
/types present 
Lesions Prevalence 
      
Boxman 
1997(93) 
RTR Degenerate PCR betaPV Eyebrow/arm/leg hairs 92% 
IC 53% 
Antonsson 
2000(92) 
RTR FAP PCR alpha/beta/gamma HPV Skin swabs (NS) 94% 
IC 80% 
Harwood 
2004(94) 
RTR Degenerate/nested PCR betaPV Biopsies (NS) 87% 
IC 35% 
Hazard 
2007(95) 
RTR FAP PCR betaPV/gamma PV Skin swabs (NS) 71-90% 
IC 69-71% 
      
Boxman 
2000(97) 
IC Nested PCR betaPV NMSC/eyebrow hairs 39%/66% 
Boxman 
2001(98) 
IC Nested PCR betaPV Eyebrow hairs males/females 49%/44% 
Struijk 
2003(99) 
IC Type-specific PCR HPV-2, -5, -8, 15-, 16-, 20, -24, -38 Eyebrow hairs  63.10% 
Antonsson 
2003(96) 
IC FAP59/64 alpha/beta/gamma HPV Skin swabs (NS) 35.70% 
Termorshuizen 
2004(100) 
IC Type-specific PCR HPV-5, -8, -15, -20, 24-, 38 Eyebrow hairs/(controls/SCC patients)  44.8%/60.4% 
De Koning 
2007(101) 
IC PM-PCR/RHA betaPV Eyebrow hairs  96% 
Bouwes Bavinck 
2010(102) 
IC PM-PCR/RHA betaPV Eyebrow hairs/ (controls/SCC patients) 89%/93% 
      
Table 3 List of studies of prevalence of HPV in normal skin biopsies, swabs and hairs.  
Abbreviations as for Table 1 and  2.
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1.5 The Biology of Human Papillomaviruses 
1.5.1 The HPV genome 
The HPV genome is a double stranded, circular DNA molecule approximately 8 
kilobases (Kb) in size. The genome is divided into three regions (i) a region 
coding for the Early genes E1, E2, E4, E5, E6 and E7, (ii) a region coding for the 
Late genes L1 and L2 which code for the structural proteins L1 and L2, and (iii) a 
non-coding region, the long control region (LCR) containing the regulatory 
elements necessary for the control of viral replication and transcription.  
All HPV have a similar genomic organisation as illustrated in Figure 3, except for 
the E5 gene which is not present in the majority of betaPV (118). 
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Figure 3 The HPV genome. 
The HPV genome is a double stranded, circular DNA molecule approximately 8 Kilobases 
(K) in size. The early region encodes the early genes E1, E2, E4, E5, E6 and E7, the functions 
of which are summarised in the box on the right. The late region encodes the late genes L1 
and L2. The non-coding region known as the long control region (LCR) of upstream 
regulator region is necessary for control of viral replication and transcription.  
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1.5.2 HPV life cycle 
The HPV life cycle begins when HPV infect the epithelial stem cells by entering 
the cutaneous or mucosal epithelia via cuts or abrasions (reviewed in (119)).  
Infected basal cells move into the upper layers of the epithelium where they 
divide and undergo differentiation. During this phase viral DNA is amplified and 
the viral genomes are packaged into infectious virions before being released as 
cells are shed from the upper terminally differentiated layers.  
 
Basement membrane
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Figure 4 HPV life cycle. 
Schematic representation of the HPV life cycle in infected epithelium. Infected basal cells 
(red) move up through the epithelium, the cells are differentiating, and viral DNA is 
amplified. In the terminally differentiated uppermost layers, viral genomes are packaged into 
infectious virions and released as the uppermost cells are shed. Figure adapted from image 
courtesy of IM Morgan. 
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 1.5.3 Integration of high risk HPV into the host genome 
In the normal viral life cycle, HPV genomes are present in a circular or episomal 
state in the basal cells and there are approximately 50-100 copies per cell 
(120;121).  In the episomal state, expression of the viral oncogenes E6 and E7 is 
tightly regulated, occurs in the supra-basal cells and allows activation of the 
host replication machinery such that the viral genomes may be amplified prior to 
production of virions. As the viral genome is retained in its episomal state, it is 
destined to be shed from the uppermost epithelial layers and does not pose a 
carcinogenic threat (reviewed in (122) . If viral oncogenes are expressed in the 
basal epithelial cells however, this inhibits cell differentiation and induces 
chromosomal instability that can drive carcinogenesis. In the vast majority of 
cervical carcinomas, this de-regulation of viral oncogene expression is seen in 
cells in which the viral genome has become integrated into the host DNA (122). 
Comparative analysis of HPV DNA status in low and high grade pre-malignant 
lesions shows that the frequency of viral DNA integration increases with the 
severity of the disease (123). Integration of the HPV genome occurs only with 
the high-risk HPV types, and is seen in 100% of HPV-18 positive cervical 
carcinomas (124-126) and up to 80% of HPV-16 positive cases (125-127).  
Integration into the host genome is not a normal part of the viral life cycle. 
When the viral genome is integrated, several key features are consistently 
observed, loss of the viral E2 gene (128) and increased expression of E6 and E7 
(129). Previous studies have demonstrated that E2 can repress the expression of 
the E6/E7 genes, therefore integration and loss of E2 results in elevated E6/E7 
expression. This increased expression can contribute to the transformation of 
the infected cell.  
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1.6 The Biology of Human Papillomaviruses 
1.6.1 The major transforming proteins of high risk mucosal HPV  
The E6 and E7 gene products are the major transforming proteins. E6 and E7 
have developed a number of strategies to evade host immunosurveillance thus 
allowing viral persistence and to alter control of the cell cycle and apoptosis 
thus allowing the accumulation of DNA damage and mutations. Often the two 
proteins target the same pathways albeit by different mechanisms thus the two 
proteins act synergistically to promote cellular transformation (reviewed in 
(118)). 
While some properties of E6 and E7 are shared between different virus types, 
some are exclusively associated with the carcinogenic HPV types (130). Of these, 
the best studied is HPV-16.  
In cervical cancer cells, viral DNA is often integrated into the cellular genome 
and the E6 and E7 proteins are consistently actively expressed (129). Continuous 
E6 and E7 expression is necessary for maintenance of the malignant phenotype 
as silencing both genes in cervical cancer cell lines results in cell death due to 
the reactivation of the p53 and retinoblastoma protein p105Rb (pRb) pathways 
(reviewed in (131)). 
1.6.1.1 The E6 protein 
The HPV-16 E6 gene encodes a 151 amino acid protein. E6 has two atypical zinc 
fingers at the base of which are two motifs containing two cysteines each which 
are conserved in all E6 types (118). One of the major actions of E6 is its ability 
to moderate the action of p53 (132).  
The role of p53 is to ensure integrity of the cellular genome by delaying the cell 
cycle and cellular division until DNA damage has been repaired or preventing 
further cell division by inducing apoptosis. Levels of p53 within the cell increase 
following stress such as UVR radiation and hypoxia (133). p53 is a transcription 
factor, and transactivation of target genes by p53 results in arrest of the cell 
cycle at G1, or apoptosis (134). One of the best known targets of p53 is p21, 
activation of which results in cell cycle arrest by the inhibition of cyclin 
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dependent kinases that are necessary for entry into the S phase of the cell cycle 
(134). Activation of p53 induces apoptosis through many pathways such as 
transactivation of pro-apoptotic genes such as Bax and PUMA (135).  
HPV-16E6 inactivates p53 by accelerating its proteolytic degradation thereby 
removing its restrictions on the cell cycle and control of apoptosis. This is 
achieved by forming a complex with the cellular ubiquitin-protein ligase E6AP 
(136-138). Ubiquitination results in targeting of p53 for proteasomal 
degradation. Induction of p53 degradation by E6 appears to occur exclusively 
with E6 from high-risk HPV types (139;140). The ability of E6 to degrade p53 is 
likely to be a key event in malignant transformation and this has been 
demonstrated in vivo by the expression of E6-binding peptides in HPV-16 positive 
cells which resulted in the abrogation of p53 degradation and thus induction of 
apoptosis (141).    
HPV-18E6 can also interfere with apoptosis independently of p53 by its 
association with Bak, a member of the Bcl-2 family. Cellular stress leading to 
apoptotic signals causes Bak to form pores in the mitochondrial membrane. This 
results in release of cytochrome C from the mitochondria and induction of the 
caspase apoptotic cascades (142). HPV-18E6 induces the degradation of pro-
apoptotic factor Bak via the ubiquitin –mediated pathway similarly to p53 
(143;144).    
HPV-16E6 induces activation of telomerase by activating transcription of the 
hTERT (human Telomerase Reverse Transcriptase) gene (145). Normal somatic 
cells have very little or no telomerase activity, telomeres shorten as the cell 
divides until they reach a critical size and the cell reaches senescence (146). 
High telomerase activity therefore allows HPV-16 infected cells to maintain 
telomere length and thus proliferate indefinitely leading to cell immortalisation 
(145). 
Another important function of E6 proteins is their ability to interact with 
proteins containing PDZ (PSD-95/ discs large/ZO-1) domains. PDZ proteins such 
as DLG, MAGI and MUPP I have all been shown to have tumour suppressor 
functions (147) and are involved in cell signalling and cell-cell adhesion(148). 
HPV-18 and HPV-16E6 have been shown to bind and degrade many of the PDZ 
proteins(149-151).  
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1.6.1.2 The E7 protein 
The HPV-16E7 gene encodes for a 98 amino acid protein. The amino acid 
terminus has two conserved regions, CR1 and CR2 and a Leu-X-Cys-X-Glu (LXCXE) 
motif that is necessary for the association between E7 and pRb (152).  
One of the main functions of E7 as a transforming protein occurs via its 
interaction with pRb and its relatives, p107 and p130, a family of proteins also 
known as the pocket proteins of which pRB is the most studied and this leads to 
disruption of the cell cycle. This function of HPV-16E7 assists in the viral life 
cycle; by deregulating the cell cycle, basal epithelial cells begin proliferating 
and are now able to support viral DNA replication (reviewed in (153)), however 
disruption of the cell cycle potentially allows the accumulation of DNA 
damage/mutations. 
The Rb proteins act as tumour suppressors by regulating entry into S phase and 
progression of the cell cycle via modulation of the transcriptional activities of 
the E2F transcription factors (reviewed in(154)). The active form of pRb is 
hypophosphorylated. During a normal cell cycle, pRb is cyclically 
phosphorylated/dephosphorylated. In G1 hypophosphorylated pRb binds to E2F 
repressing its transcriptional activity. As the cell cycle progresses, pRb is 
sequentially phosphorylated by cyclin D/cdk4 and cyclin E/cdk2 and cyclin 
A/cdk2 complexes. By late G1, pRb is hyperphosphorylated, no longer interacts 
with E2F1, therefore E2F1 is free to act as a transcriptional activator and 
activates the transcription of many genes that allow progression of the cell cycle 
through S phase (reviewed in (155)). 
HPV-16E7 forms complexes with hypophosphorylated (active) pRB resulting in 
functional inactivation of pRb and permits the cell to enter S phase thus 
contributing to the transforming activities of E7(156). HPV-16E7 also destabilises 
pRb by promoting its proteolysis (157). Furthermore, HPV-16E7 has the ability to 
directly associate with and activate E2F1 independent of pRb (158).  
In addition to targeting the pocket proteins, HPV-16E7 can alter the cell cycle 
through its interactions with cell kinases that normally have an inhibitory effect 
on the cell cycle (reviewed in (118)).  
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1.6.1.3 The E6 and E7 proteins generate genomic instability. 
The functions of the E6 and E7 proteins allow the accumulation of DNA 
damage/mutations. Additional host genomic mutations are necessary however 
for progression to a malignant phenotype and the development of aneuploidy is 
specifically associated with high-risk HPV infection in vivo (159). Cytogenetic 
abnormalities have been detected in HPV-immortalized keratinocytes suggesting 
that HPV oncogene expression may facilitate genomic destabilisation (160) and 
expression of high risk E6 and or E7 in primary human cells increases genomic 
instability (161;162). Aneuploidy arises as a consequence of gains or losses of 
chromosomes during mitosis due to mitotic abnormalities such as lagging 
chromosomal material, anaphase bridges and multipolar mitoses (163). 
Multipolar mitoses are hallmarks of high-risk HPV associated cancers (164) and 
are induced by supernumerary centrosomes that arise during abnormal 
chromosome segregation during cell division (165). HPV-16E7 induces 
supernumerary centrosomes by uncoupling centriole synthesis from the cell 
division cycle causing abnormal centriole synthesis and hence multipolar mitoses 
(166).  
1.6.1.4 E6 and E7 and immune evasion 
The majority of women with genital HPV infections clear the infection within 12-
18 months however, in a small number, infection persists and these women are 
at high risk for development of cervical carcinoma (167). There is evidence that 
E6 and E7 can modulate the host immune response to HPV infection by 
disruption of the interferon pathway. Type I interferons (alpha and beta) are 
cytokines secreted by virally infected cells that start a signalling cascade via the 
Jak-Stat pathway to initiate genes with a range of anti-viral effects (168). 
Microarray studies have shown that HPV-16 and HPV-31 downregulate the 
expression of interferon inducible genes (169;170). HPV-16E6 and HPV-16E7 have 
been shown to interact with Interferon regulatory factor 3 and 1 respectively, 
interfering with interferon-mediated signalling (171;172).  
1.6.2 The transforming proteins of the beta papillomaviruses 
In contrast to the extensively studied mucosal HPV types, little is known about 
the functions of early proteins of the cutaneous HPV types. However there is 
46 
emerging evidence to suggest that E6 and E7 of some cutaneous types have some 
ability to interfere with cell cycle regulation and apoptosis and as such may also 
act as transforming proteins. It is likely that they act in co-operation with UVR. 
1.6.2.1 The E6 protein 
To date, none of the cutaneous HPV types studied are able to promote p53 
degradation (173-175). However E6 may be able to interfere with p53 functions 
via other mechanisms. HPV-77E6 selectively attenuates UV induced 
transactivation of p53 regulated pro-apoptotic genes Fas, PUMA, APAF-1 and PIG-
3 leaving other p53 target genes such as those involved in cell cycle regulation 
unaffected (176). Furthermore the E6 protein from HPV-5 and HPV-77 inhibits 
UV-induced apoptosis in conditions where p53 is strongly stabilised and activated 
(175). HPV-38 E6 and E7 expression in keratinocytes induces stabilisation of p53 
by promoting the up regulation of an isoform of p73, Np73 which induced 
transcriptional repression of p53 thus inhibition of p53-responsive gene 
expression (177).  
E6 can interfere with apoptosis via p53 independent mechanisms by association 
with the pro-apoptotic protein Bak. Bak is a member of the Bcl-2 family. In 
normal skin, in response to UVR irradiation, Bak is highly stabilised and activated 
in the epidermis. In the presence of HPV-5, -10 and -77 E6, following UVR, 
stabilisation of Bak and apoptosis are not observed(144). HPV E6 proteins can 
stimulate the ubiquitin–ligase mediated degradation of Bak and this interaction 
has been shown for high risk mucosal HPV-18, low-risk genital mucosal types 
HPV-11 and -6 and for the betaPV types HPV-5 and -8, and cutaneous types HPV-
10 and -77 (143;175;178). 
Other functions of cutaneous HPV E6 proteins include interference with DNA 
repair pathways. HPV-5 E6 has been shown to compromise the repair of UVB 
induced cyclobutane pyrimidine dimers in epidermal cells (179). HPV-8 E6 binds 
the XRCC1 protein which is involved in repairing UVR induced single strand 
breaks in DNA. Failure to repair these can lead to the formation of double strand 
DNA breaks during DNA replication and thus is a step towards chromosomal 
instability (180).  
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1.6.2.2 The E7 protein 
The E7 proteins of the mucosal high risk HPV interfere with the regulation of the 
cell cycle via binding and degradation of pRb. Little is known about the 
biological properties E7 of the cutaneous viruses. Thus far the only betaPV to 
have been shown to have similar properties is HPV-38E7 which binds pRb in vitro 
with the same efficiency as HPV-16E7, promotes destabilisation of pRb in rodent 
and primary human cells and consistent with this, HPV-38E7 induced 
transformation in rodent cells. These properties were not shared by HPV-10 and 
HPV-20 in the same assays (84).  
1.6.2.3 Immortalization of primary keratinocytes and mouse models 
Further data to support a role for betaPV in cutaneous carcinogenesis comes 
from studies in primary human keratinocytes and mouse models. Expression of 
HPV-38E6 and E7 in primary human keratinocytes resulted in an extended 
lifespan and disruption of senescence and these cells were found to have 
detectable telomerase activity (84). Primary human keratinocytes expressing 
HPV-8E7 grown on an organotypic raft were able to migrate and invade into 
underlying dermis suggesting that HPV-8 may promote an invasive phenotype by 
degradation of components of the basement membrane and extra-cellular matrix 
by induction of the extra-cellular proteinases MMP-1, MMP-8 and MT1-MMP. 
(181).  
In studies of transgenic mice expressing the complete early genome of HPV-8, 
91% developed benign tumours and 6% developed SCC, in the absence of any 
treatment with UVR or chemical carcinogens providing evidence of the 
carcinogenic effect of HPV-8 in vivo(182). The same group then generated 
transgenic mice expressing HPV-8E2 and 60% developed ulcerated/dysplastic skin 
lesions in the absence of any UVR/carcinogen and following a single dose of UVR, 
87% developed skin tumours with histology similar to aggressive spindle cell SCC 
suggesting that HPV-8E2 has intrinsic oncogenic potential in vivo (183). 
Transgenic mice expressing HPV-38E6 and E7 developed epidermal hyperplasia 
and dysplasia, loss of UVR-induced cell cycle checkpoints and developed a high 
incidence of papillomas, keratoacanthomas following chemical carcinogenesis 
compared to controls (184). Transgenic mice expressing betaPV, HPV-20 E6/E7 
or genus alpha PV (alpha PV, associated with benign cutaneous warts), HPV-
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27E6/E7 were exposed to chronic UVR. Both HPV-20E6/7 and HPV-27E6/7 mice 
developed epidermal proliferation compared to controls however there was a 
higher rate of malignant progression to SCC in HPV-20 expressing mice, 
suggesting that betaPV may play a role in enhancing the carcinogenic potential 
of UVR (185).  
1.6.3 E4 and E5 
The HPV-16E5 protein has an additive effect to the transforming properties of E6 
and E7 (186;187) and, in conjunction with E7, has the ability to transform mouse 
fibroblasts (188;189). E5 has also been implicated in immune evasion via 
alteration of antigen presentation by virally infected cells, via the major 
histocompatibility complexes (MHC) (Human Leucocyte Antigen (HLA) pathway in 
humans), to T cells for viral recognition and clearance. In primary cells, 
expression of BPV-1E5 down regulates MHC Class I complexes (190;191). In the 
presence of HPV-16E5, cells display decreased levels of surface HLA-A and HLA-B 
and MHC II molecules are down regulated (192;193).  
The E4 protein is translated from spliced mRNA transcripts forming an E1^E4 
fusion protein containing the first five residues of E1 fused to the remainder of 
E4(194). The exact role of E4 in the virus life cycle is not clearly understood. 
Induction of high levels of E4 is associated with the switch from maintenance of 
the viral genome in the basal differentiating cells to vegetative genome 
amplification (195). E4 appears to be essential for viral genome amplification of 
HPV types -16, -18 and -31(196-198) but may not be necessary for all types such 
as HPV-11(199).  Other functions of E4 include inhibition of the G2 to M 
transition of the cell cycle (200-202) and promotion of apoptosis by alteration of 
mitochondrial function (203). E4 is also associated with the collapse of cellular 
cytokeratin networks and this may facilitate viral release late in the viral life 
cycle (204-206).  
1.6.3 Late capsid proteins 
The structure of the viral capsid or virion is consistent across HPV types and is a 
non-enveloped icosahedral structure of 55nm diameter made up of 72 
pentameric capsomeres (207). The capsid is made up of the two late proteins, L1 
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and L2 which encapsulate the viral genome. L1 is the major structural (capsid) 
protein of papillomaviruses while L2 is the minor capsid protein. L1 and L2 are 
expressed in the highly differentiated suprabasal cells of the epithelium (208). 
1.6.4 The replication proteins 
HPV DNA is replicated within the nuclei of infected epithelial cells using the host 
cellular proteins that form part of the host replication machinery and the viral 
early proteins E1 and E2.  Viral replication is initiated at the viral origin of 
replication (ori). HPV ori sequences are approximately 80-140 bp in length and 
are located in the LCR region of the HPV genome. Ori sequences consist of an E1 
protein binding site flanked by multiple E2 binding sites and A/T rich sequences 
(209). 
In order to initiate replication of double stranded DNA, the two DNA strands 
have to be separated to expose the bases and this process is known as melting. 
Once the double stranded DNA is melted, DNA helicases unwind the double 
stranded DNA in front of the replication fork(210). E1 is the viral DNA helicase; it 
is the only HPV enzyme and is essential for viral DNA replication. E1 melts the 
DNA and binds and hydrolyses Adenosine Triphosphate (ATP) to unwind the DNA 
(210).  
E2 is the primary ori recognition protein and recruits E1, the viral helicase 
protein, to the ori (209). 
1.6.4.1 Structure and functions of the E1 protein  
The HPV-16E1 protein is 649 amino acids in length and forms a dihexameric 
replicative helicase (211). The E1 protein has three domains; (i) the N-terminal 
domain, (ii) a central hinge domain and (iii) the carboxyl terminal DNA binding 
domain (DBD). The carboxyl terminal of the E1 protein has ATPase/helicase 
activities, interacts with the E2 protein and with the host cellular replication 
machinery proteins such as DNA polymerase (212;213). The DBD allows E1 to 
bind to the E1 binding site on the ori. E1 is recruited to ori by E2 where it binds 
to an E1 binding site in the AT rich region of the ori. 
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In order to initiate viral replication and elongate the replication fork, E1 also 
interacts with several proteins that are part of the cellular replication 
machinery. E1 interacts with DNA polymerase  primase. Polymerase  is the 
only polymerase able to initiate DNA synthesis so it is essential at the replication 
fork (212;214). E1 also interacts with the single stranded DNA binding protein 
complex, replication protein A, a complex essential for the correct initiation and 
elongation of the DNA replication forks (215). E1 also interacts with 
Topoisomerase I, proliferating cell nuclear antigen, replication factor C and 
polymerase .   
1.6.4.2 Structure and functions of the E2 protein 
The E2 protein is approximately 360 amino acids in length and contains three 
functional domains, (i) the carboxyl terminus DBD, (ii) a central hinge region and 
(iii) the amino acid terminus (N terminal domain) (216). 
The DBD forms homodimers that recognise and bind to palindromic DNA 
sequences within the ori region of the LCR (217). The N terminal domain is 
essential for interaction with E1, and a number of host cellular transcription 
factors and for the transcriptional control of E6 and E7; reviewed in (216).  
E2 has important function for both replication and transcription of the virus. 
There are four E2 binding sites within the LCR of the HPV genome. Following 
expression E2 binds to these sites and recruits E1 to the ori via a physical 
interaction between the amino terminus of E2 and the E1 protein. Thus E1 is 
recruited to ori by E2 and initiates viral DNA replication (218).  
E2 regulates the expression of other HPV genes by acting as a transcriptional 
activator and repressor. It does so by binding, via its DBD, to target DNA 
sequences on the LCR then activating or repressing transcription from adjacent 
promoters (reviewed in (216)). The target DNA sequences on the LCR are highly 
conserved between PV species suggesting that the organisation of the E2 target 
sequences plays an important role in the regulation of the virus life cycle. E2 
interacts with Topoisomerase II  Binding Protein 1 (TopBP1) and this interaction 
and its consequences for viral DNA replication will be discussed in greater detail 
later (219). 
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When the viral genome is integrated into the host genome, this leads to loss of 
E2 expression and the loss of control of E2 mediated control of E6 and E7 
expression (128). Reintroduction of E2 into cervical carcinoma cells lines can 
repress the expression of E6 and E7 thereby inducing growth arrest and apoptosis 
via the restoration of the normal functions of p53 and pRb (128;220;221). There 
is also evidence to suggest that the E2 proteins of high-risk HPV types can induce 
apoptosis via p53 independent mechanisms (222;223).  
E2 also has important functions in the segregation of HPV genomes between 
daughter cells after cell division. Episomal viral genomes are retained in the 
nucleus of infected keratinocytes and are segregated between daughter cells 
during cell division as they are attached to cellular chromosomes in mitotic cells 
via the E2 transactivator protein which tethers viral DNA onto the mitotic 
chromosomes (224-227).  
A summary of diagram of the main interactions involved in the initiation of viral 
DNA replication is illustrated in Figure 5. 
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1                       2                        3
E2
E1
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Figure 5 Diagram of initiation of HPV replication.  
1. The E2 protein forms homodimers and binds to 12bp palindromic sequences surrounding 
the A/T rich origin of replication.  
2. E1 is recruited to the origin via a protein-protein interaction with E2 whereupon it forms 
di-hexamers (only one shown for simplicity). 
3. E1 has helicase activity and binds to DNA polymerases in order to replicate the viral 
genome.  
Abbreviations; Pol, Polymerase  
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1.7 Therapeutic targets for HPV 
There are over one hundred types of HPV and these HPV are implicated in many 
diseases ranging from conditions such as genital and cutaneous warts which 
whilst benign have implications for healthcare provision, to cervical cancer 
which is a leading cause of mortality in young women worldwide. 
1.7.1 Prophylactic HPV vaccines 
1.7.1.1 L1 prophylactic vaccines 
The major capsid protein, L1 assembles into virus-like particles (VLPs) and it was 
this discovery that led to the development of prophylactic vaccines against HPV, 
potentially one of the most significant public health developments of recent 
years. VLPs present the epitopes for generating high titre neutralizing antibodies 
against HPV, they do not contain any viral DNA and they can be produced on a 
large scale making them ideal candidates for the development of prophylactic 
vaccines (228). Trials of vaccination with L1 VLPs have been shown to be both 
immunogenic and safe when administered to women (229-231). 
Two prophylactic vaccines have been developed and tested in large multicentre 
trials. The first is a quadrivalent vaccine, Gardasil® produced by Merck which 
protects against HPV-6, -11, -16 and -18 (232-234). The other is a bivalent 
vaccine, Cevarix®, produced by GlaxoSmithKline which protects against HPV-16 
and -18 (232;235;236). Both vaccines have proven to be nearly 100% effective in 
protecting against the virus types to which they are directed, there is a certain 
degree of cross protection against virus types although the degree of cross 
protection remains debatable, both vaccines were fully licensed in 2006 (237). In 
the UK, a national programme to vaccinate girls ages 12-13, along with a catch 
up programme vaccinating girls ages 14-17, commenced in September 2007. The 
vaccine used in the UK programme is Cevarix ®.  
1.7.1.2 L2 prophylactic vaccines 
Whilst L1-VLP based vaccines are type specific, vaccines based on the minor 
capsid protein, L2 have been shown to elicit antibody responses against a broad 
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spectrum of HPV types (238;239). As these vaccines are directed against linear 
L2 epitopes, such vaccines are peptide based and are likely to be cheaper to 
produce with longer shelf lives(240). It remains to be seen whether these 
vaccines prove useful in clinical development and trials.  
1.7.2 Limitations of available L1 prophylactic HPV vaccines 
While it is anticipated that the introduction of prophylactic vaccination 
programmes should lead to a reduction in the incidence of HPV-related genital 
diseases including cervical, vulvar and vaginal cancers, it is clear that the 
currently available prophylactic HPV vaccines have several limitations. 
Prophylactic vaccines are type specific and therefore do not protect against all 
high risk HPV types. Over time other high risk mucosal HPV types may become 
more prevalent and take over from HPV-16 and HPV-18 as the leading causes of 
cervical cancer. There is ongoing work into the development of a prophylactic 
vaccine against all high risk mucosal types (207). 
The production of VLPs occurs in eukaryotic cells and is very expensive and the 
vaccine must be transported and stored at low temperatures. Both these factors 
are likely to impact on the delivery of these vaccines in developing countries 
where the burden of HPV disease is highest and there are no cervical cancer 
screening programmes (207).  
Prophylactic vaccines do not treat existing HPV infections. Women already 
infected with HPV-16 and HPV-18 are still vulnerable to cervical cancer and will 
remain so for the rest of their lives. Strategies for the treatment of those 
already infected with HPV, such as therapeutic vaccines and other anti-viral 
agents must be explored. 
Finally, the prevention and treatment of other HPV associated diseases including 
head and neck cancers and nonmelanoma skin cancers is not addressed by the 
currently available prophylactic vaccines. In the case of NMSC, where no 
predominant HPV type has been implicated, then prophylactic vaccines may not 
be the answer; instead a therapeutic approach may be needed. 
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1.7.3 Therapeutic vaccines 
Therapeutic vaccines against HPV-associated cancers would in theory reduce the 
incidence of such cancers immediately while it will take some time before a fall 
in the incidence of cervical cancer is observed as a result of prophylactic 
vaccination programmes. Potential targets for therapeutic vaccines would be E6 
and E7 which are expressed in both pre-malignant and malignant lesions.  
HPV-16E6/E7 derived therapeutic vaccines have been tested in a small group of 
patients with cervical cancer in whom they led to expansion of HPV-16 specific 
CD4+ and CD8+ T cells (241). These vaccines have also been tested in women 
with high grade HPV-16 associated vulval intraepithelial neoplasia and induced a 
HPV-16 specific immune response as well as a promising clinical response (242).  
A number of other strategies for the development of therapeutic vaccines are 
being developed (reviewed in (240)) but as yet there are no available licensed 
therapeutic HPV vaccines.  
1.7.4 Anti-viral therapies for HPV associated disease 
There are currently no drugs for HPV related disease that directly target the 
viral life cycle. One way to therapeutically target HPV would be to interfere 
with viral replication.  
There are inhibitors of E1 but they do not work well and they do not work across 
types (243). Disruption of the E1/E2 interaction by small molecule inhibitors has 
proven successful for HPV-6 and HPV-11 but the usefulness of such inhibitors is 
limited as they do not work effectively against different HPV types due to subtle 
differences in the interaction of the E1/E2 proteins and therefore have not been 
developed for clinical use (244). Therefore one way to identify novel targets to 
disrupt the virus life cycle is to focus on the interactions between the viral 
replication proteins and host interacting proteins. In comparison with the viral 
E1/E2 interaction, it is likely that interactions between viral and host proteins 
should be conserved across HPV types suggesting that targets studied in HPV-16 
for example may also be effective in disrupting the virus life cycle of cutaneous 
types. Little is known about the cellular proteins that interact with E1/E2 to 
initiate viral replication. TopBP1 was identified as a novel interacting partner for 
56 
HPV-16E2 in the Morgan laboratory (245). Subsequently this laboratory has shown 
that TopBP1 also interacts with HPV-16E1 (unpublished data) making the 
TopBP1/E1/E2 interaction a potential target for disruption of HPV replication. 
TopBP1 is studied in this thesis as an interacting partner for HPV using HPV-16 as 
a model system and extending that work to the cutaneous type HPV-8.  
The structure and functions of TopBP1 are described below.  
1.8 Topoisomerase II β Binding Protein 1 (TopBP1) 
Topoisomerases are enzymes that catalyze structural changes of DNA. 
Topoisomerase II is essential for replication and segregation of chromosomes in 
yeast and Topoisomerase II performs similar functions in mammalian cells. 
TopBP1 is an essential nuclear protein which was identified as an interacting 
partner for Topoisomerase II  using a yeast two hybrid assay (246).  
Much of what is known of the function of TopBP1 comes from studies of TopBP1 
homologues in other organisms namely the fission yeast Schizosaccaromyces 
Pombe (Rad4), budding yeast Saccharomyces Cerevisiae (Dbp11), Drosophila 
melanogaster (Mus101), Xenopus laevi (XTopBP1) and Caernohabitis elegans 
(F37D6.1).  
1.8.1 Structure of TopBP1 
TopBP1 is a large (1435 amino acid (aa)) nuclear protein which contains eight 
BRCT domains (Breast Cancer susceptibility gene 1 (BRCA1) Carboxyl Terminus) 
(247). BRCT domains are found in proteins involved in DNA repair and cell cycle 
checkpoints. No other protein has as many as eight BRCT domains suggesting 
that TopBP1 is an important DNA repair protein and aberrant expression of 
TopBP1 protein has been identified in breast cancers (248) whilst polymorphisms 
in the TopBP1 gene have been associated with familial breast and ovarian 
cancers (249). 
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1.8.2 Functions of TopBP1 
1.8.2.1 TopBP1 and DNA damage repair 
A number of cellular proteins function to sense DNA damage and initiate the DNA 
damage cascade such as BRCA1, PML and Rad9. The nuclear protein TopBP1 is 
recruited to sites of DNA damage (250) possibly by direct interaction with 
damaged DNA or by recruitment via Rad9 (251;252). Having localised to DNA 
damage sites, TopBP1 signals that damage has been detected in order to initiate 
the cellular DNA damage cascade. To do this, TopBP1, interacts with the ATR 
(ATM and Rad3-related)-ATRIP (ATR interacting protein) complex, activating ATR 
and allowing phosphorylation of downstream targets such as Chk1 (253-257). The 
ATR pathway is activated by UVB (reviewed in (258)) thus it is likely that TopBP1 
is involved in regulating the response of keratinocytes to UV.  
1.8.2.2 TopBP1 and DNA replication initiation 
TopBP1 plays a role in the initiation of DNA replication. The Xenopus homologue 
of TopBP1, Xmus 101 is essential for the initiation of DNA replication in Xenopus 
nuclear extracts where it plays a role in loading the initiation complex onto DNA 
(259). In mammalian cells, there is some evidence to suggest that TopBP1 is 
essential for an intact S phase and that it plays a key role in monitoring genome 
integrity through S phase(260). However it appears that TopBP1 depletion by 
small interfering RNA (siRNA) does not inhibit replication in all cells (255;261).  
1.8.2.3 TopBP1 as a transcription factor 
There is also evidence to suggest that TopBP1 may act as a regulator of 
transcription. The transcription factor E2F1 coordinates cell cycle progression; 
TopBP1 directly interacts with E2F1 via BRCT6 following DNA damage thereby 
repressing E2F1 transcriptional activity, induction of S-phase entry and apoptosis 
(262;263). TopBP1 also acts as a transcriptional repressor for the Miz1 protein 
therefore regulating the function of c-Myc(264). TopBP1 can also act as a 
transcriptional activator. TopBP1 can co-activate the transcription of the HPV-
16E2 protein (219) and also with the c-Ets protein (265). Studies have identified 
several TopBP1 domains that can both activate or repress transcription(266). 
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1.9 Research Aims 
The scope of this thesis is wide ranging and will look at several aspects of HPV-
associated non-melanoma skin cancer from delineating the extent of the clinical 
problem, identifying the extent of betaPV infection in our population and 
looking at ways in which the role of betaPV in NMSC could be further clarified.  
The work of this thesis will then take a molecular approach looking at potential 
therapeutic targets to disrupt the virus life cycle using HPV-16 as a model system 
before extending the work to the betaPV type, HPV-8. 
This thesis has five main aims: 
(i) To investigate the epidemiology of nonmelanoma skin cancer in the West of 
Scotland renal transplant population. 
(ii) To identify the spectrum of betaPV found in NMSC from the West of Scotland 
renal transplant population.  
(iii) To identify whether expression of cellular biomarkers in NMSC biopsies 
differentiate between HPV-associated and non HPV-associated NMSC. 
(iv) To characterise the interaction between E2 and TopBP1 a potential target 
for interruption of the viral life cycle in HPV-associated disease.  
(v) To investigate the relationship between UVR and TopBP1. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
The materials used in this thesis including the manufacturer and distributors 
details where applicable are given in this section. 
2.1.1 Tissue samples 
The methods used to collect the tissue samples are described in detail in section 
2.2.2.  
2.1.2 Materials for HPV genotyping 
DDL Diagnostic Laboratories, Voorburg, the Netherlands 
Reverse hybridisation assay for the identification of skin (beta) human 
papillomavirus genotypes - KI00062 v 0.5 RHA KIT skin (beta) HPV   
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2.1.3 Materials for Immunohistochemistry 
2.1.3.1 Antibodies 
Dako UK LTD (Cambridgeshire, United Kingdom) 
Envision + System-HRP labelled polymer, Anti-Rabbit – Catalogue Number: K4003 
Envision + System-HRP labelled polymer, Anti-Mouse – Catalogue number: K4001 
KI67 Monoclonal mouse Anti-Human Ki-67 antigen, clone MIB-1 - Catalogue 
Number: M724001-2 
Novocastra (Newcastle, United Kingdom) 
p53, rabbit, polyclonal anti-human p53, clone CM-1 – Catalogue Number: NCL-
p53-CM1 
Panomics (California, United States of America) 
MCM2 – Mouse anti-human MCM2, Clone SPM196 – Catalogue Number: E5184 
MCM5 – Mouse anti-human MCM5, Clone SPM197 – Catalogue number: E5194 
 
TopBP1 polyclonal antibody R1180 against amino acids 861-1287 was raised in a 
rabbit. The methods of preparation of the antibody and the pre-immune have 
been described by Boner et al 2002(219). 
2.1.3.2 Chemicals and reagents 
Institute of Comparative Medicine (University of Glasgow, United Kingdom) 
Haematoxylin – Gills Haematoxylin (Triple Strength) 500ml -  (345ml distilled 
H2O, 125ml Ethylene Glycol, 3g Haematoxylin, 0.3g Sodium Iodate, 26.40g 
Aluminium Sulphate, 30ml Glacial Acetic Acid) 
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Eosin – Potts Eosin - (25g Eosin, 250ml saturated aqueous pioric acid, 2000ml 
distilled H2O, 12.5g potassium dichromate, 250ml Absolute Alcohol) 
Sigma- Aldrich Company Ltd. (Dorset, UK) 
Tween 20 (Polyoxethylene sorbitan nonolaurate) - Catalogue Number: P1379 
Tris Base (2-Amino-2-(hydroxymethyl)-1, 3-propanediol) – Catalogue Number: 
T6066 
Vector Laboratories Ltd (Peterborough, United Kingdom) 
Vectabond™ Reagent – Catalogue Number: SP1800 
2.1.3.3 Kits 
Dako UK LTD (Cambridgeshire, United Kingdom) 
CINtec ™ p16INK4a Histology Kit – Catalogue Number: K533611-2 
DakoCytomation Envision® + System-HRP (DAB) Kit (Mouse) – Catalogue Number: 
K4007 
DakoCytomation Envision® + System-HRP (DAB) Kit (Rabbit) – Catalogue Number: 
K4011 
Washbuffer, Concentrated X 10 for Immunocytochemistry- Catalogue Number: 
S300685-2 
2.1.3.4 Miscellaneous 
Leitz Wetzlar microscope 
Prestige 
Prestige microwave pressure cooker 
Sharp 
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Microwave oven 
Thermo (Cheshire, United Kingdom) 
Glass coverplates and microscope slides– Catalogue Number: 72110013 
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2.1.4 Materials for Molecular Biology 
2.1.4.1 Antibodies 
Abcam (Cambridge, United Kingdom) 
Anti-c-myc antibody, mouse monoclonal antibody – Catalougue Number: ab32 
Amersham Biosciences (part of GE Healthcare, Buckinghamshire, United 
Kingdom) 
Anti-mouse IgG peroxidase-linked whole antibody developed in sheep - 
Catalogue Number: NXA931 
Anti-rabbit IgG, peroxidase-linked species specific whole antibody (from donkey) 
- Catalogue Number: NA934 
Cell Signalling Technology (New England Biolabs UK Ltd, Hertfordshire, 
United Kingdom) 
Phospho-Chk1 (ser317) polyclonal antibody developed in rabbit – Catalogue 
Number: 2344 
Phosphor-Chk1 (ser 345) polyclonal antibody developed in rabbit – Catalogue 
Number: 2341 
Cancer Research UK (CRUK, London, United Kingdom) 
TVG 261 anti-HPV16E2 antibody developed in mouse was purchased from CRUK. 
Sigma- Aldrich Company Ltd. (Dorset, UK) 
Anti-Rabbit IgG (whole molecule) peroxidase developed in goat – Catalogue 
Number: A6154 
Monoclonal Anti--Tubulin antibody produced in mouse, clone GTU-88 – 
Catalogue Number: T6557 
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Anti-FLAG polyclonal IgG antibody developed in rabbit – Catalogue Number: 
F7425  
TopBP1 polyclonal antibody R1180 against amino acids 861-1287 was raised in a 
rabbit. The methods of preparation of the antibody and the pre-immune have 
been described by Boner et al 2002(219).  
2.1.4.2 Bacteriology 
Becton Dickinson Labware (Oxford, United Kingdom) 
15ml polypropylene tubes – Catalogue Number: 348206 
50ml polypropylene tubes - Catalogue Number: 358206 
20ml sterile syringes - Catalogue Number: 301031 
BD Bacto™ Agar - Catalogue Number: 214010 
Bibby Sterlin Ltd (Staffordshire, United Kingdom) 
90mm bacteriology petri dishes - Catalogue Number: 502014  
Invitrogen Ltd (Paisley, United Kingdom) 
Subcloning efficiency ™ DH5™ chemically competent cells - Catalogue Number: 
18265 
S.O.C medium – Catalogue Number: 15544-034 
Sigma Chemical Co. Ltd. (Dorset, United Kingdom) 
Ampicillin - Catalogue Number: 10047 
Luria Broth (LB-Broth) (1 litre: 20g dissolved in ddH2O) – Catalogue Number: 
L3022 
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Luria Bertai agar (LB agar) (1 litre: 35g dissolved in ddH2O) – Catalogue Number: 
L2897 
2.1.4.3 Cell Lines 
HaCaT cells are spontaneously immortalised human adult keratinocytes as 
described in (267). 
Human Embryonic Kidney 293T (HEK293T) are derived from the 293 cell line in 
which the SV40 T-antigen was inserted. These cells were a kind gift from Dr. 
Brian Willet, University of Glasgow. 
MCF7 cells derived from a human Caucasian breast adenocarcinoma were 
purchased from Cancer Research UK (CRUK, London, United Kingdom). 
U2OS are an osteosarcoma cell line, expressing wild type p53 and were 
purchased from Cancer Research UK (CRUK, London, United Kingdom). 
U2OS B3 are U2OS cells that stably express HPV-16E2. The method used to 
prepare this cell line has been described by Taylor et al 2003 (268).  
U2OS 4.1 are U2OS cells that stably express HPV-16E2N89YE90V and were 
prepared using the methods described to prepare the B3 cell line (268).  
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2.1.4.4 Chemicals and Reagents 
Amersham International PLC (Buckinghamshire, UK) 
Enhanced Chemiluminescence (ECL) Plus™ Western Blotting detection reagents – 
Catalogue Number: RPN2133 
Hyperfilm X-ray film – Catalogue Number: 93184 
Applied Biosystems (Warrington, United Kingdom) 
Hi-Di™ Formadide - Catalogue Number: 4440753 
Eurogentec Ltd (Southampton, United Kingdom) 
Agarose - Catalogue Number: EP-0010-05 
GE Healthcare (Buckinghamshire, United Kingdom) 
Glutathione Sepharose 4 Fast Flow, Catalogue Number: 28104 
Thrombin, 500U – Catalogue Number: 27-0846-01 
Isopopyl--D-1-thiogalactosidase (IPTG) - Catalogue Number: 15502 
Promega (Southampton, United Kingdom) 
Deoxynucleotide Triphosphates (dNTPs) 
dATP, 100mM - Catalogue Number : U120A 
dGTP, 100mM - Catalogue Number: U121A 
dCTP, 100mM - Catalogue Number: U122A  
dTTP 100mM - Catalogue Number: U123A 
Roche Applied Science (Hertfordshire, United Kingdom) 
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Complete Protease Inhibitor Cocktail Tablets - Catalogue Number: 11836145001 
TritonX-100, Catalogue Number - 10789704001 
Sigma-Aldrich (Dorset, United Kingdom) 
3’,5’,5”-Tetrabromophenolsulfophethalein (Bromophenol Blue) – Catalogue 
Number: B0126 
4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES) – Catalogue 
Number: H4034 
3-Hydroxy-4-(2-sulfo-4-[4-sulfophenylazo] phenylazo)-2, 7-naphthalenedisulfonic 
acid sodium salt (Ponceau S) – Catalogue Number: P7170 
Acetic acid sodium salt (Sodium acetate) – Catalogue Number: S2889 
Bicinchonoinic Acid (BCA) solution - Catalogue Number: B9643 
Boric Acid – 99% - Catalogue Number: B9643 
Copper (II) sulphate (pentahydrate 4% (w/v) solution) - Catalogue Number: 
C2284 
Cycloheximide ready made 100mg/ml solution– Catalogue Number: C4859 
Ethidium Bromide 10mg/ml - Catalogue Number: E-1510 
Nonidet P-40 (NP40) – Catalogue Number: I8896 
Phenol: Chloroform: Isoamyl Alcohol 25:24:1 saturated with 10mM Tris, pH8.0, 
1mM EDTA - Catalogue Number: P3803 
Tween 20 (Polyoxethylene sorbitan nonolaurate) - Catalogue Number: P1379 
Tris Base (2-Amino-2-(hydroxymethyl)-1,3-propanediol) – Catalogue Number: 
T6066 
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University of Glasgow Stores (Glasgow, United Kingdom) 
Crude Ethanol 
VWR International (Leicestershire, UK) 
Absolute 99.7-100% AnalaR® ethanol - Catalogue Number: 10107EP  
AnalaR® D-(+)-Glucose – Catalogue number: 101176K 
AnalaR® Methanol - Catalogue Number: 10158FK 
AnalaR® Potassium Chloride – Catalogue Number: 437023F 
AnalarR® Sodium dodecyl sulphate (SDS) - Catalogue Number: 108073J 
Crystal Violet - Catalogue Number: 340245L 
Dimethyl sulfoxide (DMSO) - Catalogue Number: 8029122500 
Ethylene diamine tetra acetate (EDTA) disodium salt – Catalogue number: 
30031.294 
Hydrochloric acid – Catalogue Number: 101252F  
Propan-2-ol (Isopropanol) Molecular Biology Grade - Catalogue Number: 437423R 
2.1.4.5 Enzymes and Buffers   
Cambrex Bioscience (Wokingham, United Kingdom) 
Takara DNA Ligation Kit (version V) - Catalogue Number: 6022 
Invitrogen Ltd (Paisley, United Kingdom) 
BamH1 and REact® 3 Buffer – Catalogue Number: 15201-023 and Y9004 
EcoR1 and REact® 3 Buffer – Catalogue Number: 15202-013 and Y9004 
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Xho1 and REact® 2 Buffer – Catalogue Number: 1523-012 and Y92500 
Magnesium Sulphate - 50mM Catalogue Number: 52044 
Platinum ® Pfx DNA polymerase - Catalogue Number: 11708-013 
Pfx Amplification Buffer (10x) - Catalogue Number: 52806 
New England Biolabs (Hertfordshire, United Kingdom) 
Bovine Serum Albumin 100x - Catalogue Number: B9001S 
Dpn1, 20,000U/ml - Catalogue Number: R0176L 
Exonuclease III, 100,000U/ml – Catalogue Number: M0206L 
NEBuffer 1 – Catalogue Number: B7001S 
NEBuffer 3 - Catalogue Number: B7003S 
Roche Products Ltd (Hertfordshire, United Kingdom) 
Shrimp Alkaline Phosphatase – Catalogue Number: 11370400 
Shrimp Alkaline Phosphatase Dephosphorylation Buffer (10x) – Catalogue 
Number: 70092921 
2.1.4.6 Kits 
Ambion (Applied Biosystems, Warrington, United Kindom) 
DNA-free™ Kit – Catalogue Number: AM1906 
RNase-Zap – Catalogue Number: AM9780 
Applied Biosystems (Warrington, United Kingdom) 
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ABI Prism BigDye Terminator v 3.1 Cycle sequencing kit - Catalogue Number: 
4336915 
Invitrogen (Paisley, United Kingdom) 
Purelink® HiPure plasmid maxiprep kit – Catalogue Number: K210006 
NuPage® 4-12% Bis-Tris 12 well 1.0 mm gels – Catalogue Number: NP0302BOX 
NuPage® 4-12% Bis-Tris 10 well 1.0 mm gels – Catalogue Number: NP0301BOX 
NuPage® Antioxidant – Catalogue Number: NP0005 
NuPage® MES SDS Running buffer (20X) – Catalogue Number: NP0002 
NuPage® Sample Reducing Agent (10X) – Catalogue Number: NP0009 
NuPage® LDL Sample Buffer (4x) – Catalogue Number: NP0007  
NuPage® Transfer Buffer (20X) – Catalogue Number: NP0006 
Novagen (Merck Chemicals Ltd., Nottingham, United Kingdom) 
KOD DNA Polymerase Kit (containing KOD DNA Polymerase 2.5U/µl, 10X KOD DNA 
polymerase buffer, 25mM MgCl2, 2mM dNTPs) - Catalogue Number: 71085 
Promega Ltd (Southampton, United Kingdom) 
Luciferase assay system – Catalogue Number: E1500 
Reporter Lysis Buffer (5x solution) – Catalogue Number: E3971 
Qiagen Ltd (Crawley, United Kingdom) 
Qiaquick PCR purification Kit (50) – Catalogue Number: 28104 
QiaPrep Spin Miniprep Kit (50) - Catalogue Number: 27104 
QIAquick Gel Extraction Kit - Catalogue Number: 28704 
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RNeasy® Mini Kit (50) - Catalogue Number: 74104 
Stratagene (Agilent Technologies UK Ltd, Cheshire, United Kingdom) 
Brilliant® QPCR Master Mix – Catalogue Number: 600549   
2.1.4.7 Miscellaneous 
Applied Biosystems (Cheshire, United Kingdom) 
7500 Real time PCR system and sequence detection software, Version 1.2.2 – 
Catalogue Number: 4351104 
3130X1 Genetic Analyzer, 16 capillary DNA sequencer 
MicroAmp optical 8 cap strip – Catalogue Number: 4323032 
Astec Microflow Ltd (Hampshire, United Kingdom) 
Microflow PCR workstation – Model: OMN-007 
Elkay International (Basingstoke, United Kingdom) 
1.5ml microcentrifuge tubes with attached cap – Catalogue Number: MICR050 
0.5ml microcentrifuge tubes with attached cap – Catalogue Number: MICR051 
Plastic Pasteur Pipettes – Catalogue Number: P511 
Invitrogen Ltd (Paisley, UK) 
iBlot® Gel Transfer Device – Catalogue Number: IB1001UK 
iBlot® Gel Transfer Stack Mini (Nitrocellulose) – Catalogue Number: IB301002 
iBlot® Gel Transfer Stack regular (Nitrocellulose) – Catalogue Number: IB301001 
Kimberley Clark (Brighton, United Kingdom) 
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Safeskin Disposable Purple Nitrile Exam Gloves – Catalogue Number: 014602 
Morrisons Supermarket (Anniesland, United Kingdom) 
Marvel dried skimmed milk 
Nunc™ Part of Thermo Fisher Scientific (Hereford, UK) 
96 well Fluoro flat bottom microplate – Catalogue Number: 236108 
Scientific Laboratory Suppliers (Lanarkshire, United Kingdom) 
Syngene GeneFlash System Complete – Catalogue Number: MOL5380 
Sigma-Aldrich (Dorset, United Kingdom) 
Albumin from bovine serum lyophilized powder, ≥96% (agarose gel 
electrophoresis) – Catalogue Number: A9647 
Protein A Sepharose® 4B, Fast Flow Beads – Catalogue Number: P9424 
Thermo Labsystems Corporation (Warwickshire, United Kingdom) 
Luminoskan Ascent Luminometer and Ascent Software (version 2.4.2) 
Multiskan Acent Reader and Software. 
ThermoScientific (Hampshhire, United Kingdom) 
ABgene® PCR plates – Catalogue Number: AB-0600  
2.1.4.8 Molecular weight markers 
Invitrogen Ltd (Paisley, UK) 
100bp DNA Ladder - Catalogue Number: 15628-050  
1Kb DNA Ladder – Catalogue Number: 15615 
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See Blue® Pre-stained protein standard – Catalogue Number: LC5925 
75 
2.1.4.9 Plasmids 
pGL3 control contains the SV40 promoter and enhancer sequences driving the 
expression of firefly luciferase (Promega Ltd Southhampton, United Kingdom). 
pGL3 basic lacks promoter and enhancer sequences (Promega Ltd 
Southhampton, United Kingdom). 
ptk6E2luc contains the thymidine kinase promoter from HSV-1 cloned into the 
pGL3 luciferase vector upstream of 6 HPV-16E2 binding sites(269). 
pTopBP1 expresses the full length TopBP1 under control of the cytomegalovirus 
promoter and was a kind gift from Dr Kazuhiko Yamane. 
pTopBP1 2-258BRCT1 expresses nucleotides 2-258 of the TopBP1 gene with a 
deletion mutation of the BRCT1 binding site. 
pGEX-4T-2 expressed glutathione S transferase and contains a thrombin 
cleavage site , and multiple cloning site including BamH1 and Xho1 restriction 
sites (GE Healthcare, Catalogue Number : 27-4581-01) 
p16E1myc (clone3) is a myc tagged vector expressing HPV16E1 in mammalian 
cells. It was previously made in the laboratory (Mr E. Dornan) by taking the 
multiple cloning site of pGBKT7 (a vector expressing the myc tag in yeast) and 
cloning it into pCDNA3, a mammalian vector. The E1 gene was then cloned into 
this vector between the EcoR1 and BamH1 restriction sites.  
p16E2 contains the full length HPV-16E2 sequence (nucleotides 2755-3853) 
cloned into the pJ4 plasmid as described in (270). 
p16E1 contains the full length HPV-16E1 ORF (nucleotides 865-3210) as 
described in (271). 
p16E1Ha contains the HPV-16 genome (nucleotides 83-2814) containing the E1 
ORF with the influenza haemagglutinin epitope tag (Ha) inserted in-frame into 
the E1 coding sequence within the QM-Ntag/Ai vector (as described in (272)).  
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p16oriM contains the HPV-16ori plasmid (as described in (271)) with a point 
mutation at nucleotide 115 (C to T) of the HPV genome creating a Dpn1 site 
(method described in (273)).  
The following HPV-8 plasmids were a kind gift from Dr Baki Akgul and are 
described in detail in (274). 
p8-1 contains the HPV-8 origin of replication  
pCE1 contains HPV-8E1 in pCB6 
pCE2 contains HPV-8E2 in pCB6 
pCMV2-HPV8-E2-Flag contains the HPV-8E2 open reading frame, amplified with 
specific primers and ligated to the EcoR1 and BamH1 sites of pCMV2-Flag 
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2.1.4.10 Primers, DNA probes and Oligonucleotides 
Dharmacon 
2.1.4.10.1 Oligonucleotides for siRNA 
 
Oligo name   
SiTopBP1 Target sequence GUGGUUGUAACAGCGCAUC 
 
 Sense strand 5’-3’ GUGGUUGUAACAGCGCAUCdTdT 
 
 Anti-sense strand 3’-5’ 
 
dTdTCACCAACAUUGUCGCGUAG 
SiLuciferase Target sequence CGUACGCGGAAUACUUCGA 
 
 Sense strand 5’-3’ CGUACGCGGAAUACUUCGAdTdT 
 
 Anti-sense strand 3’-5’ dTdTGCAUGCGCCUUAUGAAGCU 
 
 
Eurogentec, (Southampton, United Kingdom) 
2.1.4.10.2 Probe and primer set for HPV-16 qPCR 
 Sequence 5’-3’ 
Probe 
 
OriM 
ACC AAA AGA GAA CTG CAA TGT TTC AGG ATC C 
Forward Primer 
 
oriFwd 
ATC GGT TGA ACC GAA ACC G 
Reverse Primer 
 
oriRev 
TAA CTT TCT GGG TCG CTC CTG 
 
2.1.4.10.3 Probe and primer set for HPV-8 qPCR 
 Sequence 5’-3’ 
Probe 
 
HPV-8Ori 
CGG TAA GTT TCA TCA GTG TAC CAG GTG CG 
Forward Primer 
 
HPV-8oriFwd 
GCA TCT CCA ACG GAC CGT TA 
Reverse Primer 
 
HPV-8oriRev 
AGA CGA TGG TTG TTG GCA ATA A 
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Integrated DNA Technologies, Leuven, Belgium 
2.1.4.10.4 Primers for HPV-16E2 site directed mutagenesis 
Mutant Primer  Sequence 5’- 3’ 
 
N89Y MDP264 
(Forward) 
5' CAATATATAACTCACAATATAGTTATGAAAAGTGGACATTACAAG 3' 
 
 
 MDP265 
(Reverse) 
5' CTTGTAATGTCCACTTTTCATAACTATATTGTGAGTTATATATTG 3' 
 
 
E90A MDP262 
(Forward) 
5' CAATATATAACTCACAATATAGTAATGCAAAGTGGACATTACAAG 3' 
 
 
 MDP263 
(Reverse) 
5' CTTGTAATGTCCACTTTGCATTACTATATTGTGAGTTATATATTG 3' 
 
 
E90V MDP260 
(Forward) 
5' CAATATATAACTCACAATATAGTAATGTAAAGTGGACATTACAAG 3' 
 
 
 MDP261 
(Reverse) 
5' CTTGTAATGTCCACTTTACATTACTATATTGTGAGTTATATATTG 3' 
 
 
N89YE90V 
(template  
16E2E90A) 
LMP9 
(Forward) 
5' CAATATATAACTCACAATATAGTGCTGCAAAGTGGACATTACAAG 3' 
 
 
 
(template  
16E2E90A 
LMP10 
(Reverse) 
5' CTTGTAATGTCCACTTTGCAGCACTATATTGTGACTTATATATTG 3' 
 
 
2.1.4.10.5 Primers for sequencing HPV-16E2 plasmids 
Primer  Sequence 5’- 3’ 
 
MDP233 
(Forward) 
5' GTTGTGCTGTCTCATCATTTTG 3' 
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2.1.4.10.6 Primers for HPV-8E2 site directed mutagenesis  
Mutant Primer  Sequence 5’- 3’ 
 
E90V MDP270 
(Forward) 
5' CAGAAATCTGAGTTTGCAGATGTGCCTTGGACATTAGTGGACAC 3' 
 
 
 MDP271 
(Reverse) 
5' GTGTCCACTAATGTCCAAGGCACATCTGCAAACTCAGATTTCTG 3' 
 
 
E90A MDP272 
(Forward) 
5' CAGAAATCTGAGTTTGCAGATGCGCCTTGGACATTAGTGGACAC 3' 
 
 
 MDP273 
(Reverse) 
5' GTGTCCACTAATGTCCAAGGCGCATCTGCAAACTCAGATTTCTG 3' 
 
 
D89A LMP11 
(Forward) 
5' CAGAAATCTGAGTTTGCAGCTGAGCCTTGGACATTAGTGGACAC 3' 
 
 
 LMP12 
(Reverse) 
5' GTGTCCACTAATGTCCAAGGCTCAGCTGCAAACTCAGATTTCTG 3' 
 
 
D89AE90V LMP13 
(Forward) 
5' CAGAAATCTGAGTTTGCAGCTGTGCCTTGGACATTAGTGGACAC 3' 
 
 
 LMP14 
(Reverse) 
5' GTGTCCACTAATGTCCAAGGCACAGCTGCAAACTCAGATTTCTG 3' 
 
 
 
2.1.4.10.7 Primers for sequencing HPV-8E2 plasmids 
Primer  Sequence 5’- 3’ 
 
MDP271 
(Reverse) 
5' GTGTCCACTAATGTCCAAGGCACATCTGCAAACTCAGATTTCTG 3' 
 
LMP5 
(Forward) 
5' GAG AAT CTC AGC GAG CGT 3' 
 
 
2.1.4.10.8 Primers for moving HPV-8E2 into pE1myc clone 3 
Primer Sequence 5’ – 3’ Restriction sites 
 
LMP7  
(Forward) 
5' TGA GAA TTC ATG GAG AAT CTC AGC GAG C 3' EcoR1 
 
 
LMP8  
(Reverse) 
5' TGA GGA TCC TTA CCA TAA GAT GTA TCA ACT C 3' BamH1  
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2.1.4.10.9 Primers for cloning TopBP1 into pGEX-4T-2 
Primer Sequence 5’-3’ Restriction sites 
LMP1 CGG GGATCC CAC CAC CAG CGA TGT GTC BamH1 
LMP2 CGG GGATCC GCA AGT GTT CAA GAA TAC  BamH1 
LMP3 CGG GGATCC CCA CTC TCA GAA GTT ATT G  BamH1 
MDP50 CGG CTC GAG TTC TAG ATT TTC AAG TGT  Xho1 
MDP41 TTC CTC GAG CTG AAA GCG GTT CAT ATC TAA AGG Xho1 
MDP37 TTC CTC GAG TGG CGT ACT CGG TTT CC  Xho1 
LMP4 CGG CTC GAG AGA CAC AGC TGA GAG TAG  Xho1 
 
 
 2.1.4.11 Tissue Culture 
Corning incorporated (Leicestershire, UK) 
100mm x 20mm non-pyrogenic cell culture dishes – Catalogue Number: 3296 
60mm x 15mm non-pyrogenic cell culture dishes – Catalogue Number: 4301 
25ml disposable serological polystyrene pipettes – Catalogue Number: 4251 
10ml disposable serological polystyrene pipettes – Catalogue Number: 4101 
5ml disposable serological polystyrene pipettes – Catalogue Number: 4135 
Cell scraper – Catalogue Number: 3010  
Greiner Bio-one Ltd (Stonehouse, UK) 
50ml polypropylene centrifuge tubes – Catalogue Number: 210201 
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15ml polypropylene centrifuge tubes – Catalogue Number: 188261 
96 well ELISA microplates – Catalogue Number: 072003 
Invitrogen Ltd (Paisley, UK) 
Dulbecco’s Modified Eagle Medium (DMEM) (1x) +w/GlutaMAX™/Glucose NaPyr – 
Catalogue Number: 31966 
Dulbecco’s Modified Eagle Medium (DMEM) (1X) High Glucose – Catalogue 
Number: 21068 
Fœtal Bovine Serum – Catalogue Number: 16141 
L-Glutamine 200mM 100x – Catalogue Number: 25030 
Opti-MEM® I Reduced-Serum medium (1X), liquid - Catalogue Number: 11058 
Penicillin–Streptomycin Solution (5000:5000) liquid – Catalogue Number: 15070 
Trypsin-EDTA (1x) 0.05% trypsin 0.53mM EDTA Na – Catalogue Number: 25300 
Nunc™ Part of Thermo Fisher Scientific (Hereford, UK) 
25cm tissue culture flasks with filtered caps- Catalogue Number: 136196 
80cm tissue culture flasks with filtered flasks – Catalogue Number: 178905 
175cm tissue culture flasks with filtered flasks – Catalogue Number: 178883 
Promega Ltd (Southampton, UK) 
Phosphate buffered saline (PBS) tablets – Catalogue Number: P4417 
Thermo Scientific Dharmacon (Leicestershire, United Kingdom) 
SiLuciferase 0.05mol – Custom SiRNA synthesis 
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SiTopBP1 0.05mol – Custom SiRNA synthesis 
2.1.4.12 Microarray 
Array name: Human Gene 1.0 ST 
Array/chip type: HuGene-1_0-st-v1 
Organism: Homo sapiens 
NetAffx release: 31 (2009-11-16). 
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2.2 Methods 
The protocols used in this thesis are described in the following section. The 
manufacturers and distributors details for materials used are given in the 
previous section. 
2.2.1 Epidemiology 
A specialist Dermatology clinic for renal transplant recipients (RTRs) was 
established at the Western Infirmary Glasgow. All patients with a functioning 
renal transplant in the West of Scotland were invited to attend for Dermatology 
review. All new RTRs from this date forward received an appointment to attend 
the Dermatology clinic and referrals were taken from all sources for any RTRs 
requiring Dermatology review. The study period was from September 2005 to 
November 2008 (38 months). 610 individuals attended during the study period. 
The number and frequency of follow up visits varied according to clinical need.  
Data on all RTRs were entered into the West of Scotland renal electronic patient 
record. A Dermatology section was added to this database to collect data on risk 
factors for and episodes of skin cancer. The Dermatology section was designed to 
be intrinsically linked to the renal database in order to allow correlation 
between skin cancer data and transplant data such as immunosuppressive drugs.  
A clinical history and full dermatological examination was carried out for each 
patient. Data collected for each patient included skin type, occupation and use 
of sun beds. Previous UVR exposure was graded to be low, medium or high based 
on the patient’s occupation, leisure activities and sunbathing habits. The 
presence of viral warts and/or epidermal dysplasias (actinic keratoses and 
Bowen’s disease) was recorded. All skin cancers diagnosed on the first and any 
subsequent patient visits were recorded. Additionally, data were collected for 
all retrospectively diagnosed skin cancers.  Only histologically diagnosed tumours 
were recorded. For each cancer the date of diagnosis, tumour type, anatomical 
location and management were recorded. All tumour recurrences and 
management of recurrences were recorded. The use of oral retinoids (dose and 
duration of treatment) was recorded.  
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2.2.2 HPV genotyping 
2.2.2.1 Collection of patient samples 
Patient samples were collected from both IC patients and IS RTRs. Samples from 
IC patients were identified from the Western Infirmary Pathology database by 
searching under the diagnoses of interest.  Samples from IS patients were 
identified by cross-referencing the patients from the West of Scotland Renal 
Transplant database with the Western Infirmary Pathology database to identify 
patient samples with the diagnoses of interest.  
Once samples were identified, all pathology reports were examined. Patient 
hospital numbers from the IC group were cross-referenced with the renal 
transplant database to ensure no RTRs were included in this group. Samples 
were excluded from the study if the diagnosis was uncertain. 
2.2.2.1.1 Paraffin-embedded samples 
Archival, formalin-fixed, paraffin-embedded skin biopsy specimens of AK, IEC 
and SCC (including Keratoacanthomas from IS group only) were collected.   
Normal skin controls were collected prospectively from IC patients who were 
having dermatological surgery to remove any lesion (benign or malignant). 
Patients consented to donate either a 3mm punch biopsy from clinically normal 
photo-protected skin from the inner arm or clinically normal peri-lesional skin. 
Tissue was placed directly into formalin and was processed at the Department of 
Histopathology, Institute of Comparative Medicine. 
2.2.2.1.2 Frozen samples 
Frozen tissue samples, both lesional and normal skin, were obtained from IC and 
IS patients with consent. Where patients were donating more than one sample, 
normal skin was taken first and any subsequent surgery was performed using a 
new sterile biopsy kit to avoid cross-contamination between specimens. 
Frozen tissue was taken from any lesion where the clinical diagnosis was 
suspected SCC. A core of tissue was taken from the excised lesion placed in a 
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labelled, sterile 1.5ml microcentrifuge tube and placed directly into liquid 
nitrogen before storing at -80°C until further use. The remainder of the lesion 
was processed by the Department of Pathology, Western Infirmary and the 
histological diagnosis recorded. 
A number of patients consented to donate an additional 3mm punch biopsy of 
normal skin from the photo-protected inner arm. A 3mm punch biopsy was 
taken, placed in a labelled, sterile 1.5ml microcentrifuge tube and placed 
directly into liquid nitrogen before storing at -80°C.  
2.2.2.2 Processing of tissue sections for DNA extraction 
All tissue blocks were sectioned at the Department of Histopathology, Institute 
of Comparative Medicine. This work was carried out by Mr Colin Nixon and Mrs 
Lynne Stevenson. 
First, several sections were removed from the surface of the block and discarded 
to avoid surface contamination. Thereafter, two 10 micron thick, sections were 
placed into a 1.5 ml sterile screw cap microcentrifuge tube. The blade was 
sterilised between each sample and sterile gloves and forceps used for each 
sample. 
2.2.2.3 DNA isolation 
DNA isolation was performed at DDL Diagnostic Laboratory, Voorburg, the 
Netherlands. The work was carried out by Dr Maurits de Koning, technical staff 
from DDL Diagnostic Laboratory and by Dr Lorna Mackintosh. 
Skin biopsy specimens (10µm) were incubated in 250 µl of 1 mg/ml proteinase K 
in 50mM Tris, pH8.0, 1mM EDTA, and Tween-20 at 56˚C for 16 h to release the 
DNA, after which, proteinase K was inactivated at 95˚C for 10 min. The samples 
were then centrifuged at 13,000-x g for 5 minutes and the supernatant stored at 
-20°C or used directly for PCR. A negative control sample containing only the 
proteinase K solution was processed with each batch of 10 samples and analysed 
in parallel to the other samples. 
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2.2.2.4 PCR-reverse hybridisation assay 
The PCR-reverse hybridisation assay (PM-PCR-RHA) was performed at DDL 
Diagnostic Laboratory, Voorburg, the Netherlands. The work was carried out by 
Dr Maurits de Koning, technical staff from DDL Diagnostic Laboratory and 
assisted by Dr Lorna Mackintosh. 
BetaPV detection and genotyping was performed with the PM-PCR RHA method 
according to the instructions of the manufacturer (The skin (beta) HPV prototype 
research assay; Diassay BV, Rijswijk, The Netherlands). This method was 
designed for the amplification and identification of 25 established betaPV types, 
namely betaPV genotypes 5, 8, 9, 12, 14, 15, 17, 19, 20, 21, 22, 23, 24, 25, 36, 
37, 38, 47, 49, 75, 76, 80, 92, 93 and 96(89).  
2.2.2.4.1 PCR protocol  
DNA isolated from the tissue samples as described (2.2.2.3) was amplified by a 
broad spectrum PCR using biotinylated consensus primers (two forward and 
seevn reverse) to amplify a 117 base pair region from the E1 gene of the betaPV 
types according to the protocol described by de Koning et al(89).  
10µl of target DNA was mixed with 5µl GeneAmp 10xPCR II buffer(Applied 
Biosystems), 1.5 units AmpliTaq Gold DNA polymerase (Applied Biosystems), 
2.5mM MgCl2 (Applied Biosystems),  200µM each dNTP (Amersham Biosciences), 
10µl Primer mix (PM) (KI00062 v0.5 RHA KIT skin (beta) HPV genotyping assay) 
and distilled water to a total volume of 50µl.  
The PCR was carried out with precautions to avoid contamination. The PCR was 
performed by a nine minute pre-heating step at 94ºC, followed by 35 cycles of 
amplification comprising 30seconds at 94ºC, 45 seconds at 52ºC and 45 seconds 
at 72ºC. A final elongation step at 72ºC of five minutes ends the PCR. 
2.2.2.4.2 Reverse Hybridisation Assay (RHA) protocol 
The RHA allows the simultaneous identification of multiple HPV types in a single 
hybridisation step. Biotinylated amplimers generated by the PCR protocol were 
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hybridised to nitrocellulose strips containing probes based on sequence 
alignments from the 117 bp amplimers.  
Each nitrocellulose strip contains a conjugate probe, a universal probe and 27 
genotype specific probes. 
2.2.2.4.2.1 Conjugate Probe 
The top line of each nitrocellulose strip contained a positive control of 
biotinylated DNA. This serves as a positive control for the enzymatic colouring 
reaction (described below). 
2.2.2.4.2.2 Universal Probe  
A relatively conserved region permitted the design of additional general probes 
for broad spectrum betaPV detection. These probes detected the established 
genotypes with the exception of types 38, 92 and 96. A positive reaction on the 
universal probe in the absence of a positive reaction or pattern of reaction on 
the genotype specific probes therefore indicates presence of a known genotype 
at low copy number or detection of a new genotype that would only be 
determined by sequencing of the amplimers. 
2.2.2.4.2.3 Genotype specific probes 
Sequences from the PM amplimers shows a relatively variable region allowing the 
deduction of 27 genotyping probes. Twenty-three probes are genotype specific, 
the four remaining probes are used in pattern recognition of genotypes. HPV 
genotypes 5, 9, 12, 14, 15, 17, 19, 23, 24, 25, 36, 37, 38, 49, 75, 76, 80, cand92, 
93 and cand96 are recognised by hybridisation to a single probe line. Types 8 and 
21 yield a specific hybridisation pattern on the RHA, types 20, 22 and 47 are 
identified by a single probe line as well as by a specific reaction pattern (89). 
The RHA assay was performed using the strips and reagents contained in the 
KI00062 v0.5 RHA KIT skin (beta) HPV genotyping assay kit. 10µl of biotin-
labelled amplimer was mixed with 10µl of denaturation solution and 10µl of 3B 
buffer in a plastic trough containing the betaPV strip. The mix was incubated at 
room temperature for 5 minutes before adding 2ml of pre-warmed (37ºC) 
hybridisation buffer and incubated at 50ºC for one hour. All incubation and 
washing steps were performed automatically in an Auto-LiPA. The strips were 
washed twice for 30 seconds and once for 30 minutes with 2ml of hybridization 
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solution. The strips were then incubated with 2ml of alkaline phosphatase-
streptavidin conjugate for 30 minutes at room temperature, the streptavidin 
attaches to the biotinylated amplimers. The strips were then washed twice with 
2ml of rinse solution and once with 2ml of substrate buffer.  
Two ml of substrate (5-bromo-4-chloro-3-indolylphosphate and nitroblue 
tetrazolium) were added and incubated for 30 minutes at room temperature. 
The reaction was stopped by washing for 3 minutes and 10 minutes and by a 
wash with 2ml of water. The strips were dried and the purple bands visually 
analysed against a reference sheet.  
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2.2.3 Immunohistochemistry 
2.2.3.1 Tissue samples 
The patient samples used were paraffin-embedded samples collected and 
processed as described earlier (2.2.2). 
2.2.3.2 Processing of samples for immunohistochemical staining. 
The work was performed at the Department of Histopathology, Institute of 
Comparative Medicine and was carried out by Dr Lorna Mackintosh, Mr Colin 
Nixon and Mrs Lynne Stevenson. 
Sections were cut from tissue blocks transferred to glass microscope slides. For 
each sample, sections were prepared for each antibody under investigation 
(Ki67, p53, p16, MCM2, MCM5, and TopBP1), as well as Haematoxylin and Eosin, 
and positive and negative control slides.   
2.2.3.2.1 Heat-mediated antigen retrieval 
Slides were placed in an oven at 60°C for a minimum of 12 hours to melt the 
wax. Wax was then removed from the slides by placing in a slide rack and 
immersing in Citroclear (National Diagnostics, Charlotte, NC, USA) for 3-5 
minutes. The slides were then dehydrated by immersing 10 times in each of 
three sequential alcohol baths before placing in water for a final minute.   
A slide box was filled with antigen retrieval buffer (25ml sodium citrate buffer, 
pH6.0), 225 ml de-ionised H2O), placed in the centre of a microwave pressure 
cooker containing 600ml of de-ionised H2O before pre-heating in the microwave 
for ten minutes at maximal temperature. Slides were then transferred to the 
pre-heated antigen retrieval buffer; the pressure cooker sealed and heated in 
the microwave at maximal temperature for 3-4 minutes until the correct 
pressure was reached, then heated for a further 2 minutes at the correct 
pressure before cooling for 20 minutes. Once cooled antibodies were applied. 
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(For sections to be stained with p16 antibody, heat mediated antigen retrieval 
was carried out in a boiling bath according to the manufacturer’s instructions 
(Dako, UK, Ltd).  
2.2.3.2.2 Immunohistochemical staining of slides 
Sections from each specimen were processed for routine Haematoxylin and Eosin 
staining (H&E).  
Cooled slides were transferred to staining chambers and washed in de-ionised 
H2O for 5 minutes. Endogenous peroxidise was blocked with 2 drops of peroxidise 
block from the appropriate EnVision Kit (Dako) (mouse kit for mouse primary 
antibodies and rabbit kit for rabbit primary antibodies). The reaction was 
allowed to proceed for 5 minutes then terminated by adding buffer Tris/Tween 
and the slides washed for 7 minutes.  
Sections from each specimen were then probed with primary antibodies (150l) 
against the following antigens; Ki-67 (mouse, monoclonal anti-human Ki-67 
antigen, clone MIB-1, Dako), p53, (rabbit, polyclonal anti-human p53, clone CM-
1, Novocastra), p16 (mouse, anti-human p16, CINtec ™ p16INK4a Histology kit, 
Dako), MCM2 and MCM5 (mouse, anti-human MCM2, clone SPM196; mouse anti-
human MCM5, clone SPM197, Panomics), and TopBP1 (rabbit,  polyclonal anti-
human TopBP1, R1180). Antibodies were diluted in buffer TRIS to the correct 
dilution and were used at the following concentrations - Ki67 1:2000; p53 1:500; 
p16 (ready to use); MCM2 1:50; MCM5 1:500; TopBP1 1:1000. A positive control 
was included for each antibody and was a section of archival tissue previously 
shown to have a strongly positive reaction to that antibody. Serial sections in 
each run of slides tested, where the primary antibody was omitted, acted as 
negative controls. For mouse primary antibodies (Ki67, p16, MCM2 and MCM5), 
normal rabbit serum applied to the slide instead of antibody as a negative 
control. For rabbit primary antibodies (p53 and TopBP1), normal mouse serum 
was used as a negative control.   
Following one hours incubation, slides were washed with Tris/Tween for 7 
minutes, before applying two drops of the appropriate mouse or rabbit 
secondary antibody (Dako, UK Ltd). The secondary antibody was left on for 50 
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minutes before washing with tris/Tween for 7 minutes then washing with 
distilled water for three minutes before a final wash for seven minutes.  
100l of 3,3’-diaminobenzidine (DAB)/substrate-Chromogen mix was applied to 
each slide [1ml of (DAB + substrate buffer) + 1 drop of (DAB+ chromogen), 
EnVision™ Kit, Dako, UK, Ltd] and the reaction allowed to proceed for ten 
minutes.  
The slides were then counter-stained with Haematoxylin for one minute and 
then re-hydrated by dipping in acid alcohol and transferred to a water bath then 
to Citroclear prior to mounting. Coverslips were attached with Vectabond™ 
Reagent and left to dry on a hot plate overnight.  
Sections were analysed using a Leitz Wetzlar microscope. 
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2.2.4 Molecular Biology 
2.2.4.1 Agarose Gel Electrophoresis 
Agarose gel electrophoresis was carried out in 1- 1.5% agarose gels depending on 
the predicted size of the sample DNA. The appropriate weight of electrophoresis 
grade agarose (Eurogentec Ltd) was dissolved by heating in1xTBE Buffer (10x 
TBE: 900mM Tris base, 900mM boric acid, 25mM EDTA, pH8.0).  The solution was 
cooled to approximately 50ºC then, for a 100ml solution, 2.5ul of Ethidium 
Bromide (10mg/ml) was added before pouring into a gel cast and cooling to set. 
Once set the gel was placed into an electrophoresis tank and submerged in 
1xTBE buffer (see above). 5l of sample was mixed with 0.5 - 1l of 10x loading 
buffer (65% (w/v) sucrose, 10mM Tris-HCl, pH7.5, 10mM EDTA, pH8, 0.3% (w/v) 
bromophenol blue). The samples were then loaded into wells alongside a 100bp 
ladder (Invitrogen) as a molecular weight marker. The sample DNA was 
separated by electrophoresis at 100V for sufficient time to allow bands and sizes 
to be easily distinguishable. The DNA was then visualised by UV light and 
photographed using a UV gel documentation system (Syngene GeneFlash).  
2.2.4.2 DNA/RNA Concentration Determination 
To measure the DNA or RNA concentration, samples were measured on a 
Nanodrop (ND-1000 Spectrophotometer) according to the manufacturer’s 
instructions. 
2.2.4.3 DNA Purification using Phenol Chloroform 
2.2.4.3.1 Replication assays 
500l of Phenol Chloroform was added to each sample before vortexing to 
produce an emulsion then centrifuging for 20 minutes, 15000g at 4°C. The upper 
aqueous layer was removed to a fresh 1.5ml microcentrifuge tube, the lower 
organic layer and interface discarded and the above steps repeated before 
precipitating DNA with ethanol.  
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2.2.4.3.2 Site directed mutagenesis 
Small volume samples volumes were completed to 200l with distilled water 
before adding one volume of Phenol Chloroform. The sample was vortexed well 
to produce and emulsion before centrifuging for 10 minutes, 15000g at room 
temperature. The upper aqueous layer was removed to a fresh microcentrifuge 
tube and the lower organic layer and interface discarded before precipitating 
DNA with ethanol.  
2.2.4.4 Ethanol precipitation of DNA 
After DNA purification with Phenol Chloroform, DNA was precipitated with 
Ethanol. To each sample, one tenth the sample volume of 3M Sodium Acetate 
pH5.2 and 2.5 x the sample volume of 100% ethanol were added and the sample 
incubated at -20ºC for 10 minutes to two hours. Samples were then centrifuged 
at 15000g for 20 minutes at 4ºC, the ethanol removed and the pelleted DNA 
washed with 2x the sample volume of 70% Ethanol. Samples were centrifuged a 
final time at 15000g for 10 minutes at 4ºC before removing the ethanol and 
drying the DNA pellet. The pelleted DNA was then re-suspended in distilled 
water. 
2.2.4.5 Cloning 
2.2.4.5.1 Platinum Pfx DNA polymerase PCR 
DNA was amplified by PCR using the Platinum Pfx DNA polymerase protocol. PCR 
reactions were carried out in a reaction volume of 50µl. For each reaction, 2ng 
of template DNA was added to 10µl of 10x Pfx amplification buffer, 10mM dNTP 
mixture (dATP, dGTP, dCTP and dTTP), 3µl of forward primer (1:10), 3µl of 
reverse primer (1:10), 0.6µl of Platinum® Pfx DNA polymerase and 28.4µl of 
distilled water. Amplification was carried out using a MJ research PT200 gradient 
cycler. The cycle conditions were 94 ºC for 5 minutes (denaturation step), 94ºC 
for 25 seconds (denaturation step), 55 ºC for 30 seconds (annealing step) and 68 
ºC for 3 minutes (elongation step). After repeating the cycle 28 times the 
reaction underwent 68ºC for 10 minutes before being maintained at 4 ºC.  
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The PCR product was cleaned up using the QIAquick PCR Purification kit (Qiagen) 
before digesting with restriction digest enzymes. 
2.2.4.5.2 Restriction Enzyme Digests 
The DNA insert and the vector were digested with restriction enzymes. 10l of 
the insert or vector to be digested was mixed with 1l of each restriction 
enzyme, 5l of the appropriate restriction enzyme buffer, 0.5l of bovine serum 
albumin (BSA) and distilled water to a final volume of 50l and incubated for 
three hours at 37ºC. The insert was then cleaned up again (QIAquick PCR 
Purification kit (Qiagen)) and the vector was gel purified as described below. 
2.2.4.5.2 Gel Extraction 
Restriction digest products were purified using the QIAQuick Gel Extraction Kit 
(Qiagen). Restriction digest products were separated over 2 hours at 50V by 
Agarose gel electrophoresis. The gel was visualised under low UV light and the 
area of gel containing the DNA to be purified was cut out, placed in a sterile 
microcentrifuge tube and weighed. Three volumes of Buffer QG were added to 
the gel before incubating at 50°C for 10 minutes, vortexing every two to three 
minutes, until the gel had dissolved. One gel volume of isopropanol was added to 
the sample and mixed. The sample was then applied to a QIAquick column in a 
2ml collection tube and centrifuged for one minute at 13000g, the flow through 
was discarded, 0.5ml of Buffer QG was added and the column centrifuged again 
for 1 minute. The column was then washed by the addition of 0.75ml of Buffer 
PE and centrifuging again for one minute. The flow through was discarded and 
the centrifugation step repeated before placing the column in a clean 1.5ml 
microcentrifuge tube. To elute the DNA, 50l of Buffer EB was added and the 
column centrifuged for one minute at 13000g. The purified DNA was then stored 
at -20°C until further use.  
2.2.4.5.3 Phosphatase Treatment 
After restriction digest, cut vectors were de-phosphorylated to prevent vector 
re-ligation. 2l of Shrimp Alkaline Phosphatase (SAP) (Roche) and 10l of 10xSAP 
Buffer (Roche) was added to the restriction digest and incubated at 37ºC for 30 
minutes before heat inactivating the Phosphatase at 65ºC for 10 minutes. The 
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samples were then purified with the QiaQuick PCR Purification Kit (Qiagen) as 
described. 
2.2.4.5.4 Ligation of DNA 
After restriction enzyme digests and dephosporylation of the vector, DNA inserts 
and vector were ligated. 1l of DNA insert, 3l of dephosporylated vector, 5l of 
ligase (Takara DNA ligation kit solution 1) and 1l of distilled H20 was added to a 
sterile 1.5ml microcentrifuge tube. The reaction was incubated at 16°C 
overnight.  The next day, DH5™ chemically competent bacterial cells 
(Invitrogen) were transformed with 5l of the ligation reaction and controls.  
Colonies were picked the following day and small scale preparation of plasmid 
DNA (miniprep) carried out using the QiaPrep Spin Miniprep Kit. DNA was then 
amplified (ABI cycle sequencing protocol) and sequenced with the appropriate 
primers. 
2.2.4.6 Transformation of Chemically Competent Bacterial Cells 
DH5α™ chemically competent bacterial cells (Invitrogen) were transformed. 5µl 
of a ligation reaction was added to 50µl of bacterial cells in a sterile 1.5ml 
microcentrifuge tube and incubated on ice for 30 minutes. Cells were then heat 
shocked at 42ºC for 1 minute then incubated on ice for a further 1 minute. 200µl 
of S.O.C. medium (Invitrogen) (25ml bactotyrptone, 0.5% yeast extract, 10mM 
NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4 and 20mM glucose) was added to 
each sample before incubating at 37ºC shaking for 1 hour. After incubation, 
samples were plated onto Ampicillin containing agar plates, inverted and 
incubated overnight at 37ºC. Single colonies were picked the following day and 
grown in 3-5ml of Ampicillin containing L-Broth for 6-8 hours at 37ºC whilst 
shaking.  One ml of the bacterial culture was transferred to a conical flask 
containing 100ml Ampicillin containing L-Broth overnight and incubated at 37ºC 
whilst shaking prior to preparation of plasmid DNA.  
2.2.4.7 Large Scale Preparation of Plasmid DNA (Maxiprep) 
Plasmid DNA was purified using the PureLink™ HiPure Plasmid DNA purification 
Kit (Invitrogen) according to the manufacturer’s instructions. Briefly, bacterial 
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colonies containing plasmid DNA were picked and grown for eight hours in 5ml of 
Ampicillin containing L-Broth at 37ºC whilst shaking (200rpm). 1ml of a 5ml 
bacterial culture was used to inoculate a 200ml conical flask containing 200ml of 
Ampicillin containing L-Broth and incubated overnight at 37ºC whilst shaking 
(200rpm). The HiPure Maxi column was equilibrated with 30ml of Equilibration 
buffer (EQ1). Bacterial cells were pelleted by centrifugation at 5000g for 10 
minutes at room temperature and the resultant supernatant discarded. The 
bacterial pellet was re-suspended in 10ml of Resuspension Buffer (R3) containing 
RNase by pipetting before adding 10ml of Lysis Buffer (L7) and gently mixing by 
inverting the capped tube five times. The lysis reaction continued for five 
minutes at room temperature before adding 10ml of Precipitation Buffer (N3) 
and mixed gently by inversion until the solution was homogeneous. The solution 
was then centrifuged at 5000g for 30 minutes at room temperature and the 
supernatant loaded onto the equilibrated column and allowed to drain by 
gravity. The column was then washed with 60ml of wash Buffer (W8) and 
allowed to drain again by gravity. The column was then placed into a 50ml 
centrifuge tube, 15ml of Elution Buffer (E4) (pre-warmed to 37ºC) was added to 
the column and the eluted DNA drained by gravity into the centrifuge tube. 
10.5ml of isopropanol was then added to the elution tube and mixed well to 
precipitate the DNA before centrifuging at 5000g for one hour at 4°C.  The 
supernatant was removed and 5ml of 70% Ethanol added to the pellet before 
centrifuging again at 5000g for 30 minutes. Most of the supernatant was removed 
then the pellet and any residual ethanol transferred to a sterile 1.5ml Eppendorf 
tube before centrifuging at 15000g for 30 minutes. Any residual supernatant was 
removed and the pellet allowed to air dry before re-suspending in 200-500l of 
TE buffer according to the size of the pellet. Plasmid DNA was stored at -20°C 
until further use.  
2.2.4.8 Small Scale Plasmid Purification (Miniprep) 
Small scale plasmid DNA was purified using the QiaPrep Spin Miniprep Kit 
(Qiagen). Bacterial colonies containing plasmid DNA were picked and grown 
overnight in 5ml of Ampicillin containing L-Broth at 37ºC whilst shaking 
(200rpm).1ml of bacterial culture was transferred to a 1.5ml Eppendorf tube and 
centrifuged at 15000g for 5 minutes at room temperature. The supernatant was 
removed and the pelleted cells were re-suspended by pipetting in 250µl of 
97 
buffer P1. To lyse the cells, 250µl of buffer P2 was added and the sample mixed 
by inverting the tube five times then incubating at room temperature for 5 
minutes. To precipitate the sample, 350µl of buffer P3 was then added, the 
sample mixed by inversion again before centrifuging again at 15000g for 10 
minutes at room temperature. The supernatant was applied to a QIAprep spin 
column centrifuged for 60 seconds, the flow through discarded before washing 
the column with 750µl of buffer PE and centrifuging again for 60 seconds. The 
flow through was discarded and the centrifugation step repeated to remove 
residual wash buffer before placing the column into a clean 1.5ml 
microcentrifuge tube and eluting the DNA by adding 50µl of buffer EB to the 
centre of the column, allowing to stand for one minute before centrifuging for 
one minute at 15000g then discarding the spin column.    
 
2.2.4.9 Quantitative PCR 
To analyse the replication assays by quantitative PCR (qPCR), a standard curve 
was prepared using plasmids containing the HPV-16 or HPV-8 origin of replication 
(pOri). The following serial dilutions of pOri prepared: 10pg/l, 1pg/l, 
0.1pg/l, 0.01pg/l, 0.001pg/l, 0.0001pg/l and 0.00001 pg/l. 10l of each 
standard was added to each well thereby creating a standard curve ranging from 
100pg to 0.0001pg of DNA per well. 100pg of DNA per well on the standard curve 
equated to 1.8 x 107 viral copies and the lowest dilution of 0.0001pg DNA per 
well equated to 1.8 viral copies.  
The probe and primer set for HPV16 had previously been determined in the 
Morgan Laboratory using the Primer Express software. The probe and primer set 
for HPV was designed using the primer express software by L. Mackintosh and E. 
Dornan. Probes and primers were designed using Primer Express. Probes were 
stored at a concentration of 100M and were diluted to a concentration of 5M 
before use. Primers were stored at a concentration of 100pmol/ml and reverse 
primers were diluted 1:10 before use to a final concentration of 10pmol/ml. All 
reactions were prepared in a Microflow PCR workstation with UV 
decontamination (Astec Microflow Ltd). A master mix was prepared containing 
12.5l Brilliant® QPCR Master Mix (Stratagene), 0.5l Reference dye 15M 
(Stratagene), 0.25l forward primer, 0.25l reverse primer, 0.5l probe DNA and 
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6l distilled water. 5l of sample DNA, standard or no template control (distilled 
H2O) was used per reaction giving a final sample volume of 25l. Each sample 
was analysed in triplicate, each standard in duplicate and one non-template 
control (distilled H20) in quadruplicate. Each triplicate, duplicate or 
quadruplicate was prepared in a single tube and the appropriate amount of 
master mix added to each tube thereby eliminating a source of variability. Each 
sample was then pipetted into individual wells on a PCR plate.  
Samples were then run on an ABI 7500 machine and the results analysed against 
the standard curve using the Applied Biosystems 7500 sequence detection 
systems version 1.2.2 software.  
2.2.4.10 PCR Purification 
PCR products were purified with the QIAquick PCR Purification kit (Qiagen). To 
100µl of PCR product, 500µl of buffer PBI was added and mixed. All 
centrifugation steps were carried out at 15000g at room temperature. The 
sample was applied to a QIAquick column in a 2 ml collection tube and 
centrifuged for 1minute. The flow through was discarded and the column washed 
by adding 750µl of buffer PE and centrifuging for 1 minute before discarding the 
flow through and centrifuging for a further 1 minute. The column was placed in 
a clean 1.5ml microcentrifuge tube and the DNA eluted from the column by 
adding 30µl of buffer EB to the QIAquick membrane and centrifuging the column 
for 1 minute. The purified DNA was then stored at -20ºC.  
2.2.4.11 Site Directed Mutagenesis 
In a sterile 0.5ml PCR reaction tube, 1µl of 100ng/µl template DNA and 1µl 10µM 
each of the forward and reverse primers was mixed with 5µl 10x KOD Buffer 
number 1, 5 µl 2mM dNTPs, 4µl 25mM MgCl2, 1µl DMSO, 1µl KOD polymerase and 
the reaction was completed to 50µl with distilled H2O. PCR was carried out on a 
MJ research PT200 gradient cycler with the following conditions: 94 ºC for 5 
minutes (denaturation step), 94ºC for 15 seconds (denaturation step), 60 ºC for 
30 seconds (annealing step) and 72ºC for 20 seconds per Kilobase (Kb) 
(elongation step). After repeating the cycle a further 17 times, a final step of 
72ºC for 5 minutes was performed before being maintaining the reaction at 4 ºC. 
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The PCR product was then transferred to a clean 1.5ml microcentrifuge tube. To 
digest the DNA, 1µl of Dpn1 was added and the sample incubated at 37ºC for 90 
minutes. 150µl of distilled H2O was added to them sample before carrying out 
Phenol Chloroform extraction and Ethanol precipitation of DNA as described 
earlier. The pelleted DNA was re-suspended in 15µl of distilled H2O.  
5µl of the resultant mutated DNA was then transformed into 100µl of DH5™ 
chemically competent bacteria (Invitrogen) using the method described above. 
Single colonies were picked after 16 hours and placed in a sterile 5ml Bijoux 
container with 3-5ml of Ampicillin containing L-Broth solution. Samples were 
incubated at 37ºC whilst shaking (200rpm) for 16 hours. 1ml of the sample was 
then transferred to a sterile 1.5ml microcentrifuge tube and centrifuged at 
15000g for 30minutes at 4ºC to pellet the bacteria. The supernatant was 
removed and small scale preparation of plasmid DNA (miniprep) procedure 
carried out as described above. 
DNA was then amplified and sequenced to check for mutations (described 
below). 
2.2.4.12 DNA Sequencing 
DNA was amplified using the ABI Prism BigDye Terminator v 3.1 Cycle sequencing 
kit (Applied Biosystems). For each sample of plasmid DNA a primer 
complementary to the area of interest was used. 6l of the DNA to be sequenced 
was placed in a 1.5ml PCR tube and 2l BigDye, 4l BigDye Buffer, 2l of the 
appropriate primer and 6l distilled water were added.  After an initial step of 
95ºC for 4 minutes the samples were heated to 95 ºC for 10 seconds, 50ºC for 5 
seconds and 60 ºC for 4 minutes and the cycle was repeated 25 times before 
heating to 60 ºC for 4 minutes. The samples were then held at 4 ºC until 
required.  
Cell cycle reactions were purified by adding each sample to a 1.5ml 
microcentrifuge tube containing 16l of distilled water and 64l of 95% ethanol 
before mixing and incubating at room temperature for 15 minutes. Each sample 
was then centrifuged at 15000g for 20 minutes at 4ºC. The supernatant was 
removed and discarded before adding 250l of 70% ethanol to the pelleted DNA. 
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Samples were centrifuged at 15000g for 10 minutes at 4 ºC, the resultant 
supernatant aspirated and discarded and the pelleted DNA dried for 1-2 minutes 
on a heating block at 70ºC. The DNA pellet was re-suspended in 25l of HiDi 
Formadide and transferred to a PCR plate.  Plasmids were sequenced using an 
Applied Biosystems 3100 automated sequencer and the sequences analysed with 
the Chromas Lite version 2.01 software (Technelysium Pty Ld). 
2.2.4.13 BCA/CuSO4 Assay 
To assess the concentration of protein extracts, BSA protein standard solutions 
were prepared from powdered BSA to the following concentrations – 2000, 1000, 
500, 400, 200, 100, 80, 50µg/ml. 10µl of each standard, 10µl of ddH2O, 10µl of 
each protein lysate to be measured (both neat lysate and at a 1:10 dilution) 
were loaded into a 96 well Elisa plate. 200µl of developing solution (5ml 
Bicinchonic Acid (BCA) (Sigma) and 100µl Copper II Sulphate pentahydrate 4% 
(V/V) solution (Sigma)) was added to each occupied well. The plate was then 
incubated at 37ºC for 30 minutes before the absorbance was measured at 562nm 
(Multiskan Acent reader and software, Labsystems). The absorbance readings for 
the BSA standards were used to derive a standard curve from which the protein 
concentrations of the lysates were calculated. 
2.2.4.14 Western Blotting 
The protein concentrations of the lysates to be assessed were determined using 
a BCA/CuSO4 assay as described. Equal amounts of protein (typically 15-30µg) 
from each lysate was added to a micro-centrifuge tube before adding 4l 
NuPage™ sample loading buffer (4X) and 2l NuPage™ sample reducing agent 
(10X) (Invitrogen). Samples were heated to 70ºC for 10 minutes. Pre-cast, 4-12% 
gradient SDS-PAGE gels (Invitrogen) (either 10 or 12 wells) were placed into a gel 
tank filled with 1xMES running buffer. 400µl of 10X antioxidant (Invitrogen) was 
added to the running buffer before loading the samples. 8µl of See-Blue® kDa 
marker (Invitrogen) was added to the first well as a marker and the samples 
loaded into the wells using fine pipette tips. Gels were run at 200V for one hour. 
The buffer was then discarded and the gel cast carefully cracked open and the 
top plate removed leaving the gel in place. The gel was washed in transfer 
buffer while gently shaking at room temperature for 10 minutes (8ml NuPage® 
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Transfer Buffer (20X) (Invitrogen), 20ml methanol and 172ml distilled water). 
The gel was then transferred to a nitrocellulose membrane using the Iblot dry 
transfer method (Invitrogen) according to the manufacturer’s instructions.  
Following transfer, the membrane was incubated with 5% milk- PBS-T (5% non-
fat milk, 1xPBS 0.1% Tween) whilst gently shaking at room temperature for 1 
hour to remove any non-specific bands.  The milk – PBS-T solution was removed 
and the primary antibody prepared to an appropriate dilution in 5% milk- PBS-T 
was applied and the membrane incubated for one hour at room temperature 
while gently shaking. The antibody was removed and the membrane washed in 
PBS-T for 15 minutes followed by three five minute washes at room temperature 
whilst gently shaking. The secondary antibody at an appropriate dilution in 5% 
milk- PBS-T was added to the membrane and incubated for one hour at room 
temperature whilst gently shaking. The secondary antibody was removed and the 
membrane washed as above. The proteins were detected using ECL-plus (GE 
Healthcare). 2ml of detection reagent A and 50µl of detection reagent B were 
mixed, added to the membrane and incubated for 5 minutes at room 
temperature. The excess developing solution was removed and the membrane 
wrapped in Saran wrap, placed into a film cassette and developed with x-ray 
hyperfilm (Amersham). 
2.2.4.15 Stripping Membranes 
Nitrocellulose membranes were stripped to remove traces of previously used 
antibody before re-probing. 10mls of 0.2M NaOH was added to the membrane 
and incubated for 15 minutes at room temperature whilst gently shaking. The 
NaOH was removed and the membrane washed in PBS-T for 15 minutes then 5 
minutes three times. The membrane was then blocked in 5% milk-PBS-T for one 
hour at room temperature whilst gently shaking before the new primary 
antibody was applied. 
2.2.4.16 Immunoprecipitation 
Cell lysates were harvested as described (2.2.5.3). All centrifugation steps 
described below were carried out at 80g at 4°C.  
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Protein A Sepharose beads (Sigma) were transferred to a sterile 1.5ml 
microcentrifuge tube and centrifuged for 1 minute. The supernatant was 
removed and the beads were washed in 1 volume of Lysis buffer (0.5% NP40, 
150mM NaCl, 50mM Tris pH 8.0). This step was repeated four times. Beads were 
stored at 4°C until further use (unblocked beads). The procedure was repeated 
with a second microcentrifuge tube of beads and, after the final wash, one 
volume of 1% BSA (Sigma) in PBS was added to the beads which were then 
incubated whilst rotating, overnight at 4°C.  Beads were then washed with an 
equal volume of Lysis buffer four times and re-suspended in one volume of lysis 
buffer after the final wash and stored at 4°C until further use (blocked beads).  
Lysis buffer was chilled to 4°C, samples and beads were kept on ice unless 
otherwise stated. 100l of cell extract containing 200g of protein was added to 
a sterile 1.5ml microcentrifuge tube, 10l of unblocked beads were added and 
the bead/protein mixture incubated for one hour rotating at 4°C. The sample 
was centrifuged and the supernatant removed to a fresh microcentrifuge tube. 
2l the appropriate antibody was added and incubated whilst rotating at 4°C for 
one hour. 20l of blocked beads were then added to each sample before 
incubating for one hour whilst rotating at 4°C. Beads were then washed with 
500l of Lysis Buffer four times. After the final wash, lysis buffer was removed 
leaving a residual 5l. 2l of NuPage sample reducing agent and 5l of NuPage 
LDS sample buffer (Invitrogen) was added to the beads before heating at 70°C 
for ten minutes. Samples were then separated on a SDS-PAGE gel, 200V for 1 
hour and the proteins detected by Western Blotting.  
2.2.4.17 Preparation and purification of GST Fusion Proteins 
To induce GST fusion proteins, 3ml of Ampicillin containing L-Broth was 
inoculated with a single bacterial colony containing the plasmid DNA and grown 
overnight at 37ºC whilst shaking. Next morning 1ml of bacterial culture was 
inoculated into 100ml of Ampicillin containing L-Broth and grown for 3 hours at 
37ºC whilst shaking following which the optical density was measured. 
Incubation continued until the optical density reached the desired level. IPTG 
was added to give a final concentration of 1mM and the culture was incubated 
for a further 1hour at 37ºC whilst shaking before spinning the culture at 5000g 
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for 5 minutes and discarding the supernatant. The bacterial pellet were then 
stored at -80º until further use.  
To lyse the bacteria, pellets were then re-suspended in 2ml of ice-cold 1% 
triton-X-100 in PBS containing one protease inhibitor tablet per 10ml of solution. 
The sample was then subjected to 10 cycles of sonication (30seconds on, 30 
seconds off) at the high setting keeping the samples on ice throughout. 
Following sonication, 3mls of ice-cold 1% Triton-X-100 in PBS was added to each 
sample to bring the sample volume to 5mls before spinning for 10 minutes at 
12000g at 4ºC. The resultant supernatant was transferred to a fresh 15ml falcon 
tube and the cell debris discarded. 500l of GST-Fast Sepaharose beads were 
added to each sample and incubated for 1 hour at 4ºC whilst the rotating the 
sample.  The samples were spun at 500g at 4ºC for 2 minutes to bring the beads 
to the bottom of the tube than the supernatant was discarded and the beads 
washed with 10ml of 1% Triton-X-100. This step was repeated 5 times. 1ml of 1% 
Triton-X-100 was added to the final pellet and the beads were transferred to a 
clean 1.5ml Eppendorf tube. 100ul of beads from each sample was then 
transferred to a second clean 1.5ml micro-centrifuge tube. GST fusion proteins 
were cleaved from the beads by adding 3 X volume of Thrombin (80l in 920l 
PBS) to the beads and incubating overnight whilst rotating at 4°C. The remaining 
beads were spun at 80g for 2 minutes, the supernatant removed and 500l of 
glycerol was added to the sample before storing at -80ºC. 
2.2.4.18 Coomassie Blue Staining 
To assess the quantity of protein induced, 100l of beads retained from each 
sample was spun at 80g, 4ºC for 2 minutes, the supernatant removed before 
adding 2l of sample reducing agent and 5l off LDS sample buffer. Samples 
were then heated at 70ºC for 10 minutes to separate the proteins from the 
beads. The sample was spun briefly before loading the supernatant onto a 4-12% 
gradient SDS gel. To separate the proteins the gel was run for 1 hour at 200V 
then transferred to a gel tank and covered with Coomassie Blue. The 
gel/Coomassie Blue solution was then heated in the microwave until the solution 
reached boiling point then incubated shaking at room temperature for 1 hour. 
The Coomassie Blue was removed, the gel rinsed briefly with water twice, then 
immersed in 20% NaCl solution to de-stain and incubated at room temperature 
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whilst gently shaking overnight. The gel was then visualised and photographed 
on a light box. 
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2.2.5 Tissue Culture 
2.2.5.1 Maintenance of cells in culture 
All cell culture work was carried out in a tissue culture laboratory under strict 
sterile conditions. Cell culture work was performed inside a flow hood (Class II 
Microbiology Safety cabinets, Gelaire, BSB4).  
293T, MCF7, and U2OS cell lines were grown in DMEM (1x) 
+w/GlutaMAX™/Glucose NaPyr, 10%FCS, 1% Penicillin/Streptomycin. U2OS B3 and 
4.1 cell lines were grown in DMEM (1x) +w/GlutaMAX™/Glucose NaPyr, 10%FCS, 
G418 (600g/ml). HaCaT cells were grown in calcium free DMEM (1X) High 
Glucose, 10%FCS, 5ml L-Glutamine 200mM (100x), 1% Penicillin/Streptomycin.  
All cell lines were grown in an atmosphere containing 5% CO2 (v/v) (Napco model 
5410, Napco Scientific). Cell lines were split 1/10 twice weekly.  
2.2.5.2 Transient Cell Transfection 
Cells were plated in monolayer at the appropriate density and transient 
transfection performed 24 hours later. 
2.2.5.2.1 Calcium Phosphate Transient Transfection 
The appropriate amount of the DNA of interest was added to a sterile 1.5ml 
microcentrifuge tube and completed to 375l with distilled water. 125l of 1M 
Calcium Chloride was added and vortexed for one minute to mix. This 500l 
solution was then added drop wise whilst vortexing to a sterile 5ml Bijoux 
containing 500l of 2x HEPES buffered saline (2xHBS) (8g NaCl, 0.37g KCl, 0.135g 
1.5mM Na2HPO4.2H2O, 1g Dextrose, 5g HEPES, completed to 500ml with 
distilled H2O and adjusted to pH 7.05 with a few drops of 0.1M NaOH). The 
solution was left to incubate at room temperature for approximately 15 minutes 
until a precipitate was formed. The solution was then added to the cell 
monolayer drop wise and the cells returned to the incubator. After 16 hours, the 
media was removed from the cells which were then washed twice with 5-10mls 
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of PBS before adding an appropriate volume of fresh media and returning the 
cells to the incubator for a further 24 hours.  
2.2.5.2.2 Lipofectamine 2000™ Transient Transfection 
For siRNA treatment of HaCaT and MCF7 cells, transient transfection was carried 
out with Lipofectamine 2000™.  
Cells were trypsinised and washed twice in PBS. Cells were re-suspended in 
antibiotic free media and counted. In sterile 1.5 ml microcentrifuge tubes, two 
transfection solutions were prepared; firstly 2.5l of the desired 
oligonucleotides (siTopBP1 or siLuciferase, Dharmacon) was added to 497.5l of 
Optimem (Invitrogen) and secondly, 15l of Lipofectamine 2000™ (Invitrogen) 
was added to 485l of Optimem. The two separate cocktails were incubated at 
room temperature for 5 minutes before mixing and incubating for a further 20 
minutes at room temperature.  For mock transfected cells, the oligonucleotide 
was omitted. For no treatment plates, both the oligonucleotide and 
Lipofectamine 2000™ were omitted.  
Following the incubation, the desired volume of cells were added to the 
Optimem/Lipofectamine 2000™/oligonucleotide solution, and seeded onto tissue 
culture plates then incubated at 37°C 5% CO2 (v/v). The next day, media was 
aspirated, the plates washed with 1xPBS 5-10mls twice and fresh antibiotic 
containing media applied.  
2.2.5.3 Preparation of Protein Extracts 
For the detection of protein by Western Blotting, cells grown in monolayer were 
washed with 10ml of PBS twice before adding 1ml/4ml of Trypsin to a 
60mm/100mm cell culture plate and incubated at 37.5ºC 5% CO2 (v/v) for 5-15 
minutes. 5/10ml of fresh cell culture medium was added to the plate before 
aspirating and transferring to a 15ml centrifuge tube and spinning at 80g for 5 
minutes at room temperature. The resultant cell pellet was washed with 10ml of 
PBS and spun at 80g for 5 minutes at room temperature. The PBS was aspirated 
and the pellet re-suspended in 100-150µl of lysis buffer (0.5% NP40, 150mM 
NaCl, 50mM Tris pH 8.0 containing 1/10 volume protease inhibitor cocktail 
tablet). The lysate was transferred to a microcentrifuge tube and incubated on 
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ice for 30 minutes before centrifuging at 15000g for 30 minutes at 4ºC. The 
resultant supernatant containing the cell proteins was then transferred to a new 
microcentrifuge tube and stored at -80ºC until required.  
2.2.5.4 Replication Assays 
293T cells were plated onto 100mm tissue culture plates at a concentration of 
6x105 cells per plate. After 24 hours, cells were transiently transfected with the 
DNA(s) of interest by calcium phosphate transfection. Sixteen hours following 
transfection, cells were washed twice with 10ml of 1xPBS and fresh media 
applied. On day four post transfection cells were harvested by washing each 
plate twice with 5mls of PBS then adding 800l of HIRT solution (0.6% SDS, 10mM 
EDTA) to each plate to lyse the cells.  After a 10 minute incubation at room 
temperature the resultant lysate was scraped into a clean 1.5 ml 
microcentrifuge tube containing 200µl of 5M NaCl. The samples were gently 
vortexed and stored at 4ºC overnight. Next day samples were centrifuged for at 
15000g at 4ºC for 30mins and the supernatant removed to a fresh 1.5 ml 
microcentrifuge tube. Samples were then extracted with Phenol Chloroform 
(2.2.4.3.1) twice before ethanol precipitation was carried out (2.2.4.4).  
Pelleted DNA was re-suspended in 20l of distilled H2O. DNA was digested with 
Dpn1. To each 20l DNA sample, 5l of NEB Buffer1, 0.5l BSA, 2l Dpn1 and 
22.5l of distilled H2O water was added and the samples incubated at 37°C 
overnight. 
The next day, samples were digested with EXO III by adding 1l of EXO III to each 
sample and incubating at 37°C for 90 minutes. EXO III was then heat inactivated 
at 70°C for 30 minutes and the samples allowed to cool before analysis by qPCR 
(2.2.4.9).  
2.2.5.5 Luciferase Assay 
Luciferase assays were carried out in 293T cells. All assays were carried out in 
duplicate on 60mm cell culture plates. 3x105 293T cells were seeded onto each 
plate and transiently transfected with the DNA(s) of interest 24 hours later by 
the CaPO4 method (2.2.5.2.1). After 16 hours cells were washed twice with 5ml 
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of 1xPBS and fresh media applied. 48 hours following transfection, cell culture 
media was aspirated and the cells washed twice with 2ml of sterile PBS. The PBS 
was removed by aspiration. 300µl of 1 x reporter lysis buffer (Promega) was 
added to each plate and incubated at room temperature for 10 minutes. Cells 
were scraped off the culture plate with a cell scraper directly into a 1.5ml 
microcentrifuge tube. The lysates were centrifuged at 15000g at 4ºC for 10 
minutes to pellet the cell debris. The resultant supernatant was transferred to a 
fresh 1.5ml microcentrifuge tube.  
Luciferase activity was determined using a luminometer with an automatic 
injection (Luminoskan Ascent- Thermo Labsystems). 80µl of each lysate was 
added to a 96 well Fluoro flat bottom microplate (Nunc) and 80µl of Luciferase 
assay buffer (Promega) used at a 1:2 dilution was automatically injected into 
each well.  
2.2.5.6 Cycloheximide Treatment Time Course 
For time course experiments, 293T (6x105 cells) or U2OS (6x105 cells) cells were 
plated onto 10cm cell culture plates containing 10mls of cell culture medium 
and incubated at 37.5ºC 5% CO2 (v/v) for 24 hours.  
Cycloheximide ready made solution 1mg/ml (Sigma) was diluted with cell culture 
media to a concentration of 100g/ml. Cell culture media was aspirated from 
cells plates and replaced with 10mls of the Cycloheximide/cell culture media 
mix at different time points. Cell plates were harvested in unison. Protein 
extracts were prepared as described and analysed by Western Blotting. 
2.2.5.7 Irradiation of Cells with UVB 
Cells were plated in monolayer in cell culture plates. Twenty-four hours later, 
the media was aspirated and the cells washed with 10mls of PBS twice. Cells 
were then treated with UVB (312nM) with varying doses from 0 to 0.050 
Joules/cm2 (J/cm2). Fresh cell culture media was applied and plates were 
incubated at 37ºC 5% CO2 (v/v) for 30 minutes before the cells were harvested 
and protein or RNA extracts prepared as described.  
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2.2.5.8 Crystal Violet Colony Survival Assay 
The colony survival assay provides a measure of cell viability over a 14 day 
period. The cell lines to be assayed and controls were siRNA treated as described 
(2.2.5.2.2). 24 hours following transfection, the cells were washed twice with 
10ml of PBS and fresh medium applied. 48 hours following transfection, cell 
plates were trypsinised, harvested and counted. 500 cells from each cell line and 
controls were plated out in triplicate on a 10cm cell culture plate containing 
10mls of media. The plates were incubated and the media was replaced twice 
weekly. 14 days following transfection, the media was removed and the cells 
washed twice with 10mls of PBS. The surviving colonies were visualised by 
staining with 2mls of 0.5% crystal violet solution (25% methanol, ddH2O) for 20 
minutes at room temperature whilst gently rocking. The plates were then 
washed in tap water until the solution ran clear and the plates were left to dry 
overnight at room temperature. The colonies were then counted. 
2.2.5.9 Cell Growth Assay 
The cell growth assay provided a measure of cell viability. Cell lines and controls 
to be assayed were transfected using Lipofectamine 2000™ as described then 
seeded onto cell culture plates. 24 hours following transfection, cells were 
washed with 5-10mls of 1xPBS twice and fresh media applied. 48 hours following 
transfection, cells were trypsinised, harvested and counted. Each plate was 
counted twice and the average of two counts determined. 2x105 cells from each 
experiment were then plated out in triplicate onto a 60mm cell culture 
containing 5ml of cell culture medium. Following further 48 hours incubation, 
cell plates were again trypsinised, harvested and counted and 2x105 cells plated 
out as described above. After a further 48 hours incubation, cells were 
trypsinised, harvested and counted for the final time. The number of growing 
cells for each cell line and controls was then determined by plotting the mean 
counts of each triplicate set of plates on a graph. At each time point the 
residual cells were retained and protein extracts prepared. The extracts were 
then analysed by Western Blotting to ensure that the gene knockdown persisted 
at each time point. 
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2.2.5.10 Preparation of RNA 
For the gene expression microarray experiments, 6x105 MCF7 cells were 
transfected or mock transfected with si-RNA and seeded onto 60mm tissue 
culture plates. 48 hours later plates were treated or mock treated with UVB and 
harvested by trypsinisation 30 minutes following irradiation. The resultant 
pellets were stored at -80 ºC until required. RNA was extracted from the cell 
pellets using the RNAeasy kit (Qiagen) according to the manufacturer’s 
instructions. Briefly, the cell pellets were thawed, 350µl of buffer RLT was 
added to each pellet, mixed and the resultant lysate pipetted onto a 
Qiashredder spin column in a 2ml collection tube before centrifuging for 2 
minutes at 15000g. 350µl of 70% Ethanol was added to each sample and mixed 
before applying 700µl of the sample to an RNeasy mini column in a 2ml 
collection tube and centrifuging at 15000g for 15 seconds. The flow through was 
discarded, 700µl of buffer RW1 was added to the column before centrifuging at 
10000g for 15 seconds. The flow through was discarded and the column 
transferred to a new 2ml collection tube. 500µl of buffer RPE was added to the 
column, incubated for two minutes before centrifuging at 10000g for 15 seconds. 
The flow through was discarded and a further 500µl of buffer RPE added before 
centrifuging at 15000g for 2 minutes. The RNeasy colum was transferred to a 
new 2ml collection tube and centrifuged for 1minute at 15000g. The column was 
then transferred to a sterile 1.5ml microcentrifuge tube, 50µl of RNase free 
water pipetted directly onto the membrane and the column centrifuged at 
15000g for 1 minute.  
The column was discarded and the RNA treated with DNase to remove any 
residual traces of DNA.  
2.2.5.11 DNAse treatment of RNA samples 
RNA samples were treated to remove any contaminating DNA with the DNA-free™ 
kit (Ambion) according to the manufacturer’s instructions. Briefly, 30µl of the 
RNA sample was taken into 1.5ml microcentrifuge tube. 3l of TurboDNase 
buffer (10x) and 1l of TurboDNase was added to the RNA and gently mixed 
before incubating at 37ºC for 30 minutes. 3.4l of DNase inactivation reagent 
was added to the sample and mix well before incubating at room temperature 
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for 2 minutes then centrifuging at 15000g for 2 minutes.  The resulting 
supernatant was removed to a fresh 1.5ml microcentrifuge tube before 
centrifuging again at 15000g for 2 minutes and again the resultant supernatant 
was removed to a fresh 1.5 ml microcentrifuge tube and stored at -80ºC until 
further use. 
 2.2.6 Microarray 
The raw data in the form of Affymetrix CEL files were generated with Affymetrix 
GCOS software. The further analysis was done with the Partek Genomics Suite 
(http://www.partek.com/).  A full description of the methodology used for 
generating and analysing the microarray data is given in chapter 3.5.  
2.2.7 Statistics 
2.7.1 Epidemiology 
SPSS software package for Windows version 14 (SPSS Chicago, IL, USA) was used 
to analyse the data. The log rank test was used to show significance for the 
Kaplan Meier plots giving an estimate of probability that the three groups are 
not random samples from the same population with respect to actuarial survival. 
A p value of <0.05 was regarded as statistically significant.  
2.7.2 HPV Genotyping  
SPSS software package for Windows version 15 was used to analyse the data by 
logistic regression analysis. The Chi-squared test was used on the overall analysis 
to show significance. P <0.05 was considered to be statistically significant 
2.7.3 Immunohistochemistry 
SPSS software package for Windows version 15 (SPSS Chicago, IL, USA.) was used 
to analyse the data. Fisher’s exact test was used to show significance. P< 0.05 
was considered to be statistically significant. 
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2.7.4 Molecular Biology 
2.7.4.1 Mean and standard error 
The mean +/- the standard error of the mean (S.E.M.) are shown in several 
experiments as a control for experimental reproducibility. The S.E.M. gives a 
measure of the precision of the mean giving a representation of the spread of 
the data, indicating how far the mean of the sample is from the true mean.  
S.E.M. =Standard Deviation 
           [sample number (n)] 
 
2.7.4.2 Statistical Significance 
Statistical significance for the experimental data in this thesis (unless stated 
otherwise) was typically calculated using a Students-T-test to give a significance 
value (p). This was carried out using Microsoft Excell (T-test function). The cut 
off for all experiments was taken as 0.05, therefore if two sets of data return a 
p value of <0.05 there is a less than 5% chance that the observed result is due to 
chance and the two groups are therefore statistically significantly different.  
 
Chapter 3: Results 
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Chapter 3.1 Nonmelanoma Skin Cancer in the West 
of Scotland Renal Transplant Population  
115 
OTRs are now being transplanted at an older age and are surviving longer, 
resulting in an ageing transplant population. Improvements in 
immunosuppressive regimens and transplant techniques have led to better graft 
survival in the short and long term (15) and hence the number of patients on 
long-term immunosuppression is increasing. It is well established that one of the 
consequences of long-term immunosuppression is an increased risk of cancer. 
Transplant patients are reported to have a two to six fold increased risk of 
cancer and the highest risks are for skin cancers(16-18). Skin cancers in 
transplant recipients may be multiple, evolve rapidly, recur and metastasise 
more frequently and exhibit unusual clinical appearances when compared with 
immunocompetent patients. Transplant recipients therefore have an increased 
need for access to Dermatology services. The 2006 document from The National 
Institute for Health and Clinical Excellence (NICE), Improving Outcomes for 
people with Skin Tumours including Melanoma, recommends that transplant 
patients who have pre-cancerous skin lesions or who have developed a skin 
cancer should be seen in a dedicated “transplant patient skin clinic”(1).  
A specialist Dermatology clinic for RTRs was established at the Western 
Infirmary, Glasgow which is the transplant centre for the West of Scotland, in 
2005. The primary aims were to provide a dedicated Dermatology clinic offering 
skin cancer surveillance and education to all RTRs, to provide rapid access to 
Dermatology services for RTRs and to establish close links with transplant 
surgeons and renal physicians to allow for optimal patient management. The 
secondary aim was to collect data on skin cancer within the West of Scotland 
renal transplant population. While data exist for other UK transplant 
populations, few data pertain specifically to the Scottish transplant population. 
The results of this investigation are presented here.  
3.1.1 Age and sex distribution 
610 (374 male, 236 female) patients attended the clinic on at least one 
occasion. The mean age of the population was 50 years (median 49, range 18-
83). The mean age was similar for both male and female patients being 50 and 
49 years respectively. The mean follow up time since first renal transplantation 
was 5 years (median 10, range 0-37 years).   
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3.1.2 Skin type and sun exposure 
Four hundred and twenty-six patients (69.8%) had Fitzpatrick’s skin type I-III (I-
106; II-199; III-121). Of the remaining 184 (30.2%) patients, 20 (3.3%) had skin 
type IV, 29(4.8%) type V and skin type was not recorded in 135 (22.1%). Eleven 
(1.8%) patients had previously used sun beds. Sixty-nine (11.3%) patients had 
lived outwith the United Kingdom for a period of six months or more. On the 
basis of previous and current occupational and recreational sun exposure and 
behaviour patterns in the sun, 314 (51.5%) patients were deemed to have had 
low, 144 (23.6%) patients medium and 80 (13.1%) patients high UVR exposure. In 
the remaining 72 (11.8%) patients, UVR exposure was not recorded.    
3.1.3 Clinical examination 
On examination at the screening visit, 169 (27.7%) patients had viral warts. Only 
palmo-plantar and classical cutaneous warts were documented, plane warts 
were not recorded. 112(18.4%) patients had actinic keratoses or Bowen’s 
disease.  The presence of actinic keratoses or Bowen’s disease was associated 
with non-melanoma skin cancer. Forty-four (47.8%) of patients with skin cancer 
had actinic keratoses present on initial examination compared with 69(13.4%) of 
the non-skin cancer group.  
3.1.4 Skin cancers 
All retrospectively diagnosed skin cancers were recorded as well as those 
diagnosed at the first clinic visit and any subsequent tumours that developed 
within the study period. Of the 610 patients who attended the clinic, 95(15.6%) 
patients had a cutaneous malignancy of whom 68(72%) were male and 27(28%) 
female. 370 cutaneous malignancies were diagnosed, a mean of 3.9 tumours per 
patient (median 2, range 1-40).  
BCC were the most frequently diagnosed tumours. 74(12.1%) of all patients had a 
BCC. There were 208 BCC in total (181 nodular and 27 superficial, mean 2.8 
tumours per patient (range 1-26)). SCC were less common than BCC (42 (7%) of 
all patients had an SCC). There were 151 SCC in total (including 8 
Keratoacanthoma – like SCC), mean 3.6 SCC per patient (range 1-40).  
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The overall SCC: BCC ratio was 0.7. To determine whether the SCC: BCC ratio 
varied with length of follow up, patients with skin cancer were grouped 
according to the era in which they were transplanted (1970-1984, 1985-1994 or 
1995 onwards) (Table 4). There were 10 patients with skin cancer transplanted 
from 1970-1984, the SCC: BCC ratio was 1.1 (mean number of tumours per 
patient 8.5, mean follow up 28.2 years). From 1985-1994 there were 37 patients 
with skin cancer, the SCC: BCC ratio was 0.8 (mean number of tumours per 
patient 3.3, mean follow up 17.2 years). From 1995 onwards there were 43 
patients with skin cancer, the SCC: BCC ratio was 0.5 (mean number of tumours 
per patient 3.5, mean follow up 8.0 years). 
Era of renal 
transplant 
Patients  SCC BCC SCC:BCC 
ratio 
Mean tumours per 
patient 
(median, range) 
Mean follow  
up (years) 
(median, 
range) 
1970-1984 10 45 40 1.1 8.5  
(3.5, 1-40) 
28.2 
(27, 24-37) 
1985-1994 37 56 67 0.8 3.3 
(2, 1-15) 
17.2 
(16, 14-23) 
1995 onwards 43 50 101 0.5 3.5 
(2, 1-40) 
8.0 
(9, 0-13) 
Table 4  The SCC: BCC ratio by era of renal transplantation.  
All patients with skin cancer (n=95) were grouped according to the era in which they were 
transplanted. Five patients who had neither SCC nor BCC were excluded from the analysis. 
SCC and BCC are the number of each tumour per group. The mean number of tumours per 
patient (SCC and BCC only) and mean length of follow up are shown for each era (median, 
range).  
Abbreviations: SCC, squamous cell carcinoma; BCC, basal cell carcinoma. 
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There were eight MM in total including one Lentigo Maligna (LM), one Lentigo 
Maligna Melanoma (LMM) and one Melanoma in situ (MIS). Five (0.8%) patients 
had a melanoma. One patient had four MM, the remaining four patients each 
having a single lesion.  
There were three other skin malignancies; one cutaneous B cell lymphoma which 
had occurred prior to transplantation, and two cases of vulval intraepithelial 
neoplasia III (VIN III). There were no cases of KS, neuroendocrine or appendageal 
tumours. The number and distribution of tumours is summarised in Figure 6.  
 
Figure 6 Number and distribution of cutaneous malignancies.  
Abbreviations: VIN III, vulval intraepithelial neoplasia III. 
 
Thirty-seven (38.9%) patients had a single tumour. Twenty-five patients having a 
single BCC, eight patients a single SCC, two patients had a MM and two patients 
had VIN III. Fifty-eight (61.1%) patients had multiple tumours. Twenty-two 
patients had multiple BCC, seven had multiple SCC, one had multiple MM, 25 had 
a combination of BCC and SCC and three had BCC and/or SCC with MM or 
cutaneous B cell lymphoma.   
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3.1.5 Location of tumours 
Two hundred and thirty-one tumours (62.4%) were located on the head and neck 
area, of which 17 (5.5%) lesions were at high risk sites on the ears (9 BCC and 5 
SCC) and lips (2 BCC and 1 SCC). Fifty tumours (13.5%) were located on the 
trunk, 47 (12.7%) on the upper limbs, 14 (3.8%) on the lower limbs, 2 (0.5%) on 
the vulva. The site was not recorded in the remaining eight (2.2%) lesions. The 
location of skin tumours is summarised in Figure 7.   
Nodular BCC were predominantly located on the head and neck (132 (72.9%) 
head and neck, 24 (13.2%) trunk, 18 (9.9%) limbs, 7 (3.9%) site not recorded). 
Superficial BCC (SBCC) were more likely to be located on the trunk (ten (37.0%) 
head and neck, 16 (59.2%) trunk, one (3.7%) limbs).   
SCC were predominantly located on the head and neck (87 (57.6%), five (3.3%) 
trunk, 58 (38.4%) limbs (47 upper, 11 lower limb), one (0.7%) site not recorded). 
SCC was the only tumour located on the hands.  
Of the eight MM, one (12.5%) was located on the head and neck, five (62.5%) on 
the trunk and two (25.0%) on the limbs.  
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Figure 7 Location of skin tumours.  
Abbreviations, BCC: basal cell carcinoma; SCC, squamous cell carcinoma. 
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3.1.6 Recurrences and metastases 
Within the study period there have been three recurrent SCC. One SCC recurred 
locally and was treated by wide local re-excision. Two patients both with SCC 
occurring on the pre-auricular skin have had tumours metastasising to local 
lymph nodes. Both patients have required extensive surgical excision, lymph 
node clearance, radiotherapy and reduction of immunosuppression.  
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3.1.7 Clinical course 
Of the 610 patients, the date of their first renal transplant was recorded on the 
database for 608 patients (the data were incomplete for the remaining 2 
patients who all had transplants elsewhere and in whom the date of transplant 
was not recorded). Accurate length of follow up data was therefore available for 
608 patients and was taken as date of first transplant to date of death or 
November 2008. Follow-up data was rounded up or down to the nearest year.  
This gave us follow up data for patients on immunosuppression for 5957 patient 
years. The mean follow up time post transplantation was 5 years (median 10, 
range 0-37 years).   
Four patients who had skin cancer before first kidney transplant were excluded 
from the analyses of time to first skin cancer. For the remaining 604 patients the 
number of patients who had developed skin cancer was calculated at various 
time points following transplantation and the results are shown in Figure 8. In 
those who had been immunosuppressed for less than 3 years, 5.4% of patients 
had skin cancer. This figure rose to 12.7% by 3-7 years, 26.1% by 8-15 years and 
was 25.0% in those patients who had been immunosuppressed for over 15 years. 
The prevalence of skin cancer increased as time from transplantation increased 
but appeared to plateau after 15 years. 
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Figure 8 Number of patients with skin cancer and duration of immunosuppression. 
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3.1.8 Transplantation to first cancer 
The mean time between transplantation and the development of a first skin 
cancer varied with the age of the patient at transplantation (Figure 9). In 
patients transplanted between the ages of 15 and 29 years, the mean time to 
development of first skin cancer was 17.2 years. The mean time to develop 
cancer fell as the age of the patient at transplantation increased (30-39 yrs – 
10.5 yrs; 40-49 yrs – 9.1 yrs; 50-59 yrs – 7.7 yrs; 60-70yrs – 4.5yrs).  
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Figure 9 Time between transplant and development of first skin cancer.  
The mean time in years between transplantation and the development of a first skin cancer 
is shown for age groups 15-29, 30-39, 40-49, 50-59 and 60-70 years. Excluded from the 
analysis were six patients in whom the first skin cancer pre-dated transplantation and two 
patients in whom the date of first transplant was not recorded.   
 
3.1.9 Immunosuppression 
Alterations in immunosuppressive therapy regimens over time may influence the 
development of skin cancer. In our centre between 1970 and 1985 all patients 
received prednisolone and azathioprine. From 1985 patients were 
immunosuppressed with prednisolone, azathioprine and ciclosporin, weaning off 
either azathioprine or ciclosporin at one year post transplant. From 1990 
patients stayed on triple therapy unless major side effects. From 1995 
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mycophenolate mofetil (MMF) was increasingly used instead of azathioprine and 
tacrolimus instead of ciclosporin for any patients who had acute rejection or 
ciclosporin associated side effects. From 2007 all patients were started on 
prednisolone, tacrolimus and MMF. Sirolimus has been used in a small minority of 
patients since 2000 mainly as a way of minimising exposure to calcineurin 
inhibitors when mycophenolate was not tolerated. 
To determine whether the type of immunosuppression used influenced the 
development of skin cancer, a survival analysis was performed. Patients were 
divided into three groups according to the era in which they were transplanted; 
1970 -1984 (n=66), 1985-1994 (n=195) or 1995 onwards (n=343).  
The percentage of patients surviving without skin cancer was plotted against the 
years since transplant. The results are shown in Figure 10. In the 1970-1984 
group, it was 25 years post transplantation before 20% of patients developed skin 
cancer.  However this fell to 15 years and 10 years in the 1985-94 and 1995- 
groups respectively. The differences between the groups was significant, 
p<0.0001.  
Multivariate analysis demonstrated that the effect of era was independent of 
age at transplant and sex (table 5). 
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Figure 10 Time to first skin cancer by era of transplantation.  
Kaplan Meier analysis of survival without skin cancer over time since transplantation. 
Patients transplanted between 1970 and 1984 are represented by the blue line, between 1985 
and 1994 by the green line and after 1995 by the yellow line. The differences between the 
three groups were significant, p<0.0001. 
 Hazard ratio p 95% Confidence Interval for Hazard ratio 
Lower Upper 
Age at transplant (per year) 1.061 0.000 1.042 1.080 
Male 1.853 0.013 1.141 3.009 
First transplant 1985-94* 2.605 0.044 1.025 6.616 
First transplant 1995-* 6.952 0.000 2.372 20.379 
Table 5. Cox proportional hazards model with time from first transplant to first skin cancer 
as the independent variable. (* transplant 1970-84 as reference). 
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To compare the effect of dual therapy versus triple therapy regimens on the 
development of skin cancer a comparison was made between patients on 
prednisolone and azathioprine with those on prednisolone, azathioprine and 
ciclosporin at one year post transplant. A survival analysis was performed 
determining survival without skin cancer over time since transplantation. The 
results are illustrated in Figure 11. It was 25 years post transplantation before 
20% of patients on dual therapy developed skin cancer however for patients on 
triple therapy, 20% of patients developed skin cancer within 15 years. The 
difference between the groups were significant, p<0.0001. The data were 
similarly analysed according to immunosuppression immediately and two years 
post transplantation (data not shown), and results were similar to the analysis at 
one year post transplantation.   
Multivariate analysis of these 213 patients who were either on prednisolone and 
azathioprine or prednisolone, azathioprine and ciclosporin at one year after 
transplant demonstrated that the effect of era was not statistically significant 
independent of age at transplant and sex (Table 6). 
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Figure 11 Time to first skin cancer by immunosuppression at one year post transplant.  
Kaplan Meier analysis of survival without skin cancer over time since transplantation. 
Patients on dual therapy, consisting of prednisolone and azathioprine are represented by 
the green line. Those on triple therapy with prednisolone, azathioprine and ciclosporin are 
represented by the blue line. The difference between the groups were significant, p<0.0001.  
Abbreviations; Pred, prednisolone; Aza, azathioprine; Cic, ciclosporin. 
   95% Confidence interval for Hazard ratio 
 Hazard ratio p Lower Upper 
Age at transplant (years) 1.065 0.000 1.037 1.092 
Male 1.875 0.073 0.942 3.730 
Pred/Aza/cic at 1 year* 3.347 0.071 0.903 12.405 
Table 6. Cox proportional hazards model with time from first transplant to first skin cancer 
as the independent variable. 
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To compare triple therapy regimens based on azathioprine with those based on 
MMF or sirolimus, a survival analysis was performed determining survival without 
skin cancer over time since transplantation. The results are illustrated in Figure 
12. In this analysis, 20% of patients on triple therapy regimens incorporating 
Azathioprine developed skin cancer within 12 years whereas 20% of patients on 
MMF based regimens developed skin cancer within 10 years. The differences 
between the three groups did not reach statistical significance (p=0.43). 
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Figure 12 Time to first cancer by immunosuppression at one year post-transplant- 
comparison of triple therapy regimens.  
Kaplan Meier analysis of survival without skin cancer over time since transplantation. The 
blue line represents triple therapy with Azathioprine (with prednisolone and either 
tacrolimus or ciclosporin). The green line represents triple therapy with Mycophenolate 
Mofetil (with prednisolone and either tacrolimus or ciclosporin. The yellow line represents 
patients on sirolimus in combination with any two other agents. The differences between 
the groups did not reach statistical significance, p=0.43.  
Abbreviations; Aza, azathioprine; MMF, mycophenolate mofetil. 
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3.1.10 Discussion  
Keratinocyte cancers comprising SCC and BCC are the most common 
malignancies occurring in Caucasian transplant recipients(21). The data from this 
population of Scottish renal transplant recipients are interesting as lower cancer 
incidence rates and a different pattern of skin cancer, with fewer SCC than BCC, 
are observed in comparison with other geographical areas.  
3.1.10.1 Incidence of NMSC 
The incidence of NMSC is greater in countries at lower latitude with cumulative 
incidences of 70 – 82% at 20 years post transplantation in Australian cohorts 
(28;36) compared to 30-52% in groups from the UK and The Netherlands (22;29). 
In this study the incidence of skin cancer was 15.6%, the mean follow up period 
post transplantation being five years. This may be a reflection of smaller 
numbers of patients or incomplete data e.g. patients who did not come to this 
clinic could have already been attending elsewhere and may have had skin 
cancers. It may also reflect a shorter follow up period; it is possible that over 
time incidence rates will rise to be in keeping with reports from elsewhere in 
the UK. Alternatively the lower skin cancer incidence rates could be a reflection 
of the immunosuppression regimens used or relatively lower UV exposure in this 
location. 
3.1.10.2 SCC: BCC ratio 
Following transplantation, the risk of BCC is increased two to ten fold (22-25) 
and for SCC the risk is increased 65-250 fold SCC (22;26;27). In 
immunocompetent populations, BCC outnumber SCC four fold however in 
transplant recipients a reversal in the BCC: SCC ratio is observed. The magnitude 
of reversal varies across studies with SCC to BCC ratios of 1.7 to 3.6 reported in 
studies from South Africa 1.7(275); Australia 2.0(36), 2.9(28) and 3.1(276); 
France 2.4(40); Italy 2.6(277); Ireland 2.6(278); the UK 3.2(279), 3.6(39) and The 
Netherlands 3.6(36).  
In this study, there was no reversal of the BCC: SCC ratio - the SCC: BCC ratio 
was 0.7. There are reports of similar SCC: BCC ratios in Spanish renal transplant 
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populations; Fuente et al reported a SCC: BCC ratio of 0.7 (30) and Marcen et al 
reported a SCC:BCC ratio of 1(31).  
Based on skin type and sun exposure patterns similar SCC: BCC ratios to those 
reported from elsewhere in the UK and Ireland were expected in this study. 
Based on differences in the SCC:BCC ratio seen at different latitudes within 
Australia (280), it has been suggested that the level of sun exposure influences 
the proportion of BCC and SCC observed following transplantation with 
increasing SCC related to increased sun exposure (281). The relative paucity of 
UVR exposure in Scotland might therefore explain the low SCC: BCC ratio in this 
study compared to elsewhere in Europe and Australia however it does not 
explain the differences between our patients and those elsewhere in the UK and 
Ireland. SCC are typically associated with chronic UVR exposure whereas BCC are 
related to short intense bursts of UVR such as that obtained on sunny holidays, 
the type of sun exposure typically received by our patients and perhaps 
explaining our higher BCC rates. It has been postulated that the low SCC: BCC 
ratios seen in transplant recipients in southern Europe such as those reported by 
Fuente and Marcen, might be due to the darker skin type in such populations 
being relatively protective against SCC but less so against BCC (281). The 
similarities in SCC: BCC ratio between our population and those of southern 
Europe would not be readily explained by either skin type or sun exposure 
patterns; in our Scottish RTRs the majority of patients had fairer skin types I-III.  
In transplant recipients there appears to be an exponential rise in the incidence 
of SCC but a linear rise in BCC (28;29). Fuente et al(30) noted that the 
exponential increase in SCC increased over time post transplantation, thereby a 
gradual increase in SCC: BCC ratio was noted over time. The mean follow up 
time in this study (all patients) was five years.  To determine if the SCC:BCC 
ratio increased over time in our study it was calculated according to the era of 
transplantation revealing a SCC:BCC ratio of 1.1, 0.8 and 0.5 associated with 
follow up lengths of 28.2, 17.2 and 8.0 years respectively (skin cancer patients 
only). It is possible that as this study continues prospectively an increase in the 
overall SCC: BCC ratio may be observed.  
An alternative explanation might lie in reporting bias as it is recognised that 
there is variability in recording of NMSC. Some cancer registries combine BCC 
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and SCC as NMSC whereas some will record each SCC but only the first BCC. 
These reporting methods might lead to under-reporting of BCC in many registry 
based studies and subsequently alter the reported SCC: BCC ratio. In this study, 
a history was taken from each patient included in the study and each tumour 
recorded separately. 
3.1.10.3 Time between transplantation and first cancer 
The mean time between transplantation and development of a first skin cancer 
varied with age from a mean of 17 years in those transplanted between age 15 
and 29 to six years in those transplanted between ages 60 and 70 years. A 
shorter interval between transplantation and first cancer in older patients has 
been previously reported (29).  
3.1.10.4 Immunosuppressive regimens 
The results of this investigation suggest that patients who were transplanted in 
the era 1970 – 1984 were immunosuppressed for a longer duration before 
developing skin cancer and a similar effect was seen between 1985-1994 and 
1995 onwards. This may suggest that the introduction of ciclosporin from 1985 
onwards resulted in skin cancers appearing sooner than in the pre-ciclosporin 
era. Ciclosporin is a potent immunosuppressant that has a direct carcinogenic 
effect aiding growth of tumours and metastases via transforming growth factor ß 
(50). Lower doses of ciclosporin have been associated with reduced incidence of 
skin cancer; a single centre randomised control trial by Dantal and colleagues 
compared azathioprine and normal dose ciclosporin to azathioprine and low dose 
ciclosporin. After 66 months of follow-up, significantly fewer patients in the low 
dose ciclosporin group developed skin cancer (282).   
Similarly the results showed a shorter duration of time between transplantation 
and first cancer between the eras 1985-1995 and 1995 onwards. Over time 
increasing numbers of patients tended to stay on triple therapy rather than be 
weaned onto two agents at one year post transplant. A number of studies have 
shown that dual therapy is associated with a lower incidence of skin cancer 
(283;284).  Over time there has been increasing use of MMF instead of 
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azathioprine and although there was a trend for shorter time between transplant 
and first cancer in the MMF group, this did not reach statistical significance.  
Newer immunosuppressive agents, the mammalian target of Rapamycin 
inhibitors (mTORi), sirolimus and everolimus, exhibit both immunosuppressive 
and anti-neoplastic properties and regimens incorporating these agents may 
confer a lower risk of skin cancer(53;54). Our results showed that patients on 
sirolimus at one year post transplant had not developed any skin cancers 
however the numbers were too few and the period of follow up too short to 
allow further interpretation of this finding.  
3.1.10.5 Strengths and Limitations of the study  
3.1.10.5.1 Strengths 
Patients included in the study were all examined by Dermatologists in one 
centre, a careful history taken from each patient and data on skin cancer 
collected and entered onto the renal electronic patient record.  All data from 
2005 onwards are collected prospectively.  
3.1.10.5.2 Limitations 
Not all patients with a functioning transplant at the start of the study period 
have attended our clinic. These patients who are not included in this study could 
be attending Dermatology clinics elsewhere. Whilst an effort has been made to 
ensure that all West of Scotland RTRs attend the specialist clinic at the Western 
Infirmary, due to the large geographical area that the transplant centre serves, 
some patients prefer to attend Dermatology services local to their area. 
Data on skin tumours diagnosed prior to September 2005 were collected 
retrospectively and in some instances the data were incomplete. Retrospective 
data is subject to survivor bias. We do not know the skin cancer incidence in 
those patients transplanted prior to 2005 who either died or returned to dialysis. 
The effect of immunosuppressive regimens on any retrospectively collected data 
must therefore be interpreted with caution. 
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3.1.10.6 Conclusion  
A dedicated Dermatology clinic for the West of Scotland renal transplant 
population with close links to the renal transplant centre has been established. 
Development of a skin cancer database for this population incorporated in the 
West of Scotland renal electronic patient record has facilitated the study of skin 
cancer in this population. To our knowledge, this is the largest reported survey 
of skin cancer in Scottish renal transplant recipients. Our data reveal lower skin 
cancer incidence rates than are seen in transplant populations elsewhere in the 
UK and there is no reversal of the BCC: SCC ratio. Ongoing studies of this 
population will reveal whether these differences are intrinsic to our population, 
reflect local immunosuppression practices or are a reflection of the length of 
post transplant follow up in this study.
Chapter 3.2 HPV Genotyping of Nonmelanoma Skin 
Cancers 
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The epidemiology of nonmelanoma skin cancer in the West of Scotland renal 
transplant population is described in Chapter 3.1. The investigation examined 
the association between NMSC, age, skin type, sun exposure and 
immunosuppression. Infection with carcinogenic viruses including betaPV may 
also play a role in the development of NMSC in the immunosuppressed transplant 
population and the wider immunocompetent population. 
Skin biopsies from West of Scotland skin cancer patients, both 
immunocompetent patients and immunosuppressed renal transplant recipients 
were examined for the presence of betaPV. This was achieved utilising a 
recently described PCR reverse hybridisation technique that uses primers 
specifically designed to detect betaPV . The results of this investigation are 
presented here. 
One hundred and twenty one paraffin-embedded and 13 frozen skin tumours 
were collected along with 11 paraffin-embedded and seven frozen normal skin 
samples. The results from the series of paraffin-embedded samples are 
presented first. 
3.2.1 Paraffin-embedded samples 
One hundred and twenty one skin tumours from 103 patients were examined [27 
AK, 41 IEC and 53 SCC].  59 tumours were from IC patients and 62 from IS RTRs.  
73 tumours were from male patients and 48 were from females. Patient ages 
ranged from 37-94 years with a mean of 65.4 years. The IC patient group was 
older (mean age 73.8 years) vs. the IS group (mean age 57.4 years).   
Eleven normal skin samples from ten patients were examined, all from IC 
patients. Nine samples were of normal peri-lesional skin and two were from 
photo-protected normal inner arm skin. One was from a male patient, the 
remainder from females. The patient ages ranged from 25-80 with a mean age of 
50.2 years. 
The different attributes of the paraffin-embedded samples are summarised in 
Table 7. 
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 AK IEC SCC Total 
tumours 
Normal 
skin 
Total No. of samples 
(patients) 
27 (24) 41 (35) 53 (44) 121 (103) 11 (10) 
IC samples (patients) 16 (14) 20 (19) 23 (22) 59 (55) 11 (10) 
IS samples (patients) 11(10) 21 (16) 30 (22) 62 (48) 0 
Male/Female 13/14 22/19 38/15 73/48 1/10 
      
Mean age of all patients 
(range) 
65.4 
(37-93) 
67.4 
(48-89) 
63.8 
(35-94) 
65.4 
(37-94) 
50.2 
(25-80) 
IC patients  
(range) 
72.9 
(58-93) 
74.4 
(48-89) 
73.9 
(38-94) 
73.8 
(38-94) 
50.2 
(25-80) 
IS patients  
(range) 
54.4 
(37-69) 
60.8 
(49-75) 
56.1 
(35-74) 
57.4 
(35-75) 
N/A 
      
Table 7 Characteristics and origin of the paraffin-embedded lesions. 
AK, Actinic keratoses; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma; IC, 
immunocompetent; IS, immunosuppressed 
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3.2.2 BetaPV genotyping – paraffin-embedded samples 
Overall betaPV DNA was detected in 57 (47.1%) out of 121 skin tumours but in 
only 2 (18.2%) out of 11 normal skin samples. In IC patients, betaPV was 
detected in 30 (50.8%) out of 59 tumours but in only two (18.2%) out of 11 
normal skin samples. This was statistically significant as tested by the Chi-
squared test, p=0.046. In IS patients, betaPV was found in 27 (43.5%) out of 62 
samples. No normal skin samples from IS patients were available as control 
samples.  
3.2.2.1 Beta PV and immune status 
BetaPV infection appeared to be more common in tumours from IC patients 30 
(50.8%) out of 59 samples compared to IS patients 27 (43.5%) out of 62 samples 
(Table 6) but the difference between IC and IS patients was not statistically 
significant. 
3.2.2.2 BetaPV and tumour type 
Overall, betaPV infection was detected in 15/27 (55.6%) AK, 15/41 (36.6%) IEC 
and 27/53 (50.9%) SCC. In tumours from IC patients betaPV was detected in 
10/16 (62.5%) AK, 8/20 (40%) IEC and 12/23 (52.2%) SCC. In tumours from IS 
patients in 5/11 (45.4%) AK, 7/21 (33.3%) IEC and 15/30 (50%) SCC (Table 6). 
The results of betaPV genotyping in paraffin-embedded samples are summarised 
in Table 8.  
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 AK IEC SCC Total 
Tumours 
Normal 
skin 
Paraffin–embedded 
samples, n 
27 41 53 121 11 
      
BetaPV positive samples, n 
(%) 
15/27 
(55.6) 
15/41 
(36.6) 
27/53  
(50.9) 
57/121 
(47.1) 
2/11 
(18.2) 
      
BetaPV positive samples 
Immunocompetent, n (%) 
10/16 
(62.5) 
8/20 
(40.0) 
12/23 
(52.2) 
30/59 
(50.8) 
2/11 
(18.2) 
BetaPV positive samples 
Immunosuppressed, n (%) 
5/11 
(45.4) 
7/21 
(33.3) 
15/30 
(50.0) 
27/62 
(43.5) 
N/A 
      
Table 8 Results of betaPV genotyping in paraffin-embedded tumours and normal skin. 
AK, Actinic keratoses; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma 
 
3.2.2.3 Spectrum of BetaPV 
There were 126 betaPV detections from 57 tumours as many lesions harboured 
more than one genotype. All 25 genotypes were detected with the exception of 
HPV-21, HPV-25, HPV-47 and HPV-96. Overall, the most frequently detected 
genotypes were HPV-24 (14 samples), HPV-15 (12 samples) and HPV-38 (11 
samples) (Figure 13). The spectrum of betaPV genotypes isolated in each tumour 
type is summarised in Table 11. The most common genotypes found in SCC were 
HPV-36 (8 samples), HPV-24 (7 samples) and HPV-38 (6 samples). HPV-36 was 
only identified in SCC. In thirteen samples, betaPV was detected but the 
genotype was uncharacterised. 
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Figure 13 The spectrum of betaPV detected in paraffin-embedded and frozen tumours.  
One hundred and twenty one paraffin-embedded and thirteen frozen skin tumours were 
tested for the presence of 25 known betaPV types. 57paraffin samples and 11 frozen 
samples were positive for betaPV. The percentage of positive lesions harbouring each 
genotype is illustrated. Many tumours contained more than one genotype. 
 
3.2.2.4 BetaPV and age 
Tumours from IS patients were from a younger age group than those from IC 
patients and accordingly, betaPV were detected more frequently at a younger 
age in this group as shown in Figure 14.  
3.2.2.5 Multiple infections 
Of those tumours infected with betaPV, 28/57 (49.1%) were infected with more 
than one genotype (range 2-8). Overall, infection with multiple genotypes was 
found in 14/27 (51.9%) SCC, 5/15 (33.3%) IEC and 9/15 (60.0%) AK. Multiple 
infections were more common in tumours from IC patients than those from IS 
patients (P < 0.001). Adjustment for age did not change this association.  In IC 
patients, overall 21/30 (70.0%) of tumours were multiply infected [7/10 (70%) 
AK, 4/8 (50.0%) IEC, 10/12 (83.3%) SCC] compared with 7/27 (25.9%) of tumours 
from IS patients [2/5 (40.0%) AK, 1/7 (14.3%) IEC, 4/15 (26.7%) SCC] (Figure 15). 
Uncharacterised betaPV DNA was detected in two of eleven normal skin samples. 
There were no multiple infections in normal skin. 
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Figure 14 BetaPV infection and age 
The distribution of samples according to age in (A) immunocompetent and (B) 
immunosuppressed patients.  
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Figure 15 BetaPV infection and age. 
Total number of betaPV positive samples, number of single infections and multiple 
infections in immunocompetent (A) and immunosuppressed (B) patients. 
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3.2.3 Frozen samples 
A small number of frozen tumours and normal skin was collected and similarly 
analysed. The attributes of the lesions are summarised in Table 9.  
Thirteen tumours from 11 patients were examined (2 AK, 4 IEC and 7 SCC). 
Seven were from IC patients and six were from IS organ transplant recipients (3 
renal and 1 liver). Eight tumours were from male patients and five from females. 
The patient ages ranged from 38-81 years (mean 62.7). Again the IC patients 
were older with a mean age of 75.0 years (range 67-81) compared to the IS 
patients whose mean age was 50.4 years (range 38-73). 
Seven normal skin samples were examined; all samples were taken from normal, 
photo-protected skin from the upper inner arm.  Six samples were from IC 
patients and one from an IS renal transplant recipient.  Five samples were from 
male patients and two from females. Overall, the patient ages ranged from 67-
81 years (mean 75.0). The IC patient ages ranged from 67-81 years (mean 75.2), 
the IS patient age was 74 years. 
 AK IEC SCC Total tumours Normal skin 
Total No. of samples (patients) 2 (2) 4 (4) 7 (6) 13 (12) 7 (7) 
IC samples (patients) 2 (2) 2 (2) 3 (3) 7 (7) 6 (6) 
IS samples (patients) 0 2 (2) 4 (3) 6 (5) 1 (1) 
Male/Female 0/2 2/2 6/1 8/5 5/2 
      
Mean age of all patients (range) 73.5 
(73-74) 
67.8 
(59-76) 
65.4 
(38-81) 
62.7 
(38-81) 
75.0 
(67-81) 
IC patients  
(range) 
73.5  
(73-74) 
74.5  
(73-76) 
76.3  
(67-81) 
75.0  
(67-81) 
75.2  
(67-81) 
IS patients  
(range) 
NA 61.0  
(59-63) 
57.2  
(38-73) 
50.4  
(38-73) 
74.0  
(1 patient) 
      
Table 9 Characteristics and origin of the frozen lesions. 
AK, Actinic keratoses; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma; IC, 
immunocompetent; IS, immunosuppressed 
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3.2.4 BetaPV genotyping of frozen tissue 
BetaPV was detected in 11 (84.6%) out of 13 tumours and 4 (57.1%) out of 7 
normal skin samples (Table 10). BetaPV infection was found in 5 (71.4%) out of 7 
tumours from IC patients compared to 6 (100%) out of 6 tumours from IS 
patients. The results according to immune status and lesion type are summarised 
in Table 9.  Of those tumours harbouring betaPV, 6 (54.5%) out of 11 harboured 
more than one genotype (range 2-9). There were 3 (60.0%) out of 5 lesions 
multiply infected in IC patients and 3 (50.0%) out of 6 in IS patients. 
 AK IEC SCC Total 
Tumours 
Normal 
skin 
Frozen samples, n 2 4 7 13 7 
      
BetaPV positive frozen 
samples, n (%) 
1/2  
(50.0) 
3/4 
(75.0) 
7/7 
(100.0) 
11/13  
(84.6) 
4/7  
(57.1) 
BetaPV positive samples 
Immunocompetent, n (%) 
1/2  
(50.0) 
1/2 
(50.0) 
3/3  
(100.0) 
5/7  
(71.4) 
3/6  
(50.0) 
BetaPV positive samples 
Immunosuppressed, n (%) 
NA 2/2  
(100.0) 
4/4  
(100.0) 
6/6  
(100.0) 
1/1  
(100.0) 
      
Table 10 Results of betaPV genotyping in frozen tumours and normal skin.  
AK, Actinic keratoses; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma 
 
There were 37 HPV detections in total from the tumours. The majority of the 25 
betaPV genotypes were detected (Figure 13). The spectrum of betaPV genotypes 
detected in each lesion type is summarised in Table 11b. The most frequently 
detected genotypes were HPV-36 (6 samples), HPV-24 (4 samples), HPV-5, HPV-
12 and HPV-23 (3 samples each). There were three samples containing 
uncharacterised betaPV.  
Four out of seven frozen normal skin samples were positive: three were from IC 
patients and one was from an IS patient. Of the three IC samples, one was 
infected with HPV-15, one with an uncharacterised betaPV and one was infected 
with both HPV-23 and HPV-75. The single IS sample was positive for HPV-12 
(Table 11b). The number of frozen samples was too small for meaningful 
statistical analysis.  
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 (a) Paraffin-embedded Tumours (b) Frozen Tumours All 
Tumours 
BetaPV 
Genotype 
AK 
(n=27) 
IEC 
(n=41) 
SCC 
(n=53) 
 No. of 
detections 
AK 
(n=2) 
IEC 
(n=4) 
SCC 
(n=7) 
 No. of 
detections 
Total No. 
of 
detections 
HPV-5 2 2 4 8 1 1 1 3 11 
HPV-8  2  2   2 2 4 
HPV-9 1  2 3    0 3 
HPV-12  2  2  1 1 2 4 
HPV-14  1 1 2    0 2 
HPV-15 3 4 5 12    0 12 
HPV-17 1  3 4  1 2 3 7 
HPV-19  1 2 3    0 3 
HPV-20 1 1 1 3   1 1 4 
HPV-21    0    0 0 
HPV-22 1  2 3   1 1 4 
HPV-23 3 1 2 6   3 3 9 
HPV-24 4 3 7 14  2 2 4 18 
HPV-25    0    0 0 
HPV-36   8 8 1 1 4 6 14 
HPV-37 1 1 5 7   1 1 8 
HPV-38 3 2 6 11   1 1 12 
HPV-47    0    0 0 
HPV-49   1 1    0 1 
HPV-75   1 1    0 1 
HPV-76 1  2 3 1  1 2 5 
HPV-80 3 1 5 9   1 1 10 
HPV-92  1 3 4   2 2 6 
HPV-93 2 2 3 7 1   1 8 
HPV-96    0   1 1 1 
U 
 
Total 
Isolates 
4 4 5 13 
 
126 
 1 2 3 
 
37 
16 
 
163 
Table 11 BetaPV genotypes found in (a) paraffin-embedded and (b) frozen skin tumours.  
The number of infections can add up to more than the numbers of samples due to the 
presence of multiply infected samples.  
AK, Actinic keratoses; IEC, intraepidermal carcinoma; SCC, squamous cell carcinoma; U, 
uncharacterised 
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3.2.5 Discussion  
There is a growing body of evidence to link betaPV to NMSC. Early investigations 
of the presence of HPV in NMSC were based on Southern blotting and found HPV 
DNA infrequently. Subsequent development of broad range, genus and type 
specific PCR primers has led to HPV detection in 35-85% of AK and IEC and 30-
50% of SCC in IC patients and up to 88% of AK and 54-91% of SCC in renal 
transplant recipients. (64). The presence of betaPV is associated with the 
development of NMSC and detection of antibodies against the EV type HPV-8 is 
greater in SCC patients than in controls and has a significant association with 
presence of AKs (285-288).  
However, despite the frequent finding of HPV DNA in tumour biopsies, the 
biological significance of this observation remains unclear as betaPV DNA is also 
present in 32-87% of normal skin biopsies with higher detections in IS patients 
(287),(289). 
In this study, NMSC in a cohort of IC and IS patients from the West of Scotland 
were analysed. Similar investigations had not been conducted in this area of the 
UK.  
AK, IEC and SCC but not benign lesions or BCC were examined for the following 
reasons. AK, IEC and SCC are considered to represent the spectrum of one 
disease from epidermal dysplasia through intra-epidermal SCC to invasive 
malignancy.  Moreover in renal transplant recipients the risk of SCC is increased 
65-250 fold whereas the risk for BCC is increased only 10 fold compared to the 
immunocompetent population. This represents an exponential rise in the risk of 
SCC and a reversal of the normal SCC to BCC ratio (22;26-29;290). 
Overall betaPV DNA was present in 57/121 (47.1%) of paraffin-embedded skin 
tumours and 2/11 (18.2 %) of paraffin-embedded normal skin samples. In our 
small number of frozen samples the proportion of positive tumours remained 
higher than that in normal skin [11/13 (84.6%) and 4/7 (57.1%) respectively]. 
These findings add support to the hypothesis that betaPV has a role in 
development of NMSC.  
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The mean age of the IS patient group was 54.4 years whereas the mean age of 
the IC group was 72.9 years. It is well recognised that IS renal transplant 
recipients develop NMSC at a younger age than IC patients (29). UVR is the major 
aetiology for NMSC, the risk of NMSC is highest in countries with highest UVR 
exposure (28) and ciclosporin used in immunosuppressive regimes may contribute 
a direct neoplastic effect (50). However, the increased incidence of tumours at 
an earlier age in IS patients also suggests a role for an infective agent such as 
HPV. This hypothesis is supported by the high incidence of cancers induced by 
infection or reactivation of oncogenic viruses in OTRs including high-risk mucosal 
HPV and anogenital cancers, HHV-8 associated KS and Epstein Barr Virus 
associated lympho-proliferative malignancies (18;26;291-293).  
A wide spectrum of betaPV types was detected in our samples. Within the genus 
beta there are five species of closely linked types - species 1 (HPV-5, 8, 12, 14, 
19, 20, 21, 24, 25, 36, 47, 93,); species 2 (HPV-9, 15, 17, 22, 23, 37, 38, 80); 
species 3 (HPV-49, 75, 76); species 4 (HPV-92) and species 5 (HPV-96)(66). The 
most common genotypes we detected were HPV-24, HPV-36, HPV-38, HPV-15, 
HPV-5 and HPV-80. Sixteen betaPV were detected that could not be 
characterised. This may be due to either presence of a known genotype at low 
copy number or detection of a new genotype that would only be determined by 
sequencing. 
A recent study of lesional and normal skin in IC patients found that betaPV 
species 2 predominate in SCC whereas betaPV species 1 predominated in benign 
lesions (294).  In this study genotypes from both species 1 and 2 predominated in 
tumours. The most frequent genotype in SCC was HPV-36, a species 1 genotype.  
In EV patients, HPV-5 and HPV-8 are the most common types found in SCC and 
are regarded as high-risk types(295). However, in agreement with previous 
results, in this study, no single type prevails in NMSC in non-EV patients (296-
298). 
The lowest detection of betaPV was in samples of IEC compared to AK and SCC 
both in IC and IS patients (36.6% overall). These figures are comparable to 
previous studies that found EV-HPV DNA in 33% of paraffin–embedded IEC from IC 
patients and 40% of IEC from RTRs (299;300).  
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More multiple betaPV infections in tumours from IC patients 21/30 (70.0%) than 
from IS patients 7/27 (25.9%) (p<0.001) were present.  
Some of the results from this study differ from what has previously been 
reported in the literature. Firstly, the detection of betaPV DNA in 47.1% of 
paraffin embedded NMSC samples was lower than expected. This may reflect 
poor quality of DNA extracted from the samples as the samples utilised were 
archival. The DNA detection was similar in both IC and IS patients and a higher 
detection rate may have been expected from IS patient samples. Again, this may 
reflect the use of archival samples. More multiple infections were found in IC 
than IS patients and previous reports have found the opposite. This may be 
because this study only examined for betaPV whereas previous studies have 
included all PV types including mucosal perhaps leading to detection of greater 
numbers of multiple infections. Alternatively it may be related to the assay. The 
assay used in this investigation is highly sensitive and specific and can detect 
HPV DNA at low copy numbers however, one potential disadvantage of any 
broad-spectrum PCR primer mediated method is the competition between the 
different HPV types present in a single sample. If one type is present in a higher 
molar concentration than other type it is possible that the type at lower 
concentration will be out competed and escape detection in this assay (89). This 
could then potentially lead to under detection of multiple infections.  
One disadvantage of BetaPV DNA detection in samples is the difficulty in 
distinguishing between a clinically relevant infection and a passenger role for 
betaPV as it has been shown that betaPV DNA is ubiquitous. It has been 
suggested that detection of an antibody response to betaPV may represent a 
more clinically relevant infection. One study of betaPV detection in eyebrow 
hairs combined with multiplex serology identified that concordant DNA detection 
of HPV-36 and antibodies to HPV-36 was significantly associated with cutaneous 
SCC(117) It may be that by employing combined approaches of DNA detection 
and serological detection in future large scale studies will lead to identification 
of betaPV types which are important for the development of SCC.   
Further characterisation of betaPV in vivo is needed in order to determine the 
mechanisms by which the virus contributes to cutaneous carcinogenesis. Large-
scale epidemiological studies are needed to determine which betaPV types are 
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primarily associated with NMSC; future in vitro studies should focus on these 
HPV-types. 
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Chapter 3.3 Immunohistochemical Analysis of 
Biomarker Expression in Nonmelanoma Skin 
Cancers 
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The results presented in Chapter 3.2 demonstrated the presence of betaPV in 
skin biopsy specimens from both immunosuppressed and immunocompetent 
patients. Overall betaPV DNA was present in 57/121 (47.1%) of paraffin-
embedded skin tumours and 2/11 (18.2 %) of paraffin-embedded normal skin 
samples. In the small number of frozen samples investigated, the proportion of 
positive tumours remained higher than that in normal skin [11/13 (84.6%) and 
4/7 (57.1%) respectively]. These findings add support to the hypothesis that 
betaPV has a role in development of NMSC. It remains unclear however whether 
betaPV infection is causative of skin cancers in both immunosuppressed patients 
and the wider immunocompetent population.  
One way to gather evidence supporting a causative role of betaPV in NMSC is to 
identify betaPV infected lesions, and determine whether they have a different 
expression pattern for a variety of cell cycle markers that have been associated 
with increased proliferation and cancers in other organs and locations. In 
cervical lesions, it has been shown that immunohistochemical staining with p16 
antibody can aid the diagnosis of cervical cancer associated with alpha-
papillomaviruses such as HPV-16 (301).  MCM proteins have been proposed as 
diagnostic markers to identify HPV induced proliferative disease in the cervix 
while Ki67 is also associated with the risk of HPV associated disease in the cervix 
(302;303). Although there have been several studies examining the relationship 
between NMSC and immunohistochemical markers of cell cycle regulatory 
proteins, previous studies have been limited either in the number of markers 
examined, or the histological grades and number of lesions examined. In 
addition there are limited datasets in which these markers are studied in 
association with HPV and no datasets in which lesions have been 
comprehensively screened for betaPV. A biomarker pattern particular to betaPV 
positive skin cancers would support the hypothesis that these viruses are 
causative agents of disease. 
Skin tumours and normal skin samples from IC and IS patients, typed for the 
presence of betaPV as described in Chapter 3.2, were examined by 
immunohistochemistry. The objective was to determine if the presence or 
absence of betaPV altered cell cycle biomarker expression in nonmelanoma skin 
cancers. The results of this investigation are presented here. 
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3.3.1 Case distribution and presence of beta 
papillomaviruses 
Due to difficulties in processing frozen tissue for immunohistochemistry, of those 
specimens previously genotyped, only paraffin-embedded samples were included 
in this part of the investigation.  
One hundred and twenty one paraffin-embedded skin tumours and eleven normal 
skin samples were genotyped for betaPV. Twenty-one skin tumours were not 
suitable for analysis due to loss of tissue during processing or inadequate size of 
sample. The remaining one hundred skin tumours and eleven normal skin 
samples were included in the study.  
The samples were from 67 IC patients and 59 IS OTRs. Of the IC patients, 28 
were male and 29 female with a mean age of 69.7 years (range 25-94). Of the IS 
patients, 39 were male and 20 female with a mean age of 55.4 years (range 22-
94). 
Forty four NMSC and two normal skin samples harboured betaPV. The results are 
summarised in Table 12.  
 BetaPV negative  BetaPV positive 
 IC IS Total (%)  IC IS Total (%) 
Normal Skin, n=11 9 0 9 (81.8)  2 0 2 (18.2) 
Actinic Keratoses, n=24 6 6 12 (50.0)  7 5 12 (50.0) 
Intra-epidermal Carcinoma, n=37 11 12 23 (62.2)  8 6 14 (37.8) 
Squamous Cell Carcinoma, n=39 11 10 21 (53.8)  11 7 18 (46.2) 
Totals, n=111 37 28 65 (58.6)  28 18 46 (41.4) 
Table 12 Results of betaPV genotyping  
IC, immunocompetent; IS, immunosuppressed; BetaPV, beta papillomavirus 
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Of those 46 betaPV positive samples, the range of betaPV genotypes isolated is 
summarised in Table 13. Many lesions harboured more than one betaPV 
genotype. Some samples harboured betaPV but the genotype was 
uncharacterised, this may be due to the presence of a known genotype at low 
copy number or detection of a new genotype that could only be determined by 
cloning and sequencing. 
BetaPV  
genotype 
Normal 
skin  
(n=2) 
Actinic 
keratosis 
(n=12) 
Intra-
epidermal  
carcinoma 
(n=14) 
Squamous cell  
carcinoma 
(n=18) 
No. of  
detections 
HPV-5  2 2 4 8 
HPV-8   2  2 
HPV-9  1  2 3 
HPV-12   2  2 
HPV-14   1 1 2 
HPV-15  2 3 3 8 
HPV-17  1  2 3 
HPV-19   1 1 2 
HPV-20   1 1 2 
HPV-21      
HPV-22  1  1 2 
HPV-23  2 1 2 7 
HPV-24  3 3 7 13 
HPV-25      
HPV-36  1  4 5 
HPV-37  2 1 3 6 
HPV-38  1 2 5 8 
HPV-47      
HPV-49    1 1 
HPV-75    1 1 
HPV-76    2 2 
HPV-80  2 1 4 7 
HPV-92  1 1 2 4 
HPV-93  1 2 3 6 
HPV-96      
Uncharacterised 2 3 4 2 11 
Total isolates 2 23 27 51 103 
Table 13 BetaPV genotypes present in HPV positive samples.  
46/111 samples investigated were betaPV positive; the specific genotypes isolated in the 46 
positive samples are shown. The number of detections is greater than the number of 
BetaPV positive lesions as many were infected with multiple genotypes.  
HPV, human papillomavirus 
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3.3.2 Results of Immunohistochemical staining 
Sections from each sample were probed with antibodies directed against the 
following proteins: Ki67, MCM2, MCM5, p53, p16 and TopBP1. For each antibody, 
the expression pattern was categorised according to the intensity and 
distribution of staining (summarised in Table 14). Each section was examined 
and the expression patterns for each protein recorded. 
Antibody Distribution of staining within samples Abbreviation 
Ki67 Basal layer to mid layers of the epidermis  basal/mid 
 Extending beyond the mid layers of the epidermis up to full thickness  mid/FT 
   
MCM2/5 Basal layer to mid layers of the epidermis  basal/mid 
 Extending beyond the mid layers of the epidermis up to full thickness mid/FT 
   
p53 Negative  negative 
 Restricted to the basal layer +/- foci of full thickness staining basal/focal 
 Full thickness staining  FT 
   
p16 Negative/occasional positive cells negative 
 Patchy focal staining  focal 
 Intense staining in a band-like distribution through the full thickness  FT 
   
TopBP1 Exclusively nuclear full thickness staining  nuclear 
 Nuclear staining in association with intense cytoplasmic staining  cytoplasmic 
   
Table 14 Summary of the observed staining patterns. 
MCM2, minichromosome maintenance protein 2; MCM5, minichromosome maintenance 
protein 5; p16, p16INK4a; TopBP1, Topoisomerase II Binding Protein 1 
 
To illustrate the observed staining patterns, representative betaPV positive and 
negative samples of normal skin (Figures 16 and 17), actinic keratoses (Figures 
18 and 19), intra-epidermal carcinoma (Figures 20 and 21), and SCC (Figures 22 
and 23) are shown.  
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3.3.2.1 Biomarker expression in normal skin vs. NMSC and 
correlation with the presence of BetaPV 
3.3.2.1.1 Ki67, MCM2 and MCM5  
In normal skin, Ki67 and MCM2 and MCM5 expression was restricted to the basal 
and mid layers of the epidermis. Fewer nuclei expressed MCM2 than MCM5 and 
staining was less intense with MCM2 than MCM5 (Figure 16a-c and Figure 17 a-c).  
Ki67 expression was similar to normal skin and restricted to the basal and mid 
layers of the epidermis in 36/100 NMSC (Figures 19a, 22a).  In the remaining 
64/100 NMSC Ki67 was over-expressed extending beyond the mid layers of the 
epidermis up to full thickness as shown in Figures 18, 20, 21 and 23a. This 
increase in Ki67 expression, suggesting an increase in replicating cells in tumours 
compared to normal skin was significant (64/100 vs. 0/11, P<0.001) however it 
was not influenced by the presence of betaPV (Table 15a).  
MCM2 expression was similar to normal skin and restricted to the basal and mid 
layers of the epidermis in 52/100 NMSC. In the remaining 48/100 NMSC, MCM2 
was over-expressed  as demonstrated in Figures 18, 20, 21 and 23b. 
MCM5 expression was similar to normal skin in 13/100 NMSC and was over-
expressed in the remaining 87/100 NMSC as shown in Figures 18, 20, 21 and 23c.  
Over expression of MCM antigens was more pronounced in samples stained with 
MCM5 (87/100 vs. 0/11, P<0.002) compared to MCM2 (48/100 vs. 0/11, P<0.001). 
This may suggest that MCM5 antibody is a more sensitive detector of replicating 
cells. Similar to Ki67, expression patterns of MCM proteins did not differ 
significantly between betaPV positive and negative lesions (Table 15b and c).   
3.3.2.1.2 p53 
p53 staining was restricted to the basal layer +/- foci of full thickness (FT) 
staining (basal/focal) in two normal skin samples and throughout the full 
epidermal thickness in the remaining nine as seen in Figure 16d and 17d. In 
normal skin, there was no correlation between p53 distribution and presence of 
betaPV.   
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In NMSC, p53 expression was negative in three samples (example not shown) and 
was basal/focal in 31/100 NMSC (Figure 23d) and throughout the full epidermal 
thickness in the remaining 65/100 NMSC (Figure 18, 19, 20, 21 and 22d). 
Expression of p53 did not differ significantly between normal and lesional skin. 
There was no difference in p53 expression when comparing betaPV positive and 
negative lesions (Table 15d). 
3.3.2.1.3 p16 
11/11 normal skin samples were negative for p16 staining as shown in Figures 16 
and 17 e. 
Similar to normal skin, 6/100 NMSC samples were also negative for p16 staining 
(not shown). The remaining 94/100 NMSC exhibited over-expression of p16.  
51/100 NMSC showed focal p16 over-expression (Figures 18 and 19 e) and 43/100 
NMSC showed full thickness p16 over-expression (Figures 20, 21, 22 and 23e). In 
NMSC, p16 was clearly over-expressed in comparison with normal skin samples; 
however p16 expression patterns did not correlate with presence of betaPV 
(Table 15e).  
3.3.2.1.4 TopBP1 
TopBP1 expression was exclusively nuclear through the FT of the sample 
(nuclear) in 11/11 normal skin samples as shown in Figures 16 and 17f. 
In 76/100 NMSC, TopBP1 expression was exclusively nuclear and similar to that 
seen in normal skin (Figures 18-22 f). In a 24/100 NMSC, nuclear ToPBP1 staining 
was present in association with intense cytoplasmic staining as shown in Figure 
23 f. This aberrant TopBP1 expression pattern did not correlate with the 
presence of betaPV (Table 15 f). 
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 All samples 
Normal Skin vs. NMSC 
Normal skin 
BetaPV-ve vs. BetaPV+ve 
NMSC 
BetaPV-ve vs. BetaPV+ve 
  
Normal 
Skin 
 
 
 
n=11(%) 
 
NMSC 
 
 
 
 
n=100 (%) 
 
Normal 
Skin  
-ve 
 
 
n=9 (%) 
 
Normal 
Skin 
+ve 
 
 
n=2 (%) 
 
NMSC 
-ve 
 
 
 
n=56 (%) 
 
NMSC 
+ve 
 
 
 
n=44 (%) 
 
(a) Ki67 
      
basal/mid 11 (100.0) 36 (36.0) 9 (100.0) 2 (100.0) 22 (39.3) 14 (31.8) 
mid/FT 0 (0.0) 64 (64.0) 0 (0.0) 0 (0.00) 34 (60.7) 30 (68.2) 
 
(b) MCM2 
      
basal/mid 11 (100.0) 52 (52.0) 9 (100.0) 2 (100.0) 28 (50.0) 24 (54.6) 
mid/FT 0 (0.0) 48 (48.0) 
 
0 (0.0) 0 (0.0) 28 (50.0) 20 (45.4) 
 
(c) MCM5 
      
basal/mid 11 (100.0) 13 (13.0) 9 (100.0) 2 (100.0) 8 (14.3) 5 (11.4) 
mid/FT 0 (0.0) 87 (87.0) 0 (0.0) 0 (0.0) 48 (85.7) 39 (88.6) 
 
(d) p53 
      
negative 0 (0.0) 3 (3.0) 0 (0.0) 0 (0.0) 1 (1.8) 2 (4.6) 
basal/focal 2 (18.2) 31 (31.0) 2 (22.2) 0 (0.0) 18 (32.1) 13 (29.6) 
FT 9 (81.8) 66 (66.0) 7 (77.8) 2 (100.0) 37 (66.1) 29 (66.0) 
 
 
(e) p16 
      
negative 11(100.0) 6 (6.0) 9 (100.0) 2 (100.0) 2 (3.6) 4 (9.1) 
focal  0 (0.0) 51 (51.0) 0 (0.0) 0 (0.0) 28 (50.0) 23 (52.3) 
FT 0 (0.0) 43 (43.0) 0 (0.0) 0 (0.0) 26 (46.4) 17 (38.6) 
 
 
(f) TopBP1 
      
nuclear 11 (100.0) 76 (76.0) 9 (100.0) 2 (100.0) 45 (80.4) 31 (70.4) 
cytoplasmic 0 (0.0) 24 (24.0) 0 (0.0) 0 (0.0) 11 (19.6) 13 (29.56) 
       
Table 15 Results of immunohistochemical staining. 
The observed staining patterns and associated abbreviations are described in detail in 
Table 14. Abbreviations: NMSC, nonmelanoma skin cancer; MCM2, minichromosome 
maintenance protein 2; MCM5, minichromosome maintenance protein 5; p16, p16INK4a; 
TopBP1, Topoisomerase II Binding Protein 1 
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3.3.3 Biomarker expression in NMSC – correlation between 
different stages of carcinogenesis 
To determine whether progression through the different stages of carcinogenesis 
influenced the biomarker expression pattern seen, a comparison of the observed 
staining patterns was made in normal skin, AK, IEC and SCC. The results are 
summarised in Table 16.  
The results suggest that markers of cell proliferation (Ki67, MCM2 and MCM5) are 
up-regulated in IEC compared to AK and SCC however the numbers in each group 
are too small to allow for meaningful statistical analysis. 
Similarly, there is a trend for FT p16 staining in IEC compared to both AK and 
SCC but again, the numbers in each group are too small to allow for meaningful 
statistical analysis. 
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  BetaPV negative 
samples, 
n=65 
     BetaPV positive 
samples, 
n=46 
    
  Normal Skin 
 n=9 
AK IEC SCC Total 
NMSC 
n=56 
 Normal Skin 
n=2 
AK IEC SCC Total 
NMSC 
n=44 
(a) Ki67            
 basal/mid 9 
(100.00%) 
7 5 10 22 
(39.29%) 
 2 
(100.00%) 
6 1 7 14 
(31.82%) 
 mid/FT 0 (0.00%) 5 18 11 34 
(60.71%)  
0 (0.00%) 6 13 11 30 
(68.18%) 
             
(b) MCM2            
 basal/mid 9 
(100.00%) 
7 6 15 28 
(50.00%)  
2 
(100.00%) 
6 1 17 24 
(54.55%) 
 mid/FT 0 (0.00%) 5 17 6 28 
(50.00%) 
 0 (0.00%) 6 13 1 20 
(45.45%) 
             
(c) MCM5            
 basal/mid 9 
(100.00%) 
1 2 5 8 
(14.29%)  
2 
(100.00%) 
1 0 4 5 
(11.36%) 
 mid/FT 0 (0.00%) 11 21 16 48 
(85.71%)  
0 (0.00%) 11 14 14 39 
(88.64%) 
             
(d) p53            
 negative 0 (0.00%) 0 1 0 1 (1.79%)  0 (0.00%) 0 1 1 2 
(4.55%) 
 basal/focal 2 (22.22%) 4 8 6 18 
(32.14%)  
0 (0.00%) 3 4 6 13 
(29.55%) 
 FT 7 (77.78%) 8 14 15 37 
(66.07%)  
2 
(100.00%) 
9 9 11 29 
(65.91%) 
             
(e) p16            
 negative 9 
(100.00%) 
1 0 1 2 (3.57%)  2 
(100.00%) 
3 1 0 4 
(9.09%) 
 focal  0 (0.00%) 8 7 13 28 
(50.00%)  
0 (0.00%) 8 1 14 23 
(52.27%) 
 FT 0 (0.00%) 3 16 7 26 
(46.43%)  
0 (0.00%) 1 12 4 17 
(38.64%) 
             
(f) TopBP1            
 nuclear 9 
(100.00%) 
10 15 20 45 
(80.36%) 
 2 
(100.00%) 
11 7 13 31 
(70.45%) 
 cytoplasmic 0 (0.00%) 2 8 1 11 
(19.64%)  
0 (0.00%) 1 7 5 13 
(29.55%) 
Table 16 Immunohistochemical staining in normal skin and NMSC.  
NMSC is the sum of all AK, IEC and SCC lesions. The observed staining patterns are 
described in detail in Table 10. MCM2, minichromosome maintenance protein 2; MCM5, 
minichromosome maintenance protein 5; p16, p16INK4a; TopBP1, Topoisomerase II Binding 
Protein 1 
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(a) Ki67
(b) MCM2
(d) p53
(e) p16
(c) MCM5 (f) TopBP1
 
Figure 16 BetaPV positive normal skin. 
Normal skin stained for (a) Ki67, (b) MCM2, (c) MCM5, (d) p53, (e) p16 and (f) TopBP1. Ki67, 
MCM2 and MCM5 expressing cells are present from the basal layers to the mid layers of the 
epidermis. Nuclei stained with p53 and TopBP1 are present through the full thickness of the 
epidermis. P16 staining is absent. Original magnification x 20. 
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Figure 17 BetaPV negative normal skin. 
Normal skin stained for (a) Ki67, (b) MCM2, (c) MCM5, (d) p53, (e) p16 and (f) TopBP1. 
Original magnification x 20. 
(a) Ki67 
(f) TopBP1 (c) MCM5 
(b) MCM2 (e) p16 
(d) p53 
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(a) Ki67 (d) p53
(b) MCM2 (e) p16
(f) TopBP1(c) MCM5
(i) H&E
 
Figure 18 BetaPV positive Bowenoid actinic keratosis.  
Sections stained with (i) H&E and antibody directed against (a) Ki67, (b) MCM2, (c) MCM5, 
(d) p53, (e) p16 and (f) TopBP1. Ki67, MCM2, MCM5, P53 and TopBP1 staining is present 
through the full thickness of the lesion. Focal p16 staining is present. Original magnification 
(i) x 5; (a)-(f) x 20. 
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(ii) p53 
(a) Ki67
(b) MCM2
(c) MCM5
(d) p53
(e) p16
(f) TopBP1
(i) H&E (ii) p53
 
Figure 19 BetaPV negative actinic keratosis. 
Sections stained with (i) H&E and antibody directed against (a) Ki67, (b) MCM2, (c) MCM5, 
(d)&(ii) p53, (e) p16 and (f) TopBP1. Ki67, MCM2, MCM5, TopBP1 staining is present through 
the full thickness of the lesion. Focal p53 (see inset) is present within the lesion. Original 
magnification (insets) x 5; (a)-(f) x 20. 
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Figure 20 BetaPV positive intra-epidermal carcinoma. 
Sections stained with (i) H&E and antibody directed against (a) Ki67, (b) MCM2, (c) MCM5, 
(d) p53, (e) p16 and (f) TopBP1. Original magnification (i) x 5; (a)-(f) x 20. 
 
(a) Ki67 (d) p53 
(b) MCM2 (e) p16 
(c) MCM5 (f) TopBP1 
(i) H&E 
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(a)Ki67
(b)MCM2
(c) MCM5 (f) TopBP1
(d) p53
(e) p16
(i) H&E
 
Figure 21 BetaPV negative intra-epidermal carcinoma.  
Sections of a betaPV negative intra-epidermal carcinoma stained with (i) H&E and antibody 
directed against (a) Ki67, (b) MCM2, (c) MCM5, (d) p53, (e) p16 and (f) TopBP1. Ki67, MCM2, 
MCM5, P53 and TopBP1 staining is present through the full thickness of the lesion. p16 
staining is present in an intense band through the full thickness of the lesion. Original 
magnification (i) x 5; (a)-(f) x 20. 
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Figure 22 BetaPV positive squamous cell carcinoma (Low Grade). 
Sections stained with (i) H&E and antibody directed against (a) Ki67, (b) MCM2, (c) MCM5, 
(d) p53, (e) p16 and (f) TopBP1. Original magnification (i) x 5; (a)-(f) x 20. 
 
 
(a) Ki67 
(f) TopBP1 (c) MCM5 
(e) p16 (b) MCM2 
(d) p53 
(i) H&E 
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(a) Ki67 (d) p53
(b) MCM2 (e) p16
(c) MCM5
(i) H&E
(f) TopBP1
 
Figure 23 BetaPV negative squamous cell carcinoma (High Grade).  
Sections stained with (i) H&E and antibody directed against (a) Ki67, (b) MCM2, (c) MCM5, 
(d) p53, (e) p16 and (f) TopBP1. Ki67, MCM2 and MCM5 are present through the full 
thickness of the lesion. p53 staining is not evident in the photographed area of the section 
but was present focally elsewhere. p16 staining, although less intense than that seen in 
Figure 16(e), is present in a band like distribution through the full thickness of the lesion. 
TopBP1 staining is both nuclear and cytoplasmic. Original magnification (i) x 5; (a)-(f) x 20. 
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3.3.4 Discussion 
Ki67 protein is expressed in nuclei at all stages of the cell cycle except G0 and is 
a useful marker of proliferating/cycling cells (304). Previous studies of Ki67 
expression in normal skin and a variety of both HPV typed and un-typed skin 
lesions found no correlation between Ki67 expression and proliferative state, risk 
of SCC progression or presence of HPV(305-309). Our results are in keeping with 
lack of correlation between Ki67 and HPV status in NMSC.   
The family of MCM proteins 2-7 are components of the prereplicative complex 
essential for the initiation of DNA replication. Expression of MCM proteins is lost 
as the cell differentiates or is quiescent, thus the MCM proteins are a marker of 
cell proliferation (302). Antibodies to MCM proteins have been shown to improve 
detection of abnormal cells in Papanicolaou cervical smears and are more 
sensitive than anti-Ki67 antibody (302). Previous studies of MCM proteins in the 
skin showed a trend for a greater detection of proliferating cells with antibody 
directed against MCM5 protein compared to MCM 2 protein as seen in this 
study(310). Furthermore, expression of MCM proteins is, as expected,  higher in 
poorly differentiated SCC compared to well differentiated lesions and staining is 
absent in the well differentiated cells adjacent to keratin pearls (310;311). Our 
study did not find an association between MCM protein expression and presence 
or absence of HPV. 
The tumour suppressor gene, p53 is located on the short arm of chromosome 
17p13.1. It is the most commonly mutated gene in human cancers. Cellular 
damage as a result of exposure of skin to UVR both induces wild type p53 and 
results in UV signature p53 mutations(312). Expression of wild type p53 protein 
initiates DNA repair mechanisms or induces cell cycle arrest or apoptosis. HPV 
infected cells must avoid p53 induced cell cycle arrest or apoptosis in order to 
replicate. Cervical cancer associated high risk mucosal HPV types do so through 
the action of the viral protein E6 which induces p53 degradation via the 
ubiquitin-proteasome pathway(137). BetaPV E6 protein does not degrade p53 via 
this pathway but can target the pro-apoptotic factor Bak for degradation thus 
avoiding apoptosis in a p53-independent manner (313;314). Several studies have 
examined the relationship between p53 staining in NMSC and presence of HPV 
and have found no relationship (307;315-317). Our samples were 
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comprehensively examined for betaPV and also found no correlation between 
betaPV presence and p53 staining.  
P53 antibodies do not distinguish between mutated or wild type p53. In our 
samples we may have expected to see both over-expression of wild type p53 as a 
reflection of UVR exposure and mutated p53 as this is commonly found in all 
cancers. Furthermore betaPV E6 does not degrade p53 and therefore p53 may 
not have been a useful marker to examine for different expression patterns 
between HPV positive and negative lesions. Had they been available, antibodies 
to Bak may have been more useful as BetaPV E6 can target back in a p53 
independent manner. 
p16, encoded by the CDKN2a gene on 9p21, competes with cyclin D to bind 
CDK4/6 to prevent inactivation of pRb (318;319). The E7 oncoprotein from high-
risk HPV types inactivates pRb resulting, by negative feedback, in over-
expression of inactive p16 which is a marker to detect high risk mucosal PV 
infected cervical lesions (320).  It has been shown that the HPV-38E7 protein has 
the ability to inactivate pRb therefore over expression of p16 in cutaneous 
lesions might be expected in betaPV infected samples. Previous studies of non-
HPV typed skin lesions have shown p16 is absent in normal skin/benign controls 
and variably over-expressed in NMSC (305;321-323). Correlation of p16 
expression and HPV presence has previously been found inconclusive due to 
small numbers (324;325). Our study did not find any correlation between p16 
expression and betaPV infection. Although p16 has proven a useful marker in 
high risk mucosal HPV infected cervical lesions, because betaPV E7 does not 
inactivate pRb it may not be helpful in distinguishing between betaPV positive 
and negative skin cancers as has been shown in this case. Furthermore, p16 
expression is often aberrant in skin cancers independent of HPV status again 
suggesting that p16 may not be useful in distinguishing between betaPV positive 
and negative skin cancers.   
The marker TopBP1 has not been previously incorporated into studies of NMSC 
and betaPV. TopBP1 was included in this study as it has recently been shown to 
be aberrantly expressed in a significant percentage of breast cancers and is also 
essential for signalling DNA damage following UVR (248;254). The role of TopBP1 
in activating the DNA damage signalling pathway through ATR following UVR 
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suggests this protein has a key role in maintaining genomic integrity in skin cells 
(254;256). Aberrant expression of TopBP1 in skin would therefore compromise 
the ability of the cells to respond appropriately to UVR and could be important 
in the development of NMSC. Furthermore, TopBP1 has been shown to be an 
interacting partner for the HPV-16 replication protein E2 (219). Our results 
showed aberrant expression of TopBP1 in a sub-set of NMSC although there was 
no association with presence of betaPV.  
3.3.5.1 Conclusion  
We have analysed by immunohistochemistry the expression patterns of cell cycle 
markers in a set of 100 nonmelanoma skin cancers typed for the presence of 
betaPV. We have shown over-expression of Ki67, MCM2, MCM5, p53 and p16 in a 
significant number of skin tumours compared to normal skin.  
We have identified aberrant TopBP1 staining in skin tumours compared to normal 
skin - the first time that abnormal TopBP1 expression has been demonstrated in 
skin cancers. 
We found no correlation between staining patterns and the presence or absence 
of HPV and the data shown do not support a role for HPV in NMSC. Although p53 
and p16 are useful markers in HPV infected cervical lesions, they have not aided 
the distinction between HPV infected skin cancers. This is because UV results in 
over-expression of p53, both wild type and mutated. Furthermore, betaPV E6 
does not degrade p53 but can target Bak for degradation thus avoiding apoptosis 
in a p53 independent manner. Antibodies to Bak, had they been available may 
have been a more useful biomarker to investigate. Similarly p16 may also be 
abnormally expressed in skin cancers and is not helpful ion distinguishing 
between betaPV positive and negative lesions as betaPV E7 does not bind pRb. 
Had there been a difference in biomarker expression in betaPV positive and 
negative lesions, the results would have been validated by extending the study 
to examine the expression of these markers in other betaPV positive and 
negative lesions such as viral warts or seborrhoeic keratoses. This would have 
helped distinguish whether the patterns seen were a reflection of betaPV 
infection on replication alone or as part of malignant transformation. Another 
limitation of the study was the small numbers. A larger study would be required 
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to determine if other factors such as infection with specific types, e.g. HPV-5, -8 
and -38, are the determining factor.  
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Chapter 3.4 The effect of TopBP1 on expression of 
viral proteins. 
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 3.4.1 Interaction between E2 and TopBP1. 
All the work in this chapter was carried out by Lorna Mackintosh unless stated 
otherwise. 
Previous work in the Morgan laboratory identified TopBP1 as a cellular 
interacting partner for HPV-16E2 using a yeast-two hybrid screen (245). We 
propose that HPV replication in eukaryotic cells occurs via direct recruitment of 
TopBP1 to the E1-E2 complex resulting in DNA polymerase loading and initiation 
of replication. 
To test this hypothesis we wished to generate a mutant of E2 that does not bind 
TopBP1 and then test the replication potential of this mutant. To do this, first 
the interaction between E2 and TopBP1 was mapped (Figure 24 A and B). The 
entire TopBP1 protein was screened in overlapping fragments as in vitro 
translated proteins for interaction with a fusion protein GST-E2 2-229. Amino 
acids 2-229 on the E2 protein is the interaction domain used to identify the 
TopBP1-E2 interaction. Three interaction domains were identified on TopBP1, 
amino acids 19-86, 586-606 and 818-888 (Figure 24 A). 
To further map the domain on E2 that interacts with the domains on TopBP1, 
GST deletion mutant proteins of E2 were made and binding tested against three 
TopBP1 fragments each containing one of the TopBP1-E2 binding domains as 
described. The core interaction domain was thus mapped to between amino 
acids 50 and 110. This domain retained several amino acids that could be 
possible TopBP1 contact residues, some of which are 100% conserved between 
all E2 proteins (Figure 24 B) (Work carried out by M. Donaldson). 
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Figure 24 A complex interaction between HPV-16 E2 and TopBP1. 
A. Schematic representation of the TopBP1 protein illustrating the three E2 interaction 
domains identified (represented by thick black lines). The blue boxes numbered one to eight 
represent BRCT domains.  
B. The domain on E2 that interacts with the domains on TopBP1 was further mapped with 
GST deletion mutant proteins. A schematic representation of the proteins is illustrated with 
the grey boxes representing GST and the purple boxes the E2 fragment. The table on the 
right shows the binding affinity between each of the GST-E2 deletion mutant proteins and 
three TopBP1 fragments each of which contains a TopBP1-E2 interaction domain. From this 
it was clear the region on E2 responsible for TopBP1 binding lay between amino acids 50-
110. 
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Before generating an E2 mutant, the potential E2/TopBP1 contact residues were 
further narrowed down. To do this, amino acids on the E2 protein with 
previously assigned functions were eliminated.  
Previous studies have characterised HPV16-E2 residues between amino acids 50 
and 110 involved in transcriptional activity (transcription/Brd4 binding sites), E1 
interaction sites as well as those predicted to be required for E2 structure. 
Mutation of amino acid residues may generate an E2 mutant with a compromised 
function; however mutation of certain residues generates an E2 mutant that fails 
to function in any tested assay suggesting that the residue was critical for the 
structure and function of the E2 protein. Such residues, identified from 
published studies, were deemed multiply defective.  The locations of these 
known sites are illustrated in Figure 25. 
TopBP1 is not required for E2 transcription function (261) and we predict a triple 
complex between E2-E1-TopBP1 for replication. Therefore the E2 residues 
required for E1 interaction should be distinct from those required for TopBP1 
interaction. Therefore E2 residues required for transcription function and E1 
interaction were eliminated. Also eliminated were residues shown to be multiply 
defective and those required for E2 structure and therefore could not be 
mutated. (Work carried out by M. Donaldson). 
The residual amino acids not involved in any of the above functions are shown in 
Figure 25. These amino acids were mutated in pairs and with adjacent residues.  
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Figure 25 Selection of candidate residues for TopBP1 interaction. 
E2 residues required for transcription function (purple) and E1 interaction (blue) were 
eliminated. Also eliminated were residues shown to be multiply defective (pink) and those 
required for E2 structure and therefore could not be mutated (green).  This left the amino 
acids shown (grey). The two shaded residues represent amino acid residues 89 and 90.  
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3.4.2 Generation of an E2 mutant that does not bind 
TopBP1 
HPV-16E2 mutants were generated by site directed mutagenesis of candidate 
amino acids residues in pairs with adjacent residues. Mutation of amino acid 
residues 89 and 90 (shaded residues, Figure 25), generated an E2 mutant (N89Y 
E90V) that failed to bind TopBP1 as demonstrated by co-immunoprecipitation 
between the mutant and TopBP1 (not shown) (work done by M. Donaldson).  
To further characterise this mutant, single amino acid mutations were generated 
by site directed mutagenesis (2.2.4.11). The following HPV-16E2 mutants were 
generated N89Y, E90A and E90V with primers MDP264/265, MDP262/263 and 
MDP260/261 respectively. All mutants generated were sequenced as described 
(2.2.4.12) to ensure that the correct mutation had been inserted.  
3.4.3 Replication efficiency of HPV16E2 wild type and 
mutants 
In order to test the hypothesis that an E2 mutant that failed to bind TopBP1 
would result in compromised replication of the HPV-16 genome in vivo, 
replication assays were performed in the 293T cell line (2.2.5.4).  
293T cells were transiently transfected as described (2.2.5.2.1) with 100pg pOri 
(HPV-16 origin of replication) and 5g HPV-16E1 plus 1ng or 10ng of HPV-16E2 
wild type or mutants. Cells were harvested four days following transfection and 
the amount of replicated HPV DNA was assessed by quantitative PCR (2.2.4.9). 
The results are shown in Figure 26 A and B and demonstrate that while the N89Y 
mutant replicates in a similar fashion to wild type E2, the presence of mutations 
N89YE90V and E90V result in reduced replication of HPV DNA. The reduction in 
replication compared to wild type is statistically significant for the N89YE90V 
mutant at both 1ng and 10ng (p<0.05) however for the single E90V mutant, there 
is no difference to wild type at the 1ng titration but at statistically significant 
reduction (p<0.05) at the 10ng titration. 
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Plasmids  Mean Replication  Fold Effect/E2 WT 1ng    
  A B C A B C Mean S.E.M. p value 
Cells only  0 0 0       
E2WT 1ng 0.61 0.13 1.26 1.00 1.00 1.00 1.00 0.00  
N89Y 1ng 0.44 2.12 18.42 0.71 16.49 14.58 10.60 4.98 0.12579 
E90V 1ng 2.55 0.03 1.44 4.18 0.22 1.14 1.85 1.20 0.51790 
N89YE90V 1ng 0.03 0.03 0.06 0.05 0.22 0.05 0.11 0.05 0.00008 
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Plasmids  Mean Replication  Fold Effect/E2 WT 1ng    
  A B C A B C Mean S.E.M. p value 
E2WT 10ng 2.22 2.97 33.62 1.00 1.00 1.00 1.00 0.00  
N89Y 10ng 2.52 2.85 44.43 1.14 0.96 1.32 1.14 0.11 0.25946 
E90V 10ng 0.35 0.45 15.58 0.16 0.15 0.46 0.26 0.10 0.00197 
N89YE90V 10ng 0.66 0.48 7.28 0.30 0.16 0.22 0.22 0.04 0.00004 
 
Figure 26 A and B Replication activity of HPV-16 wild type and mutants. 
293T cells were transfected with HPV-16E2 wild type and mutants. Each experiment was 
carried out in triplicate.  
A. Replication is expressed as the fold effect in replication over E2 wild type 1ng. 
B. Replication is expressed as the fold effect in replication over E2 wild type 10ng 
The graphs shows the mean of three experiments +/- S.E.M. (standard error of the mean).  
Results from each experiment (A-C) are shown in the tables below each graph. Variation 
between replicates A-C reflects variation in the efficiency of transient transfection. Control 
plates with cells only, pOri or pOri+E1 were included to ensure there was no contamination 
(results shown for cells only). Each PCR reaction was performed in triplicate; the amount of 
replication shown is the mean of three wells.  
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3.4.4 HPV-16E2 mutants binding to TopBP1 and HPV-16E1 
The results shown above demonstrate that the N89YE90V mutant exhibits a 
compromised replication phenotype. The N89YE90V mutant is significantly 
compromised compared to wild type E2 at both 1ng and 10ng, the E90V mutant 
is significantly compromised at 10ng and the N89Y mutant replicated like wild 
type. To investigate whether the single point mutations of the E2 protein E90V, 
E90A and N89Y failed to bind TopBP1 similar to the double mutation N90YE90V, 
a co-immunoprecipitation was carried out between the E2 mutants and TopBP1. 
The results demonstrate failure of N89YE90V and E90V to bind TopBP1. HPV16E2 
mutants E90A and N89Y bind TopBP1 similar to wild type E2. The results are 
shown in Figure 27. 
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Figure 27 Western Blot of 293T protein extracts expressing HPV16E2 wild type (WT) or 
mutants N89YE90V, E90A, E90V and N89Y.  
The lower panels are probed with the E2 antibody and the left hand panel (lanes 1 to 5) 
shows the level of input E2 protein (this represented 10% of the protein used in the co-
immunoprecipitation experiment). The upper panels represent TopBP1 levels; there are no 
input levels shown as these are often difficult to detect (lanes 1 to 5). In Lane 6 the results of 
co-immunoprecipitation with the TopBP1 antibody and wild type E2 are shown. It is clear 
that in the lower panel a significant level of E2 protein is co-immunoprecipitated with 
TopBP1. Lane 7 represents the same experiment with pre-immune serum from the rabbit 
used to raise the TopBP1 antibody; neither TopBP1 nor E2 is immunoprecipitated (the faint 
E2 band detected is due to residual binding to the sepharose beads). Lanes 8-11 show the 
results of the co-immunoprecipitations of the E2 mutants by TopBP1; it is clear that TopBP1 
has been immunoprecipitated in every sample (top panel) while E2 is co-
immunoprecipitated in the E90A and N89Y samples. N89YE90V and E90V E2 mutants fail to 
co-immunoprecipitate with TopBP1. 
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Replication occurs in S phase of the cell cycle and this laboratory has previously 
shown the E2 protein is stabilised in S phase(326).  
To test if the N89YE90V mutant was also stabilised in S phase, 293T cells, 
transfected with wild type HPV-16E2 or HPV-16E2N89YE90V were treated with 
the DNA polymerase inhibitor Aphidicolin (5g/ml) for 16 hours to synchronise 
the cells. This treatment arrests the cells at the G1/S phase transition of the cell 
cycle. The drug was then removed, allowing for cell cycle progression into S 
phase and the cells were harvested at 2 and 4 hours. Protein extracts were 
prepared and TopBP1 and E2 protein levels investigated by Western Blotting. 
The results are shown in Figure 28A and illustrate that TopBP1 and wild type E2 
are stabilised in S phase however N89YE90V is not (work done by M. Donaldson). 
As the N89YE90V E2 mutant is not stabilised in S phase a Co-IP of the interaction 
between TopBP1 and N89YE90V was carried out in S phase. It can be seen that 
wild type E2 binds TopBP1 in untreated, Aphidicolin arrested and released cells, 
the strongest interaction is observed, as expected, 4 hours after release when 
both TopBP1 and E2 are stabilised. The N89YE90V mutant does not bind TopBP1 
either in untreated cells or in S phase (Figure 28B) (work done by E. Dornan).  
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Figure 28 S phase stability of E2 and CoIP with TopBP1 
A. Western Blot of 293T protein extracts, untreated, arrested with Aphidicolin and 2 and 4 
hours following removal of the drug (2h release, 4h release). The upper panels demonstrate 
that TopBP1 is stabilised in S phase. The lower panels show stabilisation of wild type E2 in 
S phase as demonstrated by an increased density band at both 2 and 4 hours whereas in 
cells transfected with the mutant E2 N89YE90V, there is no stabilisation.  
B. 293T cells were transfected with 16E2 wild type or N89YE90V treated with Aphidicolin for 
16 hours then released and harvested 2 and 4 hours later. The Western Blots of the inputs 
are shown (panels A and C). The IP with TopBP1 shows increased levels of TopBP1 at 4 hrs 
post release (panel B). The CoIP between E2 and TopBP1 (panel D) shows that E2 is pulled 
down in untreated and Aphidicolin treated cells and in S phase (2h and 4h) however the 
N89YE90V mutant does not bind TopBP1 either in untreated cells or in S phase. The positive 
control lane (+), panel D demonstrates that the E2 antibody is working. 
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In order to demonstrate that compromised replication function of the E2 mutant 
was not due to lack of binding to E1, a co-immunoprecipitation experiment was 
carried out between the E2 mutant and E1. The E1 plasmid was tagged with the 
HA epitope to allow for detection by Western Blotting.  
293T cells were transiently transfected with E2 alone or co-transfected with 
E1HA. E2 wild type or E2 N89YE90V was transfected along with two negative 
control experiments, no E2 or E2E39A, an E2 mutant that fails to bind E1. A Co-
IP experiment was then carried out and the resultant cell lysates separated by 
SDS-PAGE gel electrophoresis and probed by Western Blotting for HA and E2. 
The results of the Co-immunoprecipitation are shown in Figure 29. (Work carried 
out by E. Dornan).  
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Figure 29 Co-IP of HPV-16E2 and HPV-16E1HA 
A. Input levels.  
Lanes 1-4 are 293T cell extracts transfected with E2 or controls in the absence of E1HA. As 
expected no bands are observed when the lysates are probed by Western Blotting with the 
HA antibody (upper panels). The lower panels demonstrate the input levels of E2 with no 
band seen in lane 1 (no E2) which acts as a negative control.  
Lanes 5-8 show the input levels where E2 was co-transfected with E1HA. As expected, HA 
bands are clearly seen when the Western Blot is probed with the HA antibody (upper 
panels). The lower panels again show the presence of E2 in all but the negative control lane 
(5). In the presence of E1HA, the E2 bands are stronger as E2 is stabilised by E1. 
B. Co-IP with E1HA 
Lanes 1-4 show 293T lysates transfected with E2 alone. As expected no bands are seen with 
the HA antibody (upper panels) and E2 is not pulled down (lower panels). 
In lanes 5-8 the IP with E1HA shows the HA bands in each lane indicating that the lysates 
are co-transfected with E1HA and that the HA antibody is working (upper panels). The lower 
panels show the Co-IP. When probed for E2, no E2 band is seen in lane 5 (negative control) 
however, E1HA pulls down both wild type E2 (lane 6) and the E2N89YE90V mutant (lane 7). 
E1 does not pull down E2E39A (lane8) as expected as this E2 mutant does not bind E1. 
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3.4.5 Transcriptional activity of HPV-16E2 mutants 
In order to demonstrate that compromised replication is not due to altered 
transcription of the HPV-16E2 mutant, luciferase assays were carried out in the 
293T cell line with the ptK6E2 promoter plasmid.  
The ptk6E2 plasmid consists of an HSV tk promoter which has six consecutive E2 
binding sites. E2 binds at these sites and drives the expression of the luciferase 
reporter gene (269). Measurement of luciferase activity thus acts as a surrogate 
marker for the transcriptional activity of E2. A schematic representation of the 
ptK6E2 plasmid is illustrated in Figure 30.  
 
6 E2 binding sites Tk promoter Luciferase
 
Figure 30 Schematic representation of the ptk6E2 plasmid. 
A schematic representation of the ptk6E2 plasmid illustrating six E2 binding sites, the tk 
promoter from HSV1 and the luciferase reporter gene.  
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Luciferase assays were performed in the 293T cell line. 293T cells transiently 
transfected with 1g of ptK6E2 and 1ng, 10ng, 100ng and 1g of HPV-16E2 wild 
type and mutants were harvested two days following transfection and luciferase 
activity was measured as described (2.2.5.5).   
Each experiment was carried out in triplicate and the results are shown in Figure 
31.  
The HPV-16E2 N89YE90V mutant demonstrates a significant reduction in 
transcriptional activity compared to wild type at 10ng (p 0.0307) but is not 
significantly different at the 1ng, 100ng and 1g titrations. No significant 
differences in transcriptional activity of the HPV-16E2 N89Y or E90V mutants 
compared to wild type E2 were observed. This suggests that the reduced 
replication activity observed with the E2 mutant N89YE90V is not due to mis-
folding of the protein. However it is interesting to note that the pattern of 
transcriptional activation observed with the N89YE90V mutant is different to 
that seen with wild type E2 or the N89Y and E90V E2 mutants. Furthermore, 
transcriptional activity is present at lower levels than seen with the N89Y and 
E90V mutants, the reason for this observation is not currently clear but could be 
related to the inability to bind TopBP1. 
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  A B C A B C Mean S.E.M P 
value 
Cells only x 2.45 0.89 5.63       
pGL3 
Control 
1g 2056.02 919.07 5710.50       
pGL3 Basic 1g 3.09 3.95 13.82       
ptK6E2 1g 2.52 2.08 3.15 1.00 1.00 1.00 1.00 0.00  
16E2 WT 1ng 14.17 44.62 18.04 5.63 21.48 5.73 10.94 5.27  
 10ng 48.02 66.90 93.75 19.06 32.20 29.75 27.01 4.04  
 100ng 60.71 90.56 174.95 24.10 43.59 55.52 41.07 9.17  
 1g 77.28 20.17 91.45 30.68 9.71 29.02 23.14 6.74  
N89Y 1ng 15.71 35.12 35.41 6.24 16.91 11.24 11.46 3.09 0.9367 
 10ng 49.41 51.24 82.83 19.62 24.66 26.29 23.52 2.01 0.4825 
 100ng 141.15 70.80 555.35 56.04 34.08 176.25 88.79 44.24 0.3500 
 1g 97.32 59.74 294.20 38.64 28.76 93.37 53.59 20.12 0.2241 
E90V 1ng 20.41 51.97 157.55 8.10 25.01 50.00 27.71 12.18 0.2749 
 10ng 58.07 205.19 195.60 23.05 98.77 62.08 61.30 21.89 0.1978 
 100ng 126.82 193.00 171.85 50.35 92.90 54.54 65.93 13.56 0.2030 
 1g 120.83 60.08 144.05 47.97 28.92 45.72 40.87 6.02 0.1209 
N89YE90V 1ng 7.66 12.50 7.84 3.04 6.02 2.49 3.85 1.10 0.2578 
 10ng 11.05 26.42 44.76 4.39 12.72 14.20 10.44 3.06 0.0307 
 100ng 49.44 136.48 241.45 19.63 65.69 76.63 53.98 17.49 0.5484 
 1g 124.33 107.04 309.10 49.36 51.52 98.10 66.33 15.92 0.0666 
           
Figure 31 Transcriptional activation of HPV-16E2 wild type and mutants in 293T cells.  
Luciferase activity, is expressed as the fold activity over that seen with the ptK6E2 promoter 
alone. Each experiment was carried out in triplicate and the graph shows the mean results 
of three experiments +/- S.E.M. (standard error of the mean). Results from each experiment 
(A-C) are shown in the table. Control plates (cells only, pGL3Control and pGL3Basic, ptK6E2 
promoter) were included for each experiment. Each replicate was carried out in duplicate; 
mean luminescence is the mean from each set of duplicates. Variation between replicates 
reflects variation in the efficiency of transient transfection.  
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3.4.6 Stability of HPV-16E2 proteins 
Compromised replication of HPV DNA could result from altered stability of the E2 
protein when the E2 gene is mutated. In order to determine whether the E2 
mutant proteins differed in stability from wild type E2 protein, the 293T cell line 
was transiently transfected with E2 wild type or mutants and a Cycloheximide 
treatment time course experiment was carried out (2.2.5.6). Cell culture plates 
were treated with Cycloheximide and harvested at different time-points to 
determine the half life of the wild type and mutated E2 protein. Equal amounts 
of the resultant protein lysates were separated by protein gel electrophoresis 
and analysed by Western Blotting. Blots were probed for E2 (TVG261) and -
tubulin as a loading control. The experiment was repeated three times and a 
representative Western Blot is shown in Figure 32. There is variable expression 
of E2 wild type and mutants however there does not appear to be any major 
differences in any of the mutants in comparison to wild type E2.  
To confirm this, Western Blots from the three repeats were scanned and 
analysed using Image J software (rsbweb.nih.gov/ij/). Following normalisation of 
the intensity of each E2 protein band to the corresponding -tubulin band, the E2 
protein band density at each time point was expressed relative to the E2 protein 
band density pre-Cycloheximide treatment. The results are illustrated in Figure 
33 and confirm that there are no significant differences in the half lives of the 
E2 mutants in comparison to wild type E2. The protein half lives were Wild Type, 
6.08 hours, N89YE90V, 8.39 hours, N89Y, 9.36 hours, E90V, 7.60 hours.  
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Figure 32 Stability of HPV-16E2 wild type and mutants in transiently transfected 293T cell 
line. 
Cells transfected with wild type HPV-16E2 or mutants N89Y, E90V or N89YE90V were treated 
with Cycloheximide and harvested at 0, 2, 4, 8 and 16 hours post treatment. The resultant 
protein lysates were separated by SDS-PAGE electrophoresis and analysed by Western 
Blotting. Blots were probed for both E2 (TVG 261 antibody) (upper panels) and -tubulin as a 
loading control. The experiment was repeated three times and a representative Western Blot 
is shown. 
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Figure 33 Graph of E2 protein band density over time since Cycloheximide treatment. 
Western Blots from three experiments Cycloheximide time course experiments were 
scanned and the protein band density analysed using the Image J software.   
HPV-16E2 wild type is represented by the blue line and the N89Y, yellow, E90V, turquoise 
and N89YE90V pink. For each time point, the density of the E2 protein band was normalised 
to the corresponding protein band intensity for -tubulin. For E2 WT and each E2 mutant, 
the density of the E2 protein band pre Cycloheximide treatment was taken as 100% and all 
subsequent time points expressed relative to the pre-treatment levels. The results shown 
are the mean of three experiments +/- S.E.M. 
For each protein, a linear trendline (shown in the corresponding colour) and the equation of 
the line is shown allowing calculation of the half life of each protein. The half lives were, WT, 
6.08; N89YE90V, 8.39; N89Y, 9.86 and E90V, 7.60 hours.  
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To confirm these results, the Cycloheximide treatment time course was 
repeated in the U2OS cell line that had been stably transfected with HPV-16E2 
wild type (U2OS B3 cell line) and HPV-16E2 N89YE90V (U2OS 4.1 cell line). 
A Cycloheximide treatment time course experiment was carried out as described 
(2.2.5.6). Equal amounts of the resultant protein lysates were separated by 
protein gel electrophoresis and analysed by Western Blotting. Blots were probed 
for E2 (TVG261) and -tubulin as a loading control. The experiment was repeated 
three times and a representative Western Blot is shown in Figure 34.  
It can be seen that wild type E2 expression in the B3 cell line is more 
pronounced that E2 N89YE90V expression in the 4.1 cell line however there does 
not appear to be any difference in the overall half life of either protein.  
Western Blots from the three repeats were scanned and analysed using Image J 
software (rsbweb.nih.gov/ij/) as described above.  The results are illustrated in 
Figure 35.  The half life of both wild type E2 and E2N89YE90V are however 
similar, the half life of the wild type E2 being 10.94 hours and the half life of 
N89YE90V being 8.22 hours.   
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Figure 34 Stability of HPV-16E2 wild type and E2N89YE90V in stably transfected cell lines 
U2OS B3 and U2OS 4.1. 
U2OS B3 and 4.1 cells were treated with Cycloheximide and harvested at 0, 1, 2, 4, 8, 16 and 
24 hours post treatment. The resultant protein lysates were separated by SDS-PAGE 
electrophoresis and analysed by Western Blotting. Blots were probed for both E2 (TVG 261 
antibody) (upper panels) and -tubulin as a loading control (lower panels). The experiment 
was repeated three times and a single representative Western Blot is shown. 
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Figure 35 Graph of E2 protein band density over time since Cycloheximide treatment. 
Western Blots from three Cycloheximide time course experiments were scanned and the 
protein band density analysed using the Image J software.  The B3 cell line is represented 
by the blue line and the 4.1 cells by the pink line. For each time point, the density of the E2 
protein band was normalised to the corresponding protein band intensity for -tubulin. The 
density of the E2 protein band pre Cycloheximide treatment was taken as 100% and all 
subsequent time points expressed relative to the pre-treatment levels. The results shown 
are the mean of three experiments +/- S.E.M. 
For each protein, a linear trendline (shown in the corresponding colour) and the equation of 
the line is shown allowing calculation of the half life of each protein. The half lives were, 
WT,10.94; N89YE90V, 8.22 hours.  
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3.4.7 Generation of E2 mutants in an alternative HPV type. 
The results have demonstrated that generation of a mutant E2 that fails to bind 
TopBP1 has resulted in a compromised replication phenotype. We wished to see 
if these results could be replicated in another HPV type. For these experiments 
HPV-8 was chosen. HPV-8 belongs to the genus Betapapillomaviruses and has 
been identified in SCC from patients with EV and in NMSC from both 
immunocompetent and immunocompromised individuals.  
The amino acid at position 90 on the E2 gene is highly conserved between 
species. An amino acid alignment illustrating this is shown in Figure 36. It can be 
seen that amino acid 90 is conserved across HPV-16, -18 (high risk mucosal 
types), HPV-6, -11 (low risk mucosal types) and HPV-8, -5 (betaPV types). 
 
HPV16           ----METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKQMRLECAIYYKAREMGFKHINH 56
HPV18           MQTPKETLSERLSALQDKIIDHYENDSKDIDSQIQYWQLIRWENAIFFAAREHGIQTLNH 60
HPV11           ----MEAIAKRLDACQDQLLELYEENSIDIHKHIMHWKCIRLESVLLHKAKQMGLSHIGL 56
HPV6            ----MEAIAKRLDACQEQLLELYEENSTDLHKHVLHWKCMRHESVLLYKAKQMGLSHIGM 56
HPV8            ----MENLSERFNVLQDQLMNIYEAAEQTLEAQIAHWLLLRKEAVLLYFARQKGITRIGY 56
HPV5            ----MENLSERFNALQDQLMNIYEAAEQTLQAQIKHWQTLRKEPVLLYYAREKGVTRLGY 56
HPV16           QVVPTLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVYLTAPTGCIKKHGYT 116
HPV18           QVVPAYNISKSKAHKAIELQMALQGLAQSAYKTEDWTLQDTCEELWNTEPTHCFKKGGQT 120
HPV11           QVVPPLTVSETKGHNAIEMQMHLESLAKTQYGVEPWTLQDTSYEMWLTPPKRCFKKQGNT 116
HPV6            QVVPPLKVSEAKGHNAIEMQMHLESLLRTEYSMEPWTLQETSYEMWQTPPKRCFKKRGKT 116
HPV8            QPVPPLAVSEAKAKQAIGIMLQLQSLQKSEFADEPWTLVDTSIETYKNAPENHFKKGATP 116
HPV5            QPVPVKAVSETKAKEAIAMVLQLESLQTSDFAHEPWTLVDTSIETFRSAPEGHFKKGPLP 116  
Figure 36 Amino acid alignment.  
Amino acid alignment showing conservation of amino acid at position 90 on the E2 gene in 
HPV-16, -18, -11, -6, -8 and -5. 
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To investigate the TopBP1 /E2 interaction in HPV-8, the following plasmids were 
received as kind gifts from B.Akgul. p-8-1 containing the HPV-8 origin of 
replication;  pCE1: HPV-8E1 in pCB6; pCE2: HPV-8E2 in pCB6; pCMV2-Flag: empty 
vector and pCMV2-HPV-8E2-Flag: containing the E2 open reading frame ligated 
into the EcoR1 and BamH1 sites of pCMV2-Flag.  
For clarity from here on p-8-1 will be known as HPV-8ori, pCE1 as HPV-8E1 and 
pCE2 as HPV-8E2.  
There are no available antibodies for the detection of HPV-8E2 and detection 
therefore relies on the presence of an epitope detectable with commercially 
available antibodies.  
pCMV2-HPV-8E2-Flag (1, 2 and 5g) was transiently transfected into 293T cells. 
Equal amounts of the resultant protein lysates and controls were separated by 
SDS-PAGE gel electrophoresis and analysed by Western Blotting. The blot was 
probed with Anti-Flag antibody (SIGMA F7425) at different concentrations and 
conditions but it was not possible to detect the Flag epitope (data not shown). 
The pCMV2-HPV-8E2Flag plasmid was sequenced by ABI cycle sequencing as 
described (2.2.4.12) with primer MDP271 (2.4.10.7). Sequencing revealed that 
the Flag epitope was present however it was out of alignment with the multiple 
cloning site in pCMV2 and this was thought to be the explanation for the inability 
to detect the plasmid by Western Blotting.  To test the function of pCMV2-HPV-
8E2-Flag further, increasing amounts of HPV-8E2-Flag plasmid were tested in a 
replication assay using the non-flag tagged plasmid, HPV-8E2 as a control. pCMV-
HPV-8E2-Flag could not replicate (data not shown) therefore this plasmid was 
not used in any further experiments. 
To overcome this problem and to allow detection of HPV-8E2 by Western 
Blotting a myc epitope was attached to HPV-8E2 by cloning. HPV-8E2 was 
amplified by platinum Pfx DNA polymerase PCR (2.2.4.11.1) with primers LMP7 
and LMP8 (2.1.4.10.8). The PCR product was cleaned up using the QiaQuick PCR 
purification kit. The PCR product and plasmid vector p16E1-myc, clone 3 
(2.1.4.9) and restriction digested (2.2.4.5.2) with EcoR1 and BamH1. Restriction 
digest products were purified and gel extracted (2.2.4.5.2) before treating the 
cut vector with phosphatase as described (2.2.4.5.3). The digested insert and 
vector were ligated (2.2.4.5.4) and the chemically competent bacteria 
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transformed with the resultant ligation product (2.2.4.6). Small scale 
preparation of the resultant plasmid was performed (miniprep procedure, 
2.2.4.8) and the DNA was sequenced as described (2.2.4.12) with primer MDP271 
(2.4.10.7).  Sequencing revealed that HPV-8E2 had been correctly cloned into 
the myc tagged vector (data not shown). 
To check expression of HPV-8E2myc, 0, 1 and 5g of plasmid was transiently 
transfected into 293T cells. Cells were harvested 48 hours following 
transfection. The resultant protein lysates were separated by SDS-PAGE gel 
electrophoresis and analysed by Western Blotting. The blot was probed with 
anti-myc antibody (9E10,1:2000 dilution, AbCam). HPV-8E2myc protein could be 
clearly detected (Figure 37). 
A: Cells only
B: HPV-8E2myc 1µg 
C: HPV-8E2myc 5µg
A   B   C
E2-myc
 
Figure 37 Detection of myc tagged HPV-8E2 protein by Western Blotting. 
Western Blot was probed with anti-myc antibody at a 1:2000 dilution. HPV-8E2 protein is 
approximately 55KDa and the myc tag and multiple cloning site are approximately 2KDa. A 
57KDa protein band is visible on the Western Blot.  
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3.4.8 Replication efficiency of HPV-8E2 mutants 
We hypothesised that the HPV-8E2 mutants would behave in a similar fashion to 
the HPV-16E2 mutants and exhibit a compromised replication phenotype.  
HPV8-E2 mutants were generated in HPV-8E2 and HPV-8E2myc by site directed 
mutagenesis as described (2.2.4.11). The following HPV-8E2 mutants were 
generated, D89A, E90A, E90V and D89AE90V (equivalent to N89Y, E90A, E90V 
and N89YE90V in HPV-16E2) using primers LMP11/12, MDP 272/273, MDP270/271 
and LMP13/14 respectively (2.1.4.10). The resultant plasmids were amplified 
and sequenced as described (2.2.4.12) to ensure that the desired mutations had 
been made correctly (data not shown).   
A DNA probe and primer set for detection of HPV-8 origin of replication was 
designed (2.1.4.10.3). This was tested by preparing a standard curve of serial 
dilutions of HPV-8ori and assessing the quantity by PCR reaction. A standard 
curve was obtained indicating that the probe and primer set were efficient at 
detecting HPV-8ori (data not shown). 
293T cells transiently transfected with 100pg pOri (HPV-8 origin of replication) 
and 5g HPV8E1 plus 1ng, 10ng or 100ng of HPV-8E2 wild type or mutants were 
harvested four days following transfection (2.2.5.4) and the amount of 
replicated HPV DNA was assessed by quantitative PCR (2.2.4.9). Initial 
experiments were carried out using the HPV-8E2myc wild type and mutant 
plasmids however, similar to the findings when testing pCMV-HPV-8E2-Flag, 
replication was severely compromised when using HPV-8E2-myc plasmids in 
comparison with HPV-8E2 plasmids. Replication assays were therefore performed 
using only the HPV-8E2 wild type and mutant plasmids. The experiments were 
carried out on three occasions and the results are illustrated in Figure 38 A-C.  
The results demonstrate that there is a trend for the HPV-8E2 D89A mutant to 
replicate more efficiently than wild type HPV-8E2, this is significant at 1ng 
(p=0.067) but is not significantly different at the 10ng and 100ng doses. The 
HPV-8E2 E90A replicated in a similar fashion to wild type E2. Both the HPV-8E2 
E90V and D89AE90V mutant exhibit severely compromised replication and this is 
significant at 1, 10 and 100ng titrations (p<0.05). This pattern of reduced 
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replication is similar to that observed with HPV-16E2 E90V and N89YE90V 
mutants; however the reduction in replication is more significant with the HPV-
8E2 mutants. 
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Plasmids  Mean Replication Fold Effect/E2 WT 1ng   
  A B C A B C Mean S.E.M. p value 
Cells only  0.00 0.00 0.00       
E2 WT 1ng 0.27 0.03 0.00 1.00 1.00 1.00 1.00 0.00  
D89A 1ng 1.09 0.32 0.00 4.00 9.38 16.35 9.91 3.58 0.067336 
E90A 1ng 0.38 0.00 0.00 1.39 0.06 1.33 0.93 0.43 0.874932 
E90V 1ng 0.02 0.00 0.00 0.07 0.07 0.00 0.05 0.02 0.000002 
D89AE90V 1ng 0.00 0.00 0.00 0.02 0.00 0.00 0.01 0.01 <0.0000001 
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Plasmids  Mean Replication Fold Effect/E2 WT 10ng   
  A B C A B C Mean S.E.M. p value 
E2 WT 10ng 12.10 0.65 0.01 1.00 1.00 1.00 1.00 0.00  
D89A 10ng 20.65 10.88 0.44 1.71 16.74 43.23 20.56 12.15 0.182364 
E90A 10ng 3.84 1.04 0.03 0.32 1.61 3.01 1.65 0.78 0.453665 
E90V 10ng 1.89 0.07 0.00 0.16 0.11 0.01 0.09 0.04 0.000032 
D89AE90V 10ng 0.21 0.00 0.00 0.02 0.00 0.00 0.01 0.01 <0.0000001 
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Plasmids  Mean Replication Fold Effect/E2 WT 100ng   
  A B C A B C Mean S.E.M. p value 
E2 WT 100ng 26.69 6.61 0.72 1.00 1.00 1.00 1.00 0.00  
D89A 100ng 26.51 17.27 1.05 0.99 2.61 1.45 1.69 0.48 0.227230 
E90A 100ng 18.85 8.23 0.25 0.71 1.24 0.34 0.76 0.26 0.419252 
E90V 100ng 12.34 1.48 0.04 0.46 0.22 0.05 0.24 0.12 0.000184 
D89AE90V 100ng 7.97 0.34 0.00 0.30 0.05 0.00 0.12 0.09 0.000655 
 
 
Figure 38 Replication activity of HPV-8E2 wild type and mutants 
293T cells were transfected with HPV-8E2 wild type and mutants. Each experiment was 
carried out in triplicate.  
A. Replication is expressed as the fold effect in replication over E2 wild type 1ng 
B. Replication is the fold effect over E2 wild type 10ng 
C. Replication is the fold effect over E2 wild type 100ng 
Each graph shows the mean of three experiments +/- S.E.M. (standard error of the mean).   
Results from each experiment (A-C) are shown in the tables below each graph. Variation 
between replicates A-C reflects variation in the efficiency of transient transfection. Control 
plates with cells only, pOri or pOri+E1 were included to ensure there was no contamination 
(results shown for cells only in Table A). Each PCR reaction was performed in triplicate; the 
amount of replication shown is the mean of three wells.  
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3.4.9 Transcription efficiency of HPV8E2 mutants 
To confirm that these mutants are still functional, luciferase assays were carried 
out similarly to the HPV-16E2 mutants. 293T cells were transiently transfected 
with increasing concentrations of HPV-8E2 wild type or HPV-8E2 mutants and the 
ptk6E2 plasmid as described (2.2.5.5). Although the ptK6E2 promoter has 6 HPV-
16E2 binding sites, we hypothesised that due to the similarities between the 
HPV-16E2 and HPV-8E2 genomes, HPV-8E2 would bind to the ptK6E2 promoter.  
The results are shown in Figure 39. There is a non-significant trend for increased 
transcriptional activity of the HPV-8E2 D89A mutant, similar to the non-
significant trend for increased transcriptional activity observed with the HPV-
16E2 N89Y mutant. There are significant increases in transcriptional activity for 
both the HPV-8E2 E90A and E90V mutants at the 100ng titration but no 
significant differences at the 1ng, 10ng or 1g titrations. The results therefore 
demonstrate that transcriptional activity of the HPV-8E2 mutants is not 
compromised in comparison to wild type HPV-8E2 and suggest that the 
compromised replication seen with the HPV-8E2 mutant D89AE90V is not due to 
a fundamental structural defect in the protein.  
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  Mean Luminescence Fold Activation/ptK6E2 
Plasmids  A B C A B C Mean S.E.M P value 
Cells only x 27.11 6.22 16.66       
pGL3 
Control 
1g 25447.86 6193.23 15820.54       
pGL3 
Basic 
1g 87.97 11.85 49.91       
ptK6E2 1g 18.80 3.07 10.94 1.00 1.00 1.00 1.00 0.00  
8E2 WT 1ng 13.05 6.40 9.72 0.69 2.09 0.89 1.22 0.44  
 10ng 47.08 3.60 25.34 2.50 1.17 2.32 2.00 0.42  
 100ng 38.01 4.20 21.10 2.02 1.37 1.93 1.77 0.20  
 1g 60.65 12.71 36.68 3.23 4.15 3.35 3.58 0.29  
D89A 1ng 21.35 12.78 17.07 1.14 4.17 1.56 2.29 0.95 0.36507 
 10ng 41.34 18.71 30.02 2.20 6.10 2.75 3.68 1.22 0.26143 
 100ng 58.48 46.97 52.72 3.11 15.32 4.82 7.75 3.82 0.19290 
 1g 33.83 21.86 27.84 1.80 7.13 2.55 3.82 1.67 0.88993 
E90A 1ng 32.74 10.78 21.76 1.74 3.51 1.99 2.41 0.55 0.16616 
 10ng 44.49 5.83 25.16 2.37 1.90 2.30 2.19 0.15 0.68522 
 100ng 110.49 27.72 69.10 5.88 9.04 6.32 7.08 0.99 0.00628 
 1g 23.93 8.91 16.42 1.27 2.91 1.50 1.89 0.51 0.04560 
E90V 1ng 17.43 4.20 10.82 0.93 1.37 0.99 1.10 0.14 0.79350 
 10ng 22.65 8.45 15.55 1.20 2.76 1.42 1.79 0.49 0.76578 
 100ng 55.52 11.21 33.37 2.95 3.66 3.05 3.22 0.22 0.00851 
 1g 24.48 15.84 20.16 1.30 5.17 1.84 2.77 1.21 0.55221 
D89AE90V 1ng 19.28 9.82 14.55 1.03 3.20 1.33 1.85 0.68 0.47962 
 10ng 23.99 11.59 17.79 1.28 3.78 1.63 2.23 0.78 0.80828 
 100ng 43.38 16.75 30.06 2.31 5.46 2.75 3.51 0.99 0.16048 
 1g 25.25 15.60 20.43 1.34 5.09 1.87 2.77 1.17 0.53888 
           
Figure 39 Transcriptional activity of HPV-8E2 WT and mutants.  
293T cells transiently expressing 1g of ptK6E2 and 1ng, 10ng, 100ng or 1g of HPV8E2 
wild type and mutants were harvested two days following transfection and luciferase 
activity measured.  Each experiment was carried out in triplicate. Luciferase activity is 
expressed as the fold activity over that seen with the ptK6E2 promoter alone. The results 
show the mean of three experiments +/- S.E.M. (standard error of the mean). Control plates 
with cells only, positive and negative controls pGL3control and pGL3Basic and the ptK6E2 
promoter were included for each experiment. Each replicate was carried out in duplicate; 
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mean luminescence is the mean from each set of duplicates. Variation between replicates 
reflects variation in the efficiency of transient transfection.  
3.4.10 Discussion  
HPV replication is a possible therapeutic target that may be utilised for the 
development of anti-viral therapies. Disruption of the viral E1 /E2 interaction 
has not proven clinically useful thus far. Interactions between E1 and E2 with 
host proteins are possible alternative therapeutic targets. Little is known about 
the host cellular proteins that E1-E2 interact with in order to initiate viral DNA 
replication. Previous work in the Morgan laboratory has demonstrated that HPV-
16E2 interacts with the cellular protein TopBP1 (219;245;261) and with HPV-16E1 
(unpublished data).   
We hypothesised that viral DNA replication occurs via direct recruitment of 
TopBP1 to the E1-E2 complex resulting in DNA polymerase loading and initiation 
of replication. 
The first step towards testing this hypothesis was to map the interaction 
between TopBP1 and the HPV-16E2 DNA binding domain. Amino acids 50-110 of 
E2 were identified as being responsible for the interaction with TopBP1. 
Selection of candidate residues within this region followed by mutational 
analysis identified that when amino acids 89 and 90 were mutated, HPV-16 E2 
failed to interact with TopBP1. 
The work carried out in this Chapter has examined the TopBP1 E2 interaction. A 
double HPV16-E2 mutant was generated, N89YE90V and tested alongside single 
point mutations N89Y, E90A and E90V. We have confirmed that HPV-16E2 
N89YE90V fails to bind TopBP1 by co-immunoprecipitation and have shown that 
the single mutant E90V is sufficient to disrupt binding while mutants E90A and 
N89Y bind like wild type E2. 
To test the function of these HPV-16E2 mutants, replication assays were carried 
out and we have demonstrated that HPV-16E2 N89YE90V has a compromised 
replication phenotype whilst the replication efficiency of the single E2 mutations 
are not significantly altered compared to wild type E2 suggesting the double 
mutation is important to interrupt function. 
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The transcriptional activity of the HPV-16E2 mutants was tested by luciferase 
assays and the both the double and single mutants were functional suggesting 
that compromised replication is not due to a fundamental structural alteration 
of the E2 protein. However it is noted that there are subtle differences in the 
pattern of transcriptional activation seen with HPV-16E2 N89YE90V the reasons 
for which are currently unclear. Although TopBP1 clearly is not essential for 
transcription of E2 it but could be involved in its regulation. 
Finally, demonstration that there are no significant differences in the half life of 
the HPV-16E2 mutants when compared to wild type suggests that alteration in 
protein stability is not responsible for the alteration in replication that observed 
with HPV-16E2 N89YE90V. 
Interaction between E1-E2 and host cellular proteins are likely to be conserved 
across HPV types an important factor when considering the development of an 
anti-viral therapy. Therefore it was important to generate mutants of E2 in 
another HPV type and for this HPV-8 was chosen. The work on HPV-8E2 has 
demonstrated that generation of a mutant at amino acids 80 and 90 results in 
compromised replication of HPV-8E2. Furthermore, we have demonstrated, as in 
HPV-16 that this is not due to a fundamental alteration in the protein as the 
transcriptional activity of the HPV8E2 mutants is preserved. Interestingly 
replication is significantly altered in HPV-8E2 with the single amino acid 
mutations at position 90 but not position 89, this was not demonstrated in HPV-
16 and it is possible that in some HPV types, a single amino acid substitution is 
sufficient to induce an altered replication phenotype. 
In summary, we propose that TopBP1 interacts with E2 forming a TopBP1/E2/E1 
complex which binds polymerase  and initiated viral DNA replication (Figure 
40). By generating a mutant of E2 in HPV types -16 and -8 which fails to bind 
TopBP1, we propose that TopBP1 does not form a triple complex with E2/E1, 
polymerase  is not recruited and there is no initiation of viral DNA replication. 
This interaction is a potential future target for anti-viral therapies aimed at 
disruption of viral DNA replication. 
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E2
E1
Polymerase 
TopBP1
E2 protein forms homodimers and binds to the origin of replication
E1 is recruited to the origin via a protein-protein interaction with E2
E2 interacts with TopBP1 which binds to the E1/E2 complex
TopBP1 binds and loads polymerase 
Initiation of viral DNA replication
 
Figure 40 Schematic representation of the TopBP1/E1/E2 interaction. 
The origin of replication is represented by the black line, E2 by the blue ovals, E1 by the red 
ovals, TopBP1 is shown in green and polymerase  by the grey oval. A proposed sequence 
of events that leads to initiation of viral DNA replication is shown in the text box.  
 
 
E2 Wild type
Recruits TopBP1
Binds polymerase 
Initiation of viral DNA replication
E2 N89YE90V
X Failure to efficiently recruit TopBP1
X Failure to efficiently recruit 
polymerase 
X Failure to efficiently initiate viral DNA 
replication
 
Figure 41 Schematic representation of disruption of the TopBP1 /E2/E1 interaction following 
generation of a mutant E2. 
The proposed consequences of generation of an E2 mutant that fails to bind TopBP1. Figure 
legend as for Figure 16.  
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Chapter 3.5 The effect of TopBP1 on the cellular UV 
DNA damage response. 
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The expression of TopBP1 throughout the normal epidermis suggested that it 
may be involved in mediating the cellular response to UV irradiation due to its 
known role in activating ATR (256), the DNA damage response kinase. As TopBP1 
is also a transcription factor, we hypothesised that TopBP1 may be involved in 
mediating the transcriptional response to UVR. To investigate this, we adopted a 
siRNA approach to knock down TopBP1 and then irradiate TopBP1 depleted cells 
before running a gene expression microarray analysis comparing wild type and 
TopBP1 depleted cells that were either UV irradiated or undamaged.  
To perform a gene expression microarray analysis and allow comparison between 
the different experimental groups it was essential to firstly determine the dose 
of UVB that induced cellular DNA damage but allowed cell survival.  
Secondly, it was essential to choose a cell line that would continue to cycle in 
the absence of TopBP1. TopBP1 is involved in DNA replication; it interacts with 
DNA polymerase  (250) and directly associates with chromatin during DNA 
replication(260)  suggesting that TopBP1 may play an essential role in DNA 
replication. In previous studies, when TopBP1 was knocked down in U2OS and 
Saos-2 cells, siTopBP1 treated cells arrested at G1 phase, again suggesting that 
TopBP1 is essential for DNA replication(327). Previous work in the Morgan 
laboratory investigated the effect of TopBP1 knockdown on cell replication in 
HEK293T, U2OS, MRC5, MCF7 and HeLa cell lines. MTT assays demonstrated that 
MRC5 and HeLa cells stopped growing 24 and 36 hours respectively following 
TopBP1 knockdown however, there was no effect on growth of the MCF7, 293T 
and U2OS cell lines over a four day period (Roni Wright – unpublished data). 
The HaCat cell line, a spontaneously transformed human epithelial cell line 
derived from human adult skin which is immortal but non-tumorigenic and 
exhibits normal differentiation was chosen for this investigation (328). The 
initial experiments described in this chapter were to determine the dose of UVB 
that induced cellular DNA damage but allowed cell survival and to determine the 
effect of TopBP1 depletion on cellular replication. 
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3.5.1 The effect of UVB irradiation and TopBP1 
knockdown in the HaCaT cell line. 
To determine a dose of UVB that would induce cellular DNA damage in the 
HaCaT line, cells grown in monolayer were irradiated with increasing doses of 
UVB (2.2.5.7).  Total cell lysates were harvested 30 minutes following irradiation 
and equal amounts of protein were separated by SDS-PAGE gel electrophoresis, 
the resultant Western Blot was probed for phosphorylated Chk1. Figure 42A 
shows that cellular DNA damage, determined by the induction of phosphorylated 
Chk1, was detected when cells were irradiated with UVB at doses of 0.004 J/cm2 
and above.  
To determine the dose of UVB that would induce cellular DNA damage but allow 
cell survival, crystal violet colony survival assays were carried out over 14 days 
as described (2.2.5.8). In these assays, HaCaT cells grown in monolayer were 
mock irradiated or irradiated with increasing doses of UVB 0.004 to 0.030 J/cm2 . 
Thirty minutes following irradiation, 500 cells from each plate were re-seeded in 
triplicate. At 14 days following irradiation, surviving colonies were stained with 
crystal violet and counted. The experiment was carried out in triplicate. As 
shown in Figure 42B, following a UVB dose of 0.004J/cm2, 60% of colonies 
survived compared to those mock irradiated.  
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Figure 42 Effect of UVB irradiation on the HaCaT cell line  
A. Phospho-Chk1 expression levels following UVB irradiation. 
HaCaT cells grown in monolayer were irradiated with increasing doses of UVB. Induction of 
phosphorylated Chk1 antibody is seen following UVB doses of 0.004 J/cm2 and above.  
B. Crystal violet colony survival assay of HaCaT cells following UVB irradiation. 
The results are the mean of the triplicates for each UVB dose +/- S.E.M. The colonies 
present following mock irradiation were expressed as 100%, the number of colonies in each 
subsequent UVB dose is expressed as percentage survival compared to mock irradiation. 
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TopBP1 was knocked down in HaCaT cells using specific small interfering RNA 
(siRNA) targeted against TopBP1 (2.1.4.10.1). siRNA treatment was delivered to 
cells by transient transfection using the lipofectamine 2000™ method (2.2.5.2.2). 
For all experiments using siRNA targeted against TopBP1 (siTopBP1), untreated 
cells, mock transfected cells (using lipofectamine only) and siRNA 
oligonucleotides against luciferase were included as experimental controls. 
Seventy-two hours following transfection, equal amounts of total cell lysates 
were separated by SDS-PAGE gel electrophoresis and the resultant Western Blot 
probed for the presence of TopBP1 with -tubulin as a loading control. As shown 
in Figure 43, a greater than 90% knockdown efficiency of TopBP1 was achieved.  
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Figure 43 TopBP1 expression levels in HaCaT cells following siRNA treatment. 
HaCaT cells were transiently transfected with siTopBP1 or siLuciferase, mock transfected 
(lipids only) or received no treatment. Total cell lysates were harvested 72 hours following 
transfection and equal amounts of protein were separated on a SDS-PAGE gel. The 
resultant Western Blot was probed for the presence of TopBP1 and -Tubulin as a loading 
control. This experiment was repeated a minimum of three times and a single representative 
Western Blot is shown.  
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To determine whether TopBP1 depleted HaCaT cells would continue to 
replicate, cell growth assays (2.2.5.9) were carried out in siTopBP1 treated 
HaCaTs and controls. The results are shown in Figure 44A.  
The assays were carried out over four days. Cell lysates were harvested to 
demonstrate TopBP1 expression over the four days and were harvested at the 
same time as the cell growth assay readings (0, 48 and 96 hours).  The 
expression of TopBP1 at 0, 48 and 96 hours is shown in Figure 44B and it is clear 
that the knockdown of TopBP1 was efficient and persisted at 96 hours.  
Cell growth assays were carried out twice in triplicate. The results show a 25-
fold increase in cell growth in untreated HaCaT cells over four days. TopBP1 
depleted HaCaTs did not grow indicating that TopBP1 is essential for replication 
on the HaCaT cell line. si-Luciferase treatment and mock transfection have a 
modest effect on cell growth reducing the fold difference in cell growth to 20 
and 12 fold respectively and this probably reflects toxicity from the 
lipofectamine treatment reducing cell growth in comparison to untreated cells.  
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Figure 44 Effect of TopBP1 depletion on the HaCaT cell line  
A. Cell Growth Assay of siRNA treated HaCaT cells.  
Each experiment was carried out twice and in triplicate. The results shown are the mean of 
the triplicates and the mean of two experiments +/- S.E.M.  
B. TopBP1 expression levels following siRNA treatment.  
Cell lysates were harvested at the time points on the Cell Growth Assay as indicated, 
separated by SDS PAGE gel electrophoresis and the resultant blot probed for TopBP1 with 
-tubulin as a loading control. The Western Blot shown is a representative blot from one of 
the two experiments.  
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3.5.2 TopBP1 is not essential for replication in MCF7 cells 
As the HaCaT cell line was unable to survive in culture when TopBP1 was 
depleted, an alternative cell line was required. Previous work in this laboratory 
has demonstrated that three alternative cell lines are able to grow in the 
absence of TopBP1, MCF7, U2OS and 293T cells.  MCF7 cells are an epithelial cell 
line derived from a human breast cancer cells and were chosen as the cell line 
for further work in this chapter.  
TopBP1 was depleted in MCF7 cells using siRNA targeted against TopBP1, siRNA-
luciferase and mock transfected cells (lipofectamine only) were included as 
experimental controls. Cell growth in these cells was then measured using a MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) cell viability 
assay. The MTT assay provides a direct measure of metabolically active cells in 
culture, the yellow MTT substrate is reduced in the mitochondria of 
metabolically active cells to form insoluble purple formazan crystals which are 
then solubilised in DMSO and the absorbance reading at 570nm gives a direct 
measure of cell viability. The results of the MTT assay are shown in Figure 45 
and demonstrate that there was no reduction in cell growth when TopBP1 was 
depleted compared to siLuciferase and mock transfection controls. Cell lysates 
were harvested at the same time points as the MTT assay readings were taken, 
the lysates analysed by Western Blotting and confirmed that the TopBP1 
depletion was efficient throughout the duration of the experiment (data not 
shown). (MTT assay carried out by R.Wright).  
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Figure 45 TopBP1 is not essential for cell growth in the MCF7 cell line. 
MCF7 cells were treated with siTopBP1, siLuciferase or mock treated and the cell viability 
assay measure using the MTT assay. The experiment was carried out three times in 
duplicate and the results show the mean +/- S.E.M for the three experiments. Comparing 
results for siLuciferase against siTopBP1 using a Student paired T-Test showed there was 
no significant difference between the growth of siLuciferase and siTopBP1 treated cells 
(p=0.894) indicating that TopBP1 is not essential for growth in MCF7 cells.  
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3.5.3 The effect of UVB irradiation and TopBP1 
knockdown in the MCF7 cell line. 
To determine a dose of UVB which would induce cellular DNA damage in the 
MCF7 cell line, cells grown in monolayer were irradiated with increasing doses of 
UVB (2.2.5.7). Total cell lysates were harvested 30 minutes following irradiation 
and equal amounts of protein separated by SDS-PAGE gel electrophoresis. The 
resultant Western Blot probed for phosphoChk1 (ser317). As shown in Figure 46A 
an antibody band is just discernible at 0.002J/cm2 indicating that this is the 
minimal dose with which to induce DNA damage in MCF7 cells. 
To determine a dose of UVB that would induce DNA damage but allow MCF cells 
to survive in culture, crystal violet colony survival assays were performed 
(2.2.5.8). In these assays, carried out three times in triplicate, MCF7 cells grown 
in monolayer were mock irradiated or irradiated with increasing doses of UVB. 
Thirty minutes following irradiation, 1000 cells from each experiment were 
seeded in triplicate. All colonies were visualised with crystal violet 14 days 
following irradiation and counted. As shown in Figure 46B, when MCF7 cells were 
treated with 0.002J/cm2 of UVB, 65% of colonies survived compared with cells 
that were mock irradiated.  
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Figure 46 MCF7 cells treated with increasing doses of UVB.  
A. Western Blot probed for phospho-Chk1. A faint antibody band is seen following 
irradiation with 0.002J/cm2 of UVB. 
B. Crystal violet colony survival assay of UVB irradiated MCF7 cells. The number of 
colonies following irradiation was expressed as percentage survival relative to colonies 
following mock irradiation only (taken as 100%). The experiment was performed on three 
occasions in triplicate. The graph shows the mean of three experiments +/- S.E.M. 
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TopBP1 was depleted in MCF7 cells using siRNA targeted against TopBP1 using 
the lipofectamine 2000™ transient transfection method (2.2.5.2.2). As before, 
for all siRNA experiments, untreated, mock transfected (lipofectamine only) and 
siLuciferase treated cells were included as experimental controls. Seventy two 
hours following transfection, total cell lysates were harvested, equal amounts 
separated by SDS-PAGE gel electrophoresis and the resultant Western Blot 
probed for TopBP1 with -tubulin as a loading control. As shown in Figure 47, a 
greater than 90% knockdown efficiency of TopBP1 was achieved. 
A cell growth assay in siRNA treated MCF7 cells was not performed as previous 
work in this laboratory demonstrated that MCF7 cells are able to grow over a 
four day period in the absence of TopBP1 (as previously shown in Figure 45). 
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Figure 47 TopBP1 expression levels following siRNA treatment of MCF7 cells. 
MCF7 were untreated, mock transfected (lipids only) or siRNA treated with siTopBP1 or 
siLuciferase. Protein lysates were separated by SDS-PAGE gel electrophoresis and 
analysed by Western Blotting with antibody directed against TopBP1 and -tubulin as 
loading control.  
220 
3.5.4 Experimental design and controls for gene 
expression microarray. 
In order to investigate the genes involved in the cellular UV damage response 
that are regulated by TopBP1, a gene expression microarray experiment was 
performed. MCF7 cells were chosen for this experiment as these cells continue 
to replicate following TopBP1 depletion.  
The experimental design is illustrated in Figure 48. Four samples were prepared 
in tandem and the experiment repeated three times resulting in 12 RNA samples 
for microarray analysis. MCF7 cells were treated with siLuciferase or siTopBP1 
and plated in monolayer. After 48hours, samples were mock irradiated or 
irradiated with 0.002J/cm2 of UVB. 30 minutes following UVB irradiation, cells 
were harvested for RNA using the Qiagen RNAeasy extraction kit as described 
(2.2.5.10). RNA was prepared in duplicate, one set of samples for microarray 
analysis and one set stored at -80°C for future use. 
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Figure 48 Experimental design of gene expression microarray analysis experiment. 
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For each experimental repeat, eight extra plates of MCF7 cells were included as 
experimental controls for determining the efficiency of TopBP1 knockdown 
(untreated, mock transfected, siLuciferase and siTopBP1). 30 minutes after 
irradiation or mock irradiation, these plates were harvested for protein as 
described (2.2.5.3), equal amounts of protein lysate were separated by SDS-
PAGE gel electrophoresis and analysed by Western Blotting. The resultant blot 
was probed for TopBP1 with -tubulin as a loading control. These controls were 
included for each of the three experimental repeats. A single representative 
Western Blot is illustrated in Figure 49.  
There is a clear reduction in TopBP1 expression in siTopBP1 treated cells. 
siLuciferase had no effect on TopBP1 expression compared to controls (no 
treatment/mock transfection.  
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Figure 49 Western Blot showing TopBP1 expression levels in MCF7 cells.  
Lysates were harvested at the same time as RNA for the microarray experiment.  
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3.5.5 RNA quality control 
The concentrations and quality of the 12 RNA samples was then further analysed 
by Julie Galbraith (Sir Henry Welcome Functional genomics Facility (SHWFGF), 
University of Glasgow) on a 2100 Agilent Bioanalyzer to check the quantity and 
quality of RNA samples. The RNA concentrations of each sample are shown in 
Table 17. A summary of the quality control analysis is shown in Figure 50. To be 
suitable for microarray, the RIN value of the sample should be between 7 and 
10.  
Sample Name  Concentration of RNA (ng/l) 
6A 179 
9A 190 
12A 237 
15A 179 
6B 150 
9B 97 
12B 109 
15B 79 
6C 272 
9C 257* 
12B 129 
15B 138 
Table 17 RNA concentration of microarray samples.  
* Sample 9C was replaced with a duplicate sample from the same experimental repeat due 
to degradation of the sample.  
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Figure 50 Quality of RNA samples for microarray.  
Sample 9C exhibited degradation (RIN 4.40) and was therefore replaced with the duplicate 
sample from the same repeat. The quality of the duplicate sample was suitable for the 
microarray (data not shown).  
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3.5.6 Data analysis and quality controls 
The RNA was prepared as described above and the quantity and quality of the 
RNA assessed as described. cDNA was prepared using the GeneChip® cDNA 
synthesis and amplification kit (Affymetrix) (Julie Galbraith, SHWFGF).  
HuGene-1_0-st-v1 arrays were used for hybridisation and analysis (NetAffx 
release: 31 (2009-11-16). Hybridisation was performed with Affxmetrix 
GeneChip® Hybridisation Oven 640, the arrays were washed with Affymetrix 
fluidic Station 400 and subsequently scanned with the Affxmetrix GeneChip® 
Scanner 3000 7G.  
The raw data in the form of Affxmetrix CEL files were generated with Affymetrix 
GeneChip® Operating Software (GCOS) and subsequent analysis was carried out 
with Partek® Genomic Suite™ (Partek Inc., St.Louis, MO, USA) 
(http://www.partek.com/). This analysis was carried out by Dr Pawel Herzyk, 
SHWFGF.  
Normalization of all 12 chips was done using the GC-RMA (Robust Multichip 
Average) method (329), to correct the background levels for all probe sets 
reducing non-specific binding signals. The RNA was prepared in three sets of 
replicates, prepared on three different occasions. It is assumed that there will 
be bias between each set of replicates, known as the systematic replicate effect 
or batch effect. The batch effect was removed by ANOVA allowing all three sets 
of replicates to be combined and analysed together.  Once the batch effect is 
removed the PCA analysis shows that the TopBP1 wild type and TopBP1 
knockdown samples cluster together and both groups can be clearly separated 
from each other (Figure 51). The PCA analysis also shows that the Control 
samples (mock irradiated) and Damage samples (UVB irradiated) also cluster 
together and can be separated however the distinction between this set of 
samples is less distinct (Figure 52) suggesting that  the effect of TopBP1 knock 
down on the cells is much bigger than the effect of UVB damage.  
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Figure 51 PCA analysis of clustering of TopBP1 wild type samples and TopBP1 knockdown 
samples following removal of batch effect.  
The six TopBP1 wild type samples are represented by the red dots and the six TopBP1 
knockdown samples are in blue. There is clear separation between the two groups of 
samples. 
 
 
Figure 52 PCA analysis of clustering of mock irradiated (control samples) and UVB treated 
(Damaged) samples following removal of the batch effect.  
The six control samples are represented by the red dots and the six Damage samples are 
shown in blue. Here it can be seen that there is clustering within each set of samples 
however the distinction between Control and damage samples is less distinct when 
compared to the TopBP1 wild type versus TopBP1 knockdown samples shown above 
suggesting that TopBP1 knockdown produced a greater effect on the cells than UVB 
irradiation. 
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3.5.7 Differentially expressed gene sets 
Three sets of differentially expressed genes were generated from the microarray 
data using 2-way ANOVA. Only genes that had a p-value of less than 0.05 were 
included (confirming reproducibility in the three sets of replicates) and only 
those in which the change in expression was either increased or decreased 1.5 
fold were included. Three lists of differentially expressed genes were generated.  
1. Genes de-regulated by the absence of TopBP1 (Table 18). 
2. Genes de-regulated by UVR damage (Table 19).  
3. Genes de-regulated by UVR damage in the absence of TopBP1 (Table 20). 
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TABLE 18 
18A DOWN REGULATED GENES   
Transcript ID Gene ID// Gene p-value Fold  
8090772 NM_007027 // TOPBP1 // topoisomerase (DNA) II binding protein 1 // 3q22.1 // 110 6.39E-09 -5.09096 
7979658 NM_002083 // GPX2 // glutathione peroxidase 2 (gastrointestinal) // 14q24.1 // 2 2.22E-05 -2.90938 
8025429 NM_005968 // HNRNPM // heterogeneous nuclear ribonucleoprotein M // 19p13.3-p13. 1.40E-08 -2.87617 
7979204 NM_006832 // FERMT2 // fermitin family homolog 2 (Drosophila) // 14q22.1 // 1097 6.68E-07 -2.61178 
8024111 NM_004368 // CNN2 // calponin 2 // 19p13.3 // 1265 /// NM_201277 // CNN2 // calp 6.09E-06 -2.56983 
8085033 NM_001136049 // LMLN // leishmanolysin-like (metallopeptidase M8 family) // 3q29 1.00E-06 -2.5537 
8150906 NM_017813 // IMPAD1 // inositol monophosphatase domain containing 1 // 8q12.1 // 1.25E-05 -2.48823 
7937508 NM_004357 // CD151 // CD151 molecule (Raph blood group) // 11p15.5 // 977 /// NM 3.89E-05 -2.22592 
8063835 NM_144703 // LSM14B // LSM14B, SCD6 homolog B (S. cerevisiae) // 20q13.33 // 149 1.71E-05 -2.17166 
7996677 NM_005796 // NUTF2 // nuclear transport factor 2 // 16q22.1 // 10204 /// ENST000 9.12E-06 -2.17075 
8093826 NM_000683 // ADRA2C // adrenergic, alpha-2C-, receptor // 4p16 // 152 /// ENST00 1.25E-05 -2.16779 
8102848 NM_030648 // SETD7 // SET domain containing (lysine methyltransferase) 7 // 4q28 1.03E-07 -2.1253 
8150908 NM_017813 // IMPAD1 // inositol monophosphatase domain containing 1 // 8q12.1 // 2.14E-06 -2.11617 
8091446 NM_053024 // PFN2 // profilin 2 // 3q25.1-q25.2 // 5217 /// NM_002628 // PFN2 // 4.56E-08 -2.0553 
8079966 NM_004636 // SEMA3B // sema domain, immunoglobulin domain (Ig), short basic doma 0.000132646 -1.99527 
7952046 NM_144765 // MPZL2 // myelin protein zero-like 2 // 11q24 // 10205 /// NM_005797 5.45E-07 -1.9824 
8129071 NM_002031 // FRK // fyn-related kinase // 6q21-q22.3 // 2444 /// ENST00000368626 2.99E-06 -1.97654 
8020323 NM_003799 // RNMT // RNA (guanine-7-) methyltransferase // 18p11.22-p11.23 // 87 1.06E-06 -1.95476 
8110589 NM_015455 // CNOT6 // CCR4-NOT transcription complex, subunit 6 // 5q35.3 // 574 2.49E-07 -1.94066 
7926385 NM_003473 // STAM // signal transducing adaptor molecule (SH3 domain and ITAM mo 9.00E-06 -1.93198 
8138466 NM_182762 // MACC1 // metastasis associated in colon cancer 1 // 7p21.1 // 34638 4.71E-06 -1.91981 
7913319 NM_003760 // EIF4G3 // eukaryotic translation initiation factor 4 gamma, 3 // 1p 2.20E-07 -1.90524 
7915882 NM_014774 // KIAA0494 // KIAA0494 // 1pter-p22.1 // 9813 /// ENST00000371933 //  1.03E-07 -1.87497 
7927658 NM_003338 // UBE2D1 // ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast 2.57E-06 -1.87267 
8102342 NM_024090 // ELOVL6 // ELOVL family member 6, elongation of long chain fatty aci 0.000327338 -1.86828 
8050007 NM_012293 // PXDN // peroxidasin homolog (Drosophila) // 2p25 // 7837 /// ENST00 1.17E-05 -1.86341 
7999553 NM_018340 // CPPED1 // calcineurin-like phosphoesterase domain containing 1 // 1 1.23E-06 -1.86206 
7931728 NM_015155 // LARP4B // La ribonucleoprotein domain family, member 4B // 10p15.3  2.34E-07 -1.85228 
7937612 NM_002458 // MUC5B // mucin 5B, oligomeric mucus/gel-forming // 11p15.5 // 72789 0.00145544 -1.8473 
7967149 NM_016237 // ANAPC5 // anaphase promoting complex subunit 5 // 12q24.31 // 51433 2.81E-07 -1.83394 
8044499 NM_005415 // SLC20A1 // solute carrier family 20 (phosphate transporter), member 3.61E-07 -1.83069 
8068593 NM_005239 // ETS2 // v-ets erythroblastosis virus E26 oncogene homolog 2 (avian) 6.00E-05 -1.82779 
8078227 NM_003884 // KAT2B // K(lysine) acetyltransferase 2B // 3p24 // 8850 /// ENST000 6.68E-06 -1.80333 
7942896 NM_173556 // CCDC83 // coiled-coil domain containing 83 // 11q14.1-q14.2 // 2200 1.13E-06 -1.80293 
8158424 NM_001127244 // LRRC8A // leucine rich repeat containing 8 family, member A // 9 1.31E-07 -1.78651 
8042503 NM_002357 // MXD1 // MAX dimerization protein 1 // 2p13-p12 // 4084 /// ENST0000 3.19E-05 -1.78559 
7917148 NM_022831 // AIDA // axin interactor, dorsalization associated // 1q41 // 64853  2.33E-06 -1.77011 
8002692 NM_006885 // ZFHX3 // zinc finger homeobox 3 // 16q22.3-q23.1 // 463 /// NM_0011 0.000429008 -1.77004 
7913655 NM_002167 // ID3 // inhibitor of DNA binding 3, dominant negative helix-loop-hel 1.79E-05 -1.7651 
7993478 NM_004996 // ABCC1 // ATP-binding cassette, sub-family C (CFTR/MRP), member 1 // 0.000206196 -1.76493 
7951077 NM_144665 // SESN3 // sestrin 3 // 11q21 // 143686 /// ENST00000278499 // SESN3  5.76E-05 -1.75309 
8114287 NM_004598 // SPOCK1 // sparc/osteonectin, cwcv and kazal-like domains proteoglyc 8.92E-06 -1.74847 
8000948 NM_004765 // BCL7C // B-cell CLL/lymphoma 7C // 16p11 // 9274 /// ENST0000021511 9.98E-06 -1.73895 
7931683 NM_014974 // DIP2C // DIP2 disco-interacting protein 2 homolog C (Drosophila) // 5.70E-05 -1.7363 
7959102 NM_014365 // HSPB8 // heat shock 22kDa protein 8 // 12q24.23 // 26353 /// ENST00 4.60E-05 -1.72777 
8122818 BC011348 // C6orf211 // chromosome 6 open reading frame 211 // 6q25.1 // 79624 / 1.84E-05 -1.72524 
8013112 NM_016084 // RASD1 // RAS, dexamethasone-induced 1 // 17p11.2 // 51655 /// ENST0 0.00346768 -1.72474 
7948814 NM_001079559 // HNRNPUL2 // heterogeneous nuclear ribonucleoprotein U-like 2 //  7.02E-08 -1.72188 
7963353 NM_002281 // KRT81 // keratin 81 // 12q13 // 3887 /// ENST00000327741 // KRT81 / 6.11E-06 -1.72157 
8101916 NM_152292 // RG9MTD2 // RNA (guanine-9-) methyltransferase domain containing 2 / 3.03E-05 -1.71802 
8095751 NM_015393 // PARM1 // prostate androgen-regulated mucin-like protein 1 // 4q13.3 7.05E-06 -1.71451 
8088550 NM_198859 // PRICKLE2 // prickle homolog 2 (Drosophila) // 3p14.1 // 166336 ///  0.000155896 -1.7132 
7982597 NM_003246 // THBS1 // thrombospondin 1 // 15q15 // 7057 /// ENST00000260356 // T 1.57E-05 -1.711 
8169969 NM_032458 // PHF6 // PHD finger protein 6 // Xq26.3 // 84295 /// NM_001015877 // 2.01E-06 -1.7096 
7921970 NM_000696 // ALDH9A1 // aldehyde dehydrogenase 9 family, member A1 // 1q23.1 //  8.58E-06 -1.7088 
8009183 NM_203351 // MAP3K3 // mitogen-activated protein kinase kinase kinase 3 // 17q23 0.000165054 -1.70617 
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8116921 NM_001955 // EDN1 // endothelin 1 // 6p24.1 // 1906 /// NM_001168319 // EDN1 //  0.000303041 -1.70393 
8144078 NM_000193 // SHH // sonic hedgehog homolog (Drosophila) // 7q36 // 6469 /// ENST 3.35E-05 -1.70162 
7958275 NM_018082 // POLR3B // polymerase (RNA) III (DNA directed) polypeptide B // 12q2 1.81E-05 -1.69853 
8020308 NM_181481 // C18orf1 // chromosome 18 open reading frame 1 // 18p11.2 // 753 /// 6.20E-05 -1.69795 
8172035 NM_006520 // DYNLT3 // dynein, light chain, Tctex-type 3 // Xp21 // 6990 /// ENS 8.18E-05 -1.69675 
8140730 NM_024315 // C7orf23 // chromosome 7 open reading frame 23 // 7q21.1-q21.2 // 79 5.36E-06 -1.69438 
8105506 NM_020928 // ZSWIM6 // zinc finger, SWIM-type containing 6 // 5q12.1 // 57688 // 3.99E-05 -1.69366 
8047127 NM_001130158 // MYO1B // myosin IB // 2q12-q34 // 4430 /// NM_012223 // MYO1B // 5.18E-07 -1.69216 
8156770 NM_024642 // GALNT12 // UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylg 0.000111382 -1.6878 
8145227 NM_001160036 // RHOBTB2 // Rho-related BTB domain containing 2 // 8p21.3 // 2322 0.000222107 -1.68662 
8092541 NM_139248 // LIPH // lipase, member H // 3q27 // 200879 /// ENST00000296252 // L 7.70E-05 -1.68217 
7908940 NM_001001396 // ATP2B4 // ATPase, Ca++ transporting, plasma membrane 4 // 1q32.1 0.000132259 -1.68175 
8175121 NM_001555 // IGSF1 // immunoglobulin superfamily, member 1 // Xq25 // 3547 /// N 3.02E-07 -1.68148 
8089584 NM_015412 // C3orf17 // chromosome 3 open reading frame 17 // 3q13.2 // 25871 // 6.50E-05 -1.67967 
7980744 NM_004755 // RPS6KA5 // ribosomal protein S6 kinase, 90kDa, polypeptide 5 // 14q 2.76E-05 -1.67582 
7984517 NM_015554 // GLCE // glucuronic acid epimerase // 15q23 // 26035 /// ENST0000026 0.000106967 -1.67182 
7938834 NM_182964 // NAV2 // neuron navigator 2 // 11p15.1 // 89797 /// NM_145117 // NAV 2.92E-05 -1.66855 
7918913 NM_001542 // IGSF3 // immunoglobulin superfamily, member 3 // 1p13 // 3321 /// N 8.12E-05 -1.66139 
8115397 NM_032385 // C5orf4 // chromosome 5 open reading frame 4 // 5q31-q32 // 10826 // 0.000500769 -1.66075 
7987405 NM_005739 // RASGRP1 // RAS guanyl releasing protein 1 (calcium and DAG-regulate 4.11E-05 -1.66012 
8106122 NM_002270 // TNPO1 // transportin 1 // 5q13.2 // 3842 /// NM_153188 // TNPO1 //  2.36E-06 -1.65862 
8017162 NM_016125 // RNFT1 // ring finger protein, transmembrane 1 // 17q23.1 // 51136 / 6.78E-05 -1.65858 
8146637 NM_152758 // YTHDF3 // YTH domain family, member 3 // 8q12.3 // 253943 /// ENST0 2.52E-05 -1.65389 
8160670 NM_004925 // AQP3 // aquaporin 3 (Gill blood group) // 9p13 // 360 /// ENST00000 0.000299763 -1.65389 
8139500 NM_022748 // TNS3 // tensin 3 // 7p12.3 // 64759 /// ENST00000398879 // TNS3 //  0.00013197 -1.65304 
8006531 NM_144975 // SLFN5 // schlafen family member 5 // 17q12 // 162394 /// ENST000002 1.42E-05 -1.65039 
8091954 NM_014498 // GOLIM4 // golgi integral membrane protein 4 // 3q26.2 // 27333 ///  7.80E-05 -1.64988 
7939368 NM_017583 // TRIM44 // tripartite motif-containing 44 // 11p13 // 54765 /// ENST 0.00163902 -1.64891 
8007272 NM_025233 // COASY // CoA synthase // 17q12-q21 // 80347 /// NM_001042530 // COA 0.000129145 -1.64236 
8057599 NM_006287 // TFPI // tissue factor pathway inhibitor (lipoprotein-associated coa 8.99E-05 -1.63737 
8039086 NR_002938 // LOC284379 // solute carrier family 7 (cationic amino acid transport 0.000149906 -1.6356 
8149551 NM_015310 // PSD3 // pleckstrin and Sec7 domain containing 3 // 8pter-p23.3 // 2 0.000443744 -1.63477 
7897236 NM_003636 // KCNAB2 // potassium voltage-gated channel, shaker-related subfamily 0.000112593 -1.63194 
7933619 NM_147156 // SGMS1 // sphingomyelin synthase 1 // 10q11.2 // 259230 /// ENST0000 8.49E-06 -1.62816 
7980616 NM_007039 // PTPN21 // protein tyrosine phosphatase, non-receptor type 21 // 14q 0.000428432 -1.62417 
7989323 NM_004330 // BNIP2 // BCL2/adenovirus E1B 19kDa interacting protein 2 // 15q22.2 0.000106569 -1.61747 
7961489 NM_016312 // WBP11 // WW domain binding protein 11 // 12p12.3 // 51729 /// ENST0 1.23E-05 -1.61495 
7929596 NM_032440 // LCOR // ligand dependent nuclear receptor corepressor // 10q24 // 8 4.09E-05 -1.6103 
7973962 BC062480 // STELLAR // germ and embryonic stem cell enriched protein STELLA // 1 0.0197989 -1.6096 
8085220 NM_133480 // TADA3 // transcriptional adaptor 3 // 3p25.3 // 10474 /// NM_006354 0.000182069 -1.60777 
8161945 NM_152573 // RASEF // RAS and EF-hand domain containing // 9q21.32 // 158158 /// 2.89E-05 -1.60603 
7932407 NM_001004470 // ST8SIA6 // ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransf 0.000232003 -1.606 
8106479 NM_004866 // SCAMP1 // secretory carrier membrane protein 1 // 5q13.3-q14.1 // 9 6.20E-07 -1.6054 
7904843 NM_002614 // PDZK1 // PDZ domain containing 1 // 1q21 // 5174 /// NR_003377 // P 6.00E-08 -1.60507 
8109428 NR_024084 // SAP30L // SAP30-like // 5q33.2 // 79685 /// NM_024632 // SAP30L //  3.84E-05 -1.59272 
7971134 NM_025138 // C13orf23 // chromosome 13 open reading frame 23 // 13q13.3 // 80209 3.47E-05 -1.58922 
8024323 NM_138393 // REEP6 // receptor accessory protein 6 // 19p13.3 // 92840 /// ENST0 8.16E-06 -1.58453 
7927529 NM_002443 // MSMB // microseminoprotein, beta- // 10q11.2 // 4477 /// NM_138634  0.00183337 -1.58333 
8090162 NM_002213 // ITGB5 // integrin, beta 5 // 3q21.2 // 3693 /// ENST00000296181 //  1.49E-05 -1.58276 
7928308 NM_019058 // DDIT4 // DNA-damage-inducible transcript 4 // 10pter-q26.12 // 5454 0.0010453 -1.58227 
8129562 NM_001901 // CTGF // connective tissue growth factor // 6q23.1 // 1490 /// ENST0 0.00747396 -1.58163 
7950447 NM_182969 // XRRA1 // X-ray radiation resistance associated 1 // 11q13.4 // 1435 2.27E-06 -1.5789 
8148059 NM_022783 // DEPDC6 // DEP domain containing 6 // 8q24.12 // 64798 /// ENST00000 0.000297358 -1.5773 
8170400 ENST00000432041 // FLJ16423 // hypothetical LOC642889 // Xq28 // 642889 /// AK13 7.01E-06 -1.57616 
7974387 NM_145251 // STYX // serine/threonine/tyrosine interacting protein // --- // 681 6.69E-06 -1.5758 
8008819 NM_001005404 // YPEL2 // yippee-like 2 (Drosophila) // 17q22 // 388403 /// ENST0 0.000790589 -1.5755 
7958600 NM_033121 // ANKRD13A // ankyrin repeat domain 13A // 12q24.11 // 88455 /// ENST 5.13E-05 -1.57325 
8095009 NM_001040402 // DCUN1D4 // DCN1, defective in cullin neddylation 1, domain conta 7.07E-06 -1.57262 
8157125 NM_002874 // RAD23B // RAD23 homolog B (S. cerevisiae) // 9q31.2 // 5887 /// ENS 1.38E-07 -1.57194 
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8040587 NM_014971 // EFR3B // EFR3 homolog B (S. cerevisiae) // 2p23.3 // 22979 /// ENST 3.20E-05 -1.56481 
7923489 NM_021633 // KLHL12 // kelch-like 12 (Drosophila) // 1q32.1 // 59349 /// ENST000 4.73E-06 -1.56154 
7904082 XM_001716411 // LOC128322 // similar to nuclear transport factor 2 // 1p13.2 //  0.000789383 -1.56154 
7912292 NM_032368 // LZIC // leucine zipper and CTNNBIP1 domain containing // 1p36.22 // 4.55E-06 -1.56056 
7929932 NM_030929 // KAZALD1 // Kazal-type serine peptidase inhibitor domain 1 // 10q24. 0.000536639 -1.56022 
8063814 NM_144703 // LSM14B // LSM14B, SCD6 homolog B (S. cerevisiae) // 20q13.33 // 149 0.000301547 -1.55853 
8157264 NM_001860 // SLC31A2 // solute carrier family 31 (copper transporters), member 2 6.24E-05 -1.55772 
7927972 NM_004896 // VPS26A // vacuolar protein sorting 26 homolog A (S. pombe) // 10q21 1.13E-05 -1.55754 
8035445 NM_005354 // JUND // jun D proto-oncogene // 19p13.2 // 3727 /// ENST00000252818 7.67E-05 -1.55282 
8166442 NM_014888 // FAM3C // family with sequence similarity 3, member C // 7q31 // 104 9.16E-05 -1.55254 
7926851 NR_024557 // WAC // WW domain containing adaptor with coiled-coil // --- // 5132 0.000220327 -1.55251 
7959751 NM_152437 // ZNF664 // zinc finger protein 664 // 12q24.31 // 144348 /// ENST000 0.000102201 -1.55094 
8175177 NM_018388 // MBNL3 // muscleblind-like 3 (Drosophila) // Xq26.2 // 55796 /// NM_ 8.23E-05 -1.54903 
8058091 NM_015265 // SATB2 // SATB homeobox 2 // 2q33 // 23314 /// NM_001172517 // SATB2 2.62E-05 -1.5479 
8144802 NM_006207 // PDGFRL // platelet-derived growth factor receptor-like // 8p22-p21. 0.000320649 -1.54771 
8136614 NM_018238 // AGK // acylglycerol kinase // 7q34 // 55750 /// ENST00000355413 //  8.11E-06 -1.54738 
8121076 NM_006813 // PNRC1 // proline-rich nuclear receptor coactivator 1 // 6q15 // 109 6.48E-05 -1.54362 
7944285 NM_001655 // ARCN1 // archain 1 // 11q23.3 // 372 /// NM_001142281 // ARCN1 // a 6.15E-07 -1.54335 
7915870 NM_022745 // ATPAF1 // ATP synthase mitochondrial F1 complex assembly factor 1 / 8.92E-05 -1.54078 
8168472 NM_000052 // ATP7A // ATPase, Cu++ transporting, alpha polypeptide // Xq13.2-q13 6.59E-06 -1.54052 
8132964 NM_015411 // SUMF2 // sulfatase modifying factor 2 // 7q11.1 // 25870 /// NM_001 0.00030698 -1.53773 
8151890 NM_033285 // TP53INP1 // tumor protein p53 inducible nuclear protein 1 // 8q22 / 0.000803295 -1.53578 
7934979 NM_014391 // ANKRD1 // ankyrin repeat domain 1 (cardiac muscle) // 10q23.31 // 2 0.000539834 -1.5357 
7908072 NM_005562 // LAMC2 // laminin, gamma 2 // 1q25-q31 // 3918 /// NM_018891 // LAMC 0.00156595 -1.53398 
7946228 NM_000391 // TPP1 // tripeptidyl peptidase I // 11p15 // 1200 /// ENST0000029942 0.00153193 -1.53108 
8161192 NM_194328 // RNF38 // ring finger protein 38 // 9p13 // 152006 /// NM_194330 //  5.34E-05 -1.53089 
8113073 NM_020801 // ARRDC3 // arrestin domain containing 3 // 5q14.3 // 57561 /// ENST0 1.90E-05 -1.52953 
7975779 NM_005252 // FOS // FBJ murine osteosarcoma viral oncogene homolog // 14q24.3 // 0.00494673 -1.52724 
8142540 NM_014888 // FAM3C // family with sequence similarity 3, member C // 7q31 // 104 5.36E-05 -1.52709 
8110721 NM_024786 // ZDHHC11 // zinc finger, DHHC-type containing 11 // 5p15.33 // 79844 0.0029148 -1.52618 
7975344 NM_018375 // SLC39A9 // solute carrier family 39 (zinc transporter), member 9 // 1.03E-05 -1.5248 
7903742 NM_000850 // GSTM4 // glutathione S-transferase mu 4 // 1p13.3 // 2948 /// NR_02 0.00153528 -1.52399 
8097801 NM_001109977 // FAM160A1 // family with sequence similarity 160, member A1 // 4q 0.000670545 -1.52213 
8162744 NM_003389 // CORO2A // coronin, actin binding protein, 2A // 9q22.3 // 7464 ///  0.000264467 -1.52058 
8026490 NR_015379 // UCA1 // urothelial cancer associated 1 (non-protein coding) // 19p1 0.00440711 -1.51997 
8152845 BC017297 // FAM49B // family with sequence similarity 49, member B // 8q24.21 // 6.58E-06 -1.51677 
7966259 NM_016433 // GLTP // glycolipid transfer protein // 12q24.11 // 51228 /// ENST00 0.000473221 -1.51625 
7931081 NM_021622 // PLEKHA1 // pleckstrin homology domain containing, family A (phospho 0.000172979 -1.5161 
8117120 NM_001546 // ID4 // inhibitor of DNA binding 4, dominant negative helix-loop-hel 0.00515598 -1.5111 
8046306 NM_015530 // GORASP2 // golgi reassembly stacking protein 2, 55kDa // 2q31.1-q31 1.55E-06 -1.51069 
8067206 BC137482 // CTCFL // CCCTC-binding factor (zinc finger protein)-like // 20q13.31 0.0102587 -1.51022 
8098041 NM_018342 // TMEM144 // transmembrane protein 144 // 4q32.1 // 55314 /// ENST000 8.32E-06 -1.50876 
8123181 NM_000876 // IGF2R // insulin-like growth factor 2 receptor // 6q26 // 3482 ///  0.000108385 -1.50558 
8153497 NM_182706 // SCRIB // scribbled homolog (Drosophila) // 8q24.3 // 23513 /// NM_0 0.00030922 -1.50287 
8090866 NR_024400 // ANAPC13 // anaphase promoting complex subunit 13 // 3q22.2 // 25847 0.000121744 -1.50274 
7902687 NM_001554 // CYR61 // cysteine-rich, angiogenic inducer, 61 // 1p31-p22 // 3491  0.00781138 -1.50257 
7903507 NM_001010883 // FAM102B // family with sequence similarity 102, member B // 1p13 5.10E-06 -1.5003 
230 
TABLE 18 continued 
18B UP REGULATED GENES   
Transcript ID Gene ID// Gene p-value Fold  
8154135 NM_004170 // SLC1A1 // solute carrier family 1 (neuronal/epithelial high affinit 1.33E-07 2.3755 
8053733 NM_020382 // SETD8 // SET domain containing (lysine methyltransferase) 8 // 12q2 5.08E-08 2.34297 
7991777 NM_001008393 // C4orf46 // chromosome 4 open reading frame 46 // 4q32.1 // 20172 0.000231828 2.25829 
8107868 NM_020240 // CDC42SE2 // CDC42 small effector 2 // 5q23.3-q31.1 // 56990 /// NM_ 8.33E-07 2.09077 
8075322 NM_001037666 // GATSL3 // GATS protein-like 3 // 22q12 // 652968 /// CR456449 // 1.13E-05 2.05567 
7973433 NM_182908 // DHRS2 // dehydrogenase/reductase (SDR family) member 2 // 14q11.2 / 1.75E-05 2.02608 
7959574 NM_020382 // SETD8 // SET domain containing (lysine methyltransferase) 8 // 12q2 3.33E-05 1.97277 
8043413 NM_144563 // RPIA // ribose 5-phosphate hosphati A // 2p11.2 // 22934 /// ENST0 2.08E-05 1.96329 
7908766 NM_006335 // TIMM17A // translocase of inner mitochondrial membrane 17 homolog A 8.55E-07 1.93699 
8114691 NM_003883 // HDAC3 // histone deacetylase 3 // 5q31 // 8841 /// ENST00000305264  1.80E-06 1.8618 
8171561 NM_006089 // SCML2 // sex comb on midleg-like 2 (Drosophila) // Xp22 // 10389 // 3.70E-05 1.85549 
8103431 NM_001008393 // C4orf46 // chromosome 4 open reading frame 46 // 4q32.1 // 20172 0.000117264 1.85146 
8156826 NM_004612 // TGFBR1 // transforming growth factor, beta receptor 1 // 9q22 // 70 8.49E-06 1.84841 
8107847 ENST00000334562 // KIAA1024L // KIAA1024-like // 5q23.3 // 100127206 1.06E-05 1.83643 
8134091 NM_012129 // CLDN12 // claudin 12 // 7q21 // 9069 /// ENST00000287916 // CLDN12  8.73E-08 1.82784 
7996393 NM_001755 // CBFB // core-binding factor, beta subunit // 16q22.1 // 865 /// NM_ 6.44E-07 1.82325 
8059642 NM_152527 // SLC16A14 // solute carrier family 16, member 14 (monocarboxylic aci 0.00209908 1.82021 
8092534 NM_080652 // TMEM41A // transmembrane protein 41A // 3q27.2 // 90407 /// ENST000 8.20E-05 1.79431 
8036840 NM_001626 // AKT2 // v-akt murine thymoma viral oncogene homolog 2 // 19q13.1-q1 1.72E-05 1.79034 
7998233 NM_021259 // TMEM8A // transmembrane protein 8A // 16p13.3 // 58986 /// ENST0000 1.07E-06 1.78626 
8054771 NM_025181 // SLC35F5 // solute carrier family 35, member F5 // 2q14.1 // 80255 / 2.56E-06 1.78541 
7925492 NM_014322 // OPN3 // opsin 3 // 1q43 // 23596 /// NM_003679 // KMO // kynurenine 2.96E-05 1.77957 
8079346 NM_014016 // SACM1L // SAC1 suppressor of actin mutations 1-like (yeast) // 3p21 3.24E-06 1.77796 
8117045 NM_001143942 // RBM24 // RNA binding motif protein 24 // 6p22.3 // 221662 /// NM 3.42E-05 1.76691 
8045795 NM_002239 // KCNJ3 // potassium inwardly-rectifying channel, subfamily J, member 2.69E-05 1.76548 
7912239 NM_024980 // GPR157 // G protein-coupled receptor 157 // 1p36.23 // 80045 /// EN 7.95E-05 1.75029 
7947784 NM_032389 // ARFGAP2 // ADP-ribosylation factor GTPase activating protein 2 // 1 6.98E-06 1.75017 
7899737 NM_003757 // EIF3I // eukaryotic translation initiation factor 3, subunit I // 1 5.77E-06 1.7403 
8173999 NM_212559 // XKRX // XK, Kell blood group complex subunit-related, X-linked // X 5.03E-05 1.72866 
7919591 AB096683 // FAM72D // family with sequence similarity 72, member D // 1q21.1 //  2.18E-06 1.72287 
8153201 NM_012154 // EIF2C2 // eukaryotic translation initiation factor 2C, 2 // 8q24 // 2.20E-06 1.71968 
7970577 NM_005932 // MIPEP // mitochondrial intermediate peptidase // 13q12 // 4285 ///  3.13E-05 1.71844 
8040190 NM_198182 // GRHL1 // grainyhead-like 1 (Drosophila) // 2p25.1 // 29841 /// ENST 4.48E-08 1.70688 
7967002 NM_001080855 // PXN // paxillin // 12q24.31 // 5829 /// NM_002859 // PXN // paxi 7.81E-07 1.69777 
8117535 NM_021064 // HIST1H2AG // histone cluster 1, H2ag // 6p22.1 // 8969 /// L19778 / 0.00010364 1.69602 
8107133 NM_000919 // PAM // peptidylglycine alpha-amidating monooxygenase // 5q14-q21 // 1.27E-05 1.69235 
8159220 NM_014279 // OLFM1 // olfactomedin 1 // 9q34.3 // 10439 /// NM_006334 // OLFM1 / 0.000397312 1.68799 
7927710 NM_001786 // CDK1 // cyclin-dependent kinase 1 // 10q21.1 // 983 /// NM_033379 / 0.000252271 1.68718 
8011275 NM_024086 // METT10D // methyltransferase 10 domain containing // 17p13.3 // 790 6.88E-05 1.65271 
7917954 NM_001013660 // FRRS1 // ferric-chelate reductase 1 // 1p21.2 // 391059 /// ENST 0.000112193 1.64623 
7999834 NM_015161 // ARL6IP1 // ADP-ribosylation factor-like 6 interacting protein 1 //  4.76E-08 1.64334 
8032265 NM_203304 // MEX3D // mex-3 homolog D (C. elegans) // 19p13.3 // 399664 /// NM_0 4.36E-06 1.64321 
8027323 NM_033468 // ZNF257 // zinc finger protein 257 // 19q13 // 113835 /// ENST000004 0.00274997 1.63847 
8052626 NM_016516 // VPS54 // vacuolar protein sorting 54 homolog (S. cerevisiae) // 2p1 0.000111432 1.63182 
8054769 AY427952 // PS1TP4 // HBV preS1-transactivated protein 4 // --- // 414327 0.000536096 1.63178 
8042705 NM_006062 // SMYD5 // SMYD family member 5 // 2p13.2 // 10322 /// ENST0000038950 9.22E-06 1.62314 
7954077 NM_020853 // KIAA1467 // KIAA1467 // 12p13.1 // 57613 /// ENST00000197268 // KIA 9.58E-05 1.61565 
7951614 NM_002716 // PPP2R1B // protein hosphatise 2, regulatory subunit A, beta // 11q 1.27E-07 1.61138 
8089072 NM_000097 // CPOX // coproporphyrinogen oxidase // 3q12 // 1371 /// ENST00000264 6.24E-05 1.61112 
7914194 NM_014280 // DNAJC8 // DnaJ (Hsp40) homolog, subfamily C, member 8 // 1p35.3 //  0.000491171 1.61012 
7946559 NM_001017998 // GNG10 // guanine nucleotide binding protein (G protein), gamma 1 3.72E-05 1.60788 
7990269 BC111368 // C15orf59 // chromosome 15 open reading frame 59 // 15q24.1 // 388135 0.000964013 1.60403 
7971027 NM_013338 // ALG5 // asparagine-linked glycosylation 5, dolichyl-phosphate beta- 0.000203071 1.60269 
8124423 NM_003518 // HIST1H2BG // histone cluster 1, H2bg // 6p21.3 // 8339 0.00124977 1.59843 
7985752 NR_026869 // NCRNA00052 // non-protein coding RNA 52 // 15q25.3 // 145978 6.37E-05 1.58282 
8039928 AB096683 // FAM72D // family with sequence similarity 72, member D // 1q21.1 //  7.82E-06 1.58218 
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7974366 NM_000956 // PTGER2 // prostaglandin E receptor 2 (subtype EP2), 53kDa // 14q22 0.000189853 1.57839 
7904452 AB096683 // FAM72D // family with sequence similarity 72, member D // 1q21.1 //  0.000118303 1.57268 
7924888 NM_033445 // HIST3H2A // histone cluster 3, H2a // 1q42.13 // 92815 /// ENST0000 0.00897968 1.56991 
8073032 NM_020243 // TOMM22 // translocase of outer mitochondrial membrane 22 homolog (y 3.69E-05 1.56862 
8003875 NM_001124758 // SPNS2 // spinster homolog 2 (Drosophila) // 17p13.2 // 124976 // 4.41E-05 1.56603 
8146900 NM_001011720 // XKR9 // XK, Kell blood group complex subunit-related family, mem 1.54E-06 1.56537 
8073645 NM_015380 // SAMM50 // sorting and assembly machinery component 50 homolog (S. c 8.88E-05 1.5613 
8117614 NM_003527 // HIST1H2BO // histone cluster 1, H2bo // 6p22-p21.3 // 8348 /// ENST 0.0131485 1.56068 
7909146 AB096683 // FAM72D // family with sequence similarity 72, member D // 1q21.1 //  0.00010545 1.55733 
8045974 NM_001178015 // SLC4A10 // solute carrier family 4, sodium bicarbonate transport 0.000839872 1.54946 
8107356 NM_152624 // DCP2 // DCP2 decapping enzyme homolog (S. cerevisiae) // 5q22.2 //  5.06E-06 1.54821 
7928937 NM_004897 // MINPP1 // multiple inositol-polyphosphate phosphatase 1 // 10q23 // 3.28E-05 1.54749 
7961983 NM_016551 // TM7SF3 // transmembrane 7 superfamily member 3 // 12q11-q12 // 5176 1.22E-06 1.54637 
8065817 NM_000178 // GSS // glutathione synthetase // 20q11.2 // 2937 /// ENST0000021695 2.46E-05 1.54258 
8092177 NM_001146276 // NCEH1 // neutral cholesterol ester hydrolase 1 // 3q26.31 // 575 2.07E-06 1.54218 
8034482 NM_001136196 // TNPO2 // transportin 2 // 19p13.2 // 30000 /// NM_001136195 // T 2.47E-05 1.5397 
8094278 NM_022346 // NCAPG // non-SMC condensin I complex, subunit G // 4p15.33 // 64151 9.05E-05 1.53822 
8005501 NM_001135036 // FAM18B2 // family with sequence similarity 18, member B2 // 17p1 1.61E-05 1.53736 
7963577 NM_032840 // SPRYD3 // SPRY domain containing 3 // 12q13.13 // 84926 /// ENST000 4.97E-05 1.53569 
7965918 NM_001031701 // NT5DC3 // 5'-nucleotidase domain containing 3 // 12q22-q23.1 //  8.89E-05 1.53552 
8068361 NM_006933 // SLC5A3 // solute carrier family 5 (sodium/myo-inositol cotransporte 0.000175137 1.53297 
7951422 NM_032424 // KIAA1826 // KIAA1826 // 11q22 // 84437 /// ENST00000301919 // KIAA1 0.000116541 1.53185 
7931479 NM_005539 // INPP5A // inositol polyphosphate-5-phosphatase, 40kDa // 10q26.3 // 8.26E-05 1.53091 
8135587 NM_001233 // CAV2 // caveolin 2 // 7q31.1 // 858 /// NM_198212 // CAV2 // caveol 1.18E-06 1.5305 
7969374 NM_024808 // C13orf34 // chromosome 13 open reading frame 34 // 13q22.1 // 79866 4.55E-05 1.52665 
7969626 NM_180989 // GPR180 // G protein-coupled receptor 180 // 13q32.1 // 160897 /// E 2.54E-07 1.52548 
8176286 NM_018390 // PLCXD1 // phosphatidylinositol-specific phospholipase C, X domain c 0.000411832 1.52251 
7999079 NM_001116 // ADCY9 // adenylate cyclase 9 // 16p13.3 // 115 /// ENST00000294016  4.63E-05 1.51751 
7941587 NM_182553 // CNIH2 // cornichon homolog 2 (Drosophila) // 11q13.2 // 254263 ///  3.97E-05 1.51471 
7942679 NM_018367 // ACER3 // alkaline ceramidase 3 // 11q13.5 // 55331 /// ENST00000278 1.98E-05 1.51269 
7905733 NM_006118 // HAX1 // HCLS1 associated protein X-1 // 1q21.3 // 10456 /// NM_0010 1.29E-06 1.50972 
7983811 NM_004855 // PIGB // phosphatidylinositol glycan anchor biosynthesis, class B // 2.20E-05 1.50703 
8148124 NM_022045 // MTBP // Mdm2, transformed 3T3 cell double minute 2, p53 binding pro 0.000433133 1.50643 
7989501 NM_001218 // CA12 // carbonic anhydrase XII // 15q22 // 771 /// NM_206925 // CA1 8.39E-06 1.50605 
7943218 NM_015368 // PANX1 // pannexin 1 // 11q21 // 24145 /// ENST00000227638 // PANX1  7.26E-05 1.50466 
8007643 NM_001145080 // C17orf104 // chromosome 17 open reading frame 104 // 17q21.31 // 0.000331352 1.50311 
8111220 NM_004934 // CDH18 // cadherin 18, type 2 // 5p15.2-p15.1 // 1016 /// NM_0011676 0.000457046 1.50198 
8036351 BC052603 // ZNF850P // zinc finger protein 850 (pseudogene) // 19q13.12 // 34289 3.43E-05 1.50197 
8059854 NM_005737 // ARL4C // ADP-ribosylation factor-like 4C // 2q37.1 // 10123 /// ENS 2.11E-05 1.50096 
Table 18 Genes down regulated (A) and up regulated (B) by the absence of TopBP1 
List of 162 genes that were down regulated and 95 genes that were up regulated in the 
TopBP1 knockdown cells compared to controls. 
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TABLE 19 
19A DOWN REGULATED GENES   
Transcript 
ID Gene ID//Gene p-value Fold 
8165672 L23320 // RFC1 // replication factor C (activator 1) 1, 145kDa // 4p14-p13 // 59 0.0029891 -1.86885 
8156571 NR_029665 // MIR27B // microRNA 27b // 9q22.32 // 407019 /// AF043897 // C9orf3  0.017733 -1.64005 
8090529 NM_198490 // RAB43 // RAB43, member RAS oncogene family // 3q21.3 // 339122 ///  0.000895159 -1.63546 
    
    
17B UP REGULATED GENES   
Transcript 
ID Gene ID//Gene p-value Fold 
8116921 NM_001955 // EDN1 // endothelin 1 // 6p24.1 // 1906 /// NM_001168319 // EDN1 //  0.000342525 2.08968 
8108370 NM_001964 // EGR1 // early growth response 1 // 5q31.1 // 1958 /// ENST000002399 0.00831533 1.99951 
7941707 NM_006328 // RBM14 // RNA binding motif protein 14 // 11q13.2 // 10432 /// BC007 0.044985 1.89393 
8129562 NM_001901 // CTGF // connective tissue growth factor // 6q23.1 // 1490 /// ENST0 0.00860706 1.87448 
8144228 AK094159 // FLJ36840 // hypothetical LOC645524 // --- // 645524 0.0274894 1.8458 
7975779 NM_005252 // FOS // FBJ murine osteosarcoma viral oncogene homolog // 14q24.3 // 0.00608993 1.77322 
8131263 X58060 // SNORD13P2 // small nucleolar RNA, C/D box 13 pseudogene 2 // 7p22.1 // 0.0476685 1.77105 
7955589 NM_002135 // NR4A1 // nuclear receptor subfamily 4, group A, member 1 // 12q13 / 0.0116315 1.76044 
7896754 AK290103 // LOC100287934 // similar to hCG2042721 // 1p36.33 // 100287934 /// EN 0.0342072 1.73316 
7909990 AK290103 // LOC100287934 // similar to hCG2042721 // 1p36.33 // 100287934 /// EN 0.0348099 1.70884 
7938366 BX641032 // WEE1 // WEE1 homolog (S. pombe) // 11p15.3-p15.1 // 7465 0.0214025 1.69439 
8053797 ENST00000456556 // LOC400986 // protein immuno-reactive with anti-PTH polyclonal 0.0249957 1.68428 
8069511 NR_027270 // C21orf81 // ankyrin repeat domain 20 family, member A3 pseudogene / 0.021898 1.6783 
7952451 BC040288 // LOC100130428 // IGYY565 // 11q24.2 // 100130428 0.0488411 1.66138 
8138592 AB052759 // TRA2A // transformer 2 alpha homolog (Drosophila) // 7p15.3 // 29896 0.0165506 1.62935 
7937612 NM_002458 // MUC5B // mucin 5B, oligomeric mucus/gel-forming // 11p15.5 // 72789 0.0287124 1.56548 
8115831 NM_004417 // DUSP1 // dual specificity phosphatase 1 // 5q34 // 1843 /// ENST000 0.00560495 1.53586 
7952986 NM_213655 // HSN2 // hereditary sensory neuropathy, type II // 12p13.3 // 378465 0.0302536 1.52215 
7938364 BX641032 // WEE1 // WEE1 homolog (S. pombe) // 11p15.3-p15.1 // 7465 0.0273611 1.51529 
8149720 NM_004430 // EGR3 // early growth response 3 // 8p23-p21 // 1960 /// ENST0000031 0.0292799 1.50607 
Table 19 Genes down regulated (A) and up regulated (B) by UVR damage. 
List of three genes that were down regulated and 20 genes that were up regulated in UV 
irradiated cells compared to controls. 
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TABLE 20 
20A DOWN REGULATED GENES   
Transcript 
ID Gene ID//Gene p-value Fold  
8052669 NM_014755 // SERTAD2 // SERTA domain containing 2 // 2p14 // 9792 /// ENST000003 0.0185909 -1.50349 
    
    
20B UP REGULATED GENES   
Transcript 
ID Gene ID//Gene p-value Fold 
8152506 NM_207506 // SAMD12 // sterile alpha motif domain containing 12 // 8q24.12 // 40 0.00430001 1.51212 
7985555 NM_024580 // EFTUD1 // elongation factor Tu GTP binding domain containing 1 // 1 0.0290991 1.55648 
8116921 NM_001955 // EDN1 // endothelin 1 // 6p24.1 // 1906 /// NM_001168319 // EDN1 //  0.00411235 1.57695 
7955589 NM_002135 // NR4A1 // nuclear receptor subfamily 4, group A, member 1 // 12q13 / 0.0269104 1.58396 
7967486 NM_025140 // CCDC92 // coiled-coil domain containing 92 // 12q24.31 // 80212 /// 0.00276351 1.59316 
7975779 NM_005252 // FOS // FBJ murine osteosarcoma viral oncogene homolog // 14q24.3 // 0.00355786 1.89949 
8108370 NM_001964 // EGR1 // early growth response 1 // 5q31.1 // 1958 /// ENST000002399 0.00843497 1.9951 
Table 20 Genes down regulated (A) and up regulated (B) by UVR in the absence of TopBP1. 
List of one gene down regulated and seven genes up regulated by UVR in the absence of 
TopBP1. 
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3.5.8 Analysis of micro-array data 
To characterise the microarray data further, the data were analysed with the 
Ingenuity Pathway Analysis (IPA) software, a web based software application 
designed to analyse data derived from gene expression microarray analysis and 
other sources (www.ingenuity.com). IPA is based on the Ingenuity Knowledge 
Base, which is a repository of biological interactions and functional annotations 
created from millions of individually modelled relationships between proteins, 
genes, drugs, and diseases. These modelled relationships are derived from 
published literature and the Knowledge Base is updated manually on a weekly 
basis according to strict protocols. IPA is a widely accepted tool that has been 
widely published in peer reviewed articles.  
The three lists of altered genes generated by the microarray analysis were 
uploaded separately into the IPA software and analysed using the IPA Core 
Analysis function. The Functional Analysis identifies biological functions and 
diseases that are significantly represented in the respective gene sets and uses a 
Fisher’s Exact Test to generate p values for significance measurement. The 
Pathways are known metabolic and signalling pathways compiled from literature 
analysis. 
The biological functions and diseases are listed in the order of significance. The 
number of differentially expressed genes from the dataset that are involved in 
each function/disease are listed and the function of that gene described.   
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3.5.8.1 Pathway analysis of genes altered by the absence of 
TopBP1 
The expression of 257 genes was significantly altered in MCF7 TopBP1 knockdown 
cells compared to controls (Table 18). The genes listed in Table 18 were 
analysed for functional gene sets and disease gene sets using the Ingenuity 
Pathway Analysis (IPA) software and this identified significant changes in 62 
different biological functions and diseases. 
The ten most significantly altered functions and diseases are illustrated in Figure 
53 in order of significance. The genes down or up regulated in each function 
/disease are listed in Table 21.  
The ten most significantly altered functions and diseases shown in Figure 53 
tended to involve the highest numbers of differentially expressed genes, 
however, in this large gene set, a further nine significantly altered functions and 
diseases were identified, involving eight or more differentially expressed genes. 
These further nine functions/diseases are illustrated in Figure 54 in order of 
significance and the genes down or up regulated in each function/disease are 
listed in Table 22.  
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Figure 53 Top ten functions/diseases altered by genes regulated by the absence of TopBP1. 
62 diseases/functions were significantly altered in this dataset. The ten most significantly 
altered are shown here. The threshold for significance (indicated by the orange line) is the 
log of the p-value 0.05.  
237 
 
Function / 
Disease 
p- values    No. of 
genes 
Altered genes 
Lipid  
Metabolism 
1.92E-04-
4.34E-02 
9 GLTP, LIPH, ACER3, THBS1, ABCC1, PTGER2, AGK, 
SGMS1, SACM1L 
 
Molecular 
Transport 
1.92E-04-
4.11E-02 
8 GLTP, TNPO2, ATP7A, THBS1, ABCC1, AGK, 
ATP2B4, SLC31A2 
 
Small Molecule 
Biochemistry 
1.92E-04-
4.34E-02 
15 LIPH, MINPP1, THBS1, COASY, ALDH9A1, NUTF2, 
CDK1, SGMS1, SACM1L, GLTP, ATP7A, ACER3, 
ABCC1, PTGER2, AGK 
 
Carbohydrate 
Metabolism 
5.71E-04-
2.76E-02 
 
6 ATP7A, LIPH, THBS1, ABCC1, AGK, SACM1L 
 
Gene 
Expression 
1.06E-03-
4.11E-02 
12 FOS, DYNLT3, TADA3, TGFBR1, HDAC3, TOPBP1, 
PNRC1, ETS2, JUND, DCP2, ID3, CDK1  
 
Cellular 
Movement 
1.87E-03-
4.11E-02 
16 CNN2, AKT2, PXN, TGFBR1, CTGF, THBS1, HAX1, 
LAMC2, ID3, CDK1, EDN1, RASGRP1, AGK, CYR61, 
ITGB5, CD151 
 
Cellular 
Assembly and 
Organisation 
2.17E-03-
4.11E-02 
 
7 CTGF, EDN1, THBS1, CAV2, LAMC2, ITGB5, CDK1 
 
 
 
Cellular Growth 
and Proliferation 
2.78E-03-
4.87E-02 
27 CTGF, TGFBR1, HSPB8, ETS2, GSS, SGMS1, EDN1, 
PXDN, RHOBTB2, JUND, SEMA3B, ZFHX3, AKT2, 
THBS1, PFN2, EIF2C2, ID3, HNRNPM, IGF2R, CDK1, 
FOS, HDAC3, EIF3I (includes EG:8668), ANAPC5, 
RPS6KA5, PTGER2, CYR61 
 
Cancer 3.46E-03-
4.81E-02 
54 SHH, TGFBR1, CTGF, ABCC1, PXDN, JUND, ITGB5, 
ZFHX3, SCAMP1, AKT2, TP53INP1, DDIT4, TOPBP1, 
THBS1, PDGFRL, FERMT2, EIF4G3, SLC1A1, 
C6ORF211, ELOVL6, MEX3D, KAT2B, PSD3, HDAC3, 
C18ORF1, PTGER2, CYR61, TFPI, MSMB, PTPN21, 
CD151, HAX1, HSPB8, AQP3, ARL4C, EDN1, 
PNRC1, MXD1, RHOBTB2, LIPH, PXN, MIPEP, 
EIF2C2, OLFM1, LAMC2, UBE2D1, SLC5A3, IGF2R, 
CDK1, FOS, GPX2, ADRA2C, PPP2R1B, ID4 
 
Reproductive 
System 
Disease 
3.46E-03-
4.11E-02 
23 PXN, AKT2, TGFBR1, CTGF, DDIT4, TOPBP1, 
THBS1, FERMT2, HSPB8, C6ORF211, ELOVL6, FOS, 
PSD3, HDAC3, EDN1, PNRC1, RHOBTB2, PXDN, 
ADRA2C, JUND, PTGER2, CYR61, PPP2R1B 
 
    
Table 21 List of altered genes in the top ten functions/diseases illustrated in Figure 53. 
Top ten biological functions/diseases altered by genes de-regulated by the absence of 
TopBP1. Genes which were up regulated are shown in red, down regulated genes are shown 
in blue. The diseases/functions in which TopBP1 (always down regulated in this dataset) 
was involved are highlighted in yellow. 
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Figure 54 Further functions/diseases altered by genes de-regulated by the absence of 
TopBP1. 
A further nine functions/diseases in which more than 8 altered genes were involved are 
illustrated. The threshold for significance (indicated by the orange line) is the log of the p-
value 0.05.  
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Function / 
Disease 
p- values    No. of 
genes 
Altered genes 
Haematological 
Disease 
4.36E-03-
2.81E-02 
19 AKT2, CTGF, THBS1, HAX1, UBE2D1, GSS, CDK1, 
NUTF2, HDAC3, EDN1, ABCC1, PXDN, ADRA2C, 
PTGER2, TFPI, LRRC8A, ID4, ITGB5, CD151 
 
Cell Death 7.68E-03-
3.39E-02 
28 CNN2, SHH, CTGF, HSPB8, ETS2, SGMS1, AQP3, 
TADA3, EDN1, ABCC1, RHOBTB2, CBFB, SEMA3B, 
ITGB5, RAD23B, DEPDC6 (includes EG:64798), 
AKT2, TP53INP1, TOPBP1, THBS1, IGF2R, CDK1, 
BNIP2, FOS, ANKRD1, HDAC3, GPX2, CYR61 
 
Cell Cycle 1.39E-02-
4.11E-02 
8 EDN1, THBS1, GORASP2, ANAPC5, AGK, ID3, 
CDK1, ZFHX3 
 
Cell Morphology 1.39E-02-
4.11E-02 
8 SLC20A1, AQP3, AKT2, EDN1, THBS1, CDC42SE2, 
VPS26A, CD151 
 
Cell-To-Cell 
Signalling and 
Interaction 
1.39E-02-
4.36E-02 
14 PXN, AKT2, CTGF, THBS1, IGSF1, MPZL2, KCNAB2, 
LAMC2, RASGRP1, SEMA3B, SPOCK1, CYR61, 
ITGB5, CD151 
 
Cellular 
Development 
1.39E-02-
4.11E-02 
17 SHH, AKT2, CTGF, THBS1, HSPB8, ETS2, IGF2R, 
SGMS1, CDK1, FOS, HDAC3, EDN1, RHOBTB2, 
CDC42SE2, PTGER2, CYR61, CD151 
 
Dermatological  
Diseases and 
Conditions 
1.39E-02-
4.81E-02 
8 SHH, LIPH, HDAC3, GPX2, SLC1A1, KRT81 (includes 
EG:3887), CDK1, CD151 
 
 
Genetic Disorder 1.39E-02-
4.11E-02 
10 SHH, LIPH, CTGF, TGFBR1, THBS1, TPP1, RPIA, 
LRRC8A, KRT81 (includes EG:3887), CD151 
 
Tissue 
Development 
1.39E-02-
4.36E-02 
12 AKT2, PXN, CTGF, THBS1, RASGRP1, IGSF1, 
MPZL2, CYR61, SPOCK1, LAMC2, ITGB5, CD151 
 
    
 
Table 22 List of altered genes in the functions/diseases illustrated in Figure 54. 
Further nine biological functions/diseases altered by genes de-regulated by the absence of 
TopBP1. Genes which were up regulated are shown in red, down regulated genes are shown 
in blue. The diseases/functions in which TopBP1 (always down regulated in this dataset) 
was involved are highlighted in yellow. 
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3.5.8.2 Pathway analysis of genes de-regulated by UV damage 
The expression of 23 genes was significantly altered in MCF7 cells following UV 
damage compared to controls (Table 19). The genes listed in Table 19 were 
analysed for functional gene sets and disease gene sets using the Ingenuity 
Pathway Analysis (IPA) software and this identified significant changes in 50 
different biological functions and diseases. 
The ten most significantly altered functions and diseases are illustrated in Figure 
55 in order of significance. The genes down or up regulated in each function 
/disease are listed in Table 23.  
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Figure 55 Top ten functions/diseases altered by genes de-regulated by UVR.  
50 diseases/functions were significantly altered in this dataset. The ten most significantly 
altered are shown here. The threshold for significance (indicated by the orange line) is the 
log of the p-value 0.05.  
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Function / 
Disease 
p- values    No. of 
genes 
Altered genes 
Reproductive 
System Disease 
 
1.39E-06-
2.14E-02 
 
7 FOS, CTGF, EDN1, DUSP1, WEE1, EGR1, NR4A1 
 
 
Cell Death 
 
 
4.37E-06-
4.98E-02 
 
7 FOS, CTGF, EDN1, DUSP1, EGR1, WEE1, NR4A1 
 
 
Cell Cycle 
 
 
4E-05-
2.23E-02 
 
5 FOS, EDN1, DUSP1, WEE1, NR4A1 
 
 
Cancer 
 
 
1.29E-04-
2.14E-02 
 
9 TRA2A, FOS, CTGF, EDN1, DUSP1, WEE1, EGR1, 
WNK1, NR4A1 
 
Cellular 
Assembly and 
Organization 
 
1.85E-04-
2.23E-02 
 
3 
CTGF, EDN1, RFC1 
 
 
Hepatic System 
Disease 
 
6.15E-04-
2.38E-03 
 
2 CTGF, NR4A1 
 
 
Inflammatory 
Disease 
 
6.15E-04-
2.71E-02 
 
4 FOS, CTGF, WNK1, NR4A1 
 
 
Cellular Growth 
and Proliferation 
 
6.81E-04-
3.47E-02 
 
7 TRA2A, FOS, CTGF, EDN1, WEE1, EGR1, NR4A1 
 
 
DNA Replication, 
Recombination, 
and Repair 
 
8.79E-04-
2.28E-02 
 
 
5 FOS, EDN1, DUSP1, NR4A1, RFC1 
 
 
 
Cardiovascular 
System 
Development 
and Function 
 
9.8E-04-
3.19E-02 
 
 
 
2 EDN1, NR4A1 
 
 
 
 
    
Table 23 List of altered genes in the top ten functions/diseases illustrated in Figure 55. 
Top ten biological functions/diseases altered by genes de-regulated by UVR. Genes which 
were up regulated are shown in red, down regulated genes are shown in blue.  
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3.5.8.3 Pathway analysis of genes de-regulated by UV damage in 
the absence of TopBP1 
The expression of eight genes was significantly altered in MCF7 TopBP1 
knockdown cells following UV damage compared to controls (Table 20). The 
genes listed in Table 20 were analysed for functional gene sets and disease gene 
sets using the Ingenuity Pathway Analysis (IPA) software and this identified 
significant changes in 45 different biological functions and diseases. 
The ten most significantly altered functions and diseases are illustrated in Figure 
56 in order of significance. The genes down or up regulated in each function 
/disease are listed in Table 24.  
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Figure 56 Top ten functions/diseases altered by genes de-regulated by UVR in the absence 
of TopBP1.  
45 diseases/functions were significantly altered in this dataset. The ten most significantly 
altered are shown here. The threshold for significance (indicated by the orange line) is the 
log of the p-value 0.05.  
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Function / 
Disease 
p- values    No. of 
genes 
Altered genes 
DNA Replication, 
Recombination, 
and Repair 
 
9.08E-05-
6.84E-03 
 
 
3 FOS, EDN1, NR4A1 
 
 
 
Cell Morphology 
 
 
2.4E-04-
1.61E-02 
 
2 EDN1, NR4A1 
 
 
Cell Death 
 
 
3.1E-04-
4.99E-02 
 
4 FOS, EDN1, EGR1, NR4A1 
 
 
Cardiovascular 
System 
Development 
and Function 
 
4.9E-04-
2.62E-02 
 
 
 
2 EDN1, NR4A1 
 
 
 
 
Cell Cycle 
 
 
4.9E-04-
2.8E-02 
 
3 FOS, EDN1, NR4A1 
 
 
Connective 
Tissue 
Development 
and Function 
 
4.9E-04-
2.94E-03 
 
 
 
1 EDN1 
 
 
 
 
Gene 
Expression 
 
 
4.9E-04-
2.19E-02 
 
2 
FOS, EGR1 
 
 
Haematological 
Disease 
 
4.9E-04-
4.9E-04 
 
1 EDN1 
 
 
Skeletal and 
Muscular 
System 
Development 
and Function 
 
 
4.9E-04-
2.71E-02 
 
 
 
 
 
2 FOS, EDN1 
 
 
 
 
 
 
Cellular 
Development 
 
5.32E-04-
3.24E-02 
 
4 FOS, EDN1, EGR1, NR4A1 
 
 
    
Table 24 List of altered genes in the top ten functions/diseases illustrated in Figure 56. 
Top ten biological functions/diseases altered by genes de-regulated by UVR in the absence 
of TopBP1. Genes which were up regulated are shown in red, down regulated genes are 
shown in blue.  
246 
3.5.9 Discussion  
3.5.9.1 Summary of Experimental Design 
The results in Chapter 3.5 have shown that the HaCaT cell line was unable to 
grow in the absence of TopBP1. This is in keeping with previously published 
results suggesting that TopBP1 is essential for cell growth and replication on 
cultured cells (330). However, previous work in this laboratory had shown that 
TopBP1 was essential for growth in the MRC5 and HeLa cell lines but the 293T, 
MCF7 and U2OS cell lines were able to survive in culture for a four day period 
following knockdown of TopBP1 (R. Wright, unpublished data).  
The MCF7 cell line was chosen for these experiments and it was demonstrated 
that DNA damage could be induced in this cell line following irradiation with 
0.002J/cm2 of UVB (Figure 46). Furthermore, the results demonstrate that 
TopBP1 could be efficiently knocked down in MCF7 cells by siRNA as shown in 
Figure 47.  
3.5.9.2 Microarray Results 
3.5.9.2.1 Genes de-regulated by the absence of TopBP1 
The list of genes altered in the absence of TopBP1 and the biological 
functions/diseases in which they are involved highlight the functions that 
TopBP1 is known to be involved in. 
In the 19 altered biological functions/ diseases listed in Figures 53 and 54, 
TopBP1 has already been shown to have a role in six of them including cancer, 
cellular growth and proliferation, gene expression, reproductive system disease, 
cell death and cell cycle.  
Cancer: TopBP1 is known to be involved in cancer, particularly breast cancer. 
TopBP1 protein has been shown by immunohistochemistry to be aberrantly 
expressed in a significant number of breast cancers compared to normal breast 
tissue controls (248) and, in a separate study, those with over expression of 
TopBP1 were shown to have a more aggressive breast cancer phenotype and 
reduced survival (331) . A heterozygous Arg309Cys variant in the TopBP1 gene 
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has been associated with a slightly elevated risk for familial breast and/or 
ovarian cancer (249).  
Cell Growth and Proliferation: TopBP1 is involved in cellular DNA replication. 
TopBP1 interacts with DNA polymerase , a polymerase essential for DNA 
replication and repair (250). TopBP1 monitors the replication; TopBP1 is 
essential for an intact S phase an displays a key role in monitoring genome 
integrity throughout S phase(260). Furthermore, TopBP1 recruits the replication 
pre-initiation complex to chromatin (330).  
The seventh and eighth BRCT domains of TopBP1 interact with the DNA binding 
domain of p53 leading to inhibition of p53 promoter binding activity. By actively 
repressing p53, TopBP1 keeps p53 at a low level under physiological conditions 
and allows a normal G1/S transition. However, over expression of TopBP1 leads 
to inhibition of p53 target gene expression and therefore inhibition of p53 
mediated apoptosis and G1 arrest as a response to DNA damage (331). Therefore 
through its interaction with p53, TopBP1 appears to be essential for normal cell 
growth and proliferation however aberrant expression of TopBP1 may enhance 
DNA damage and contribute to the malignant phenotype by inhibition of p53.  
TopBP1 is involved in cell growth and proliferation via its involvement in the DNA 
damage/repair response. TopBP1 is recruited to sites of DNA damage (250) 
possibly by direct interaction with damaged DNA (247) and/or via recruitment by 
Rad9 (251;252). TopBP1 signals the detection of DNA damage by interacting with 
the ATR/ATRIP complex thus activating ATR and allowing phosphorylation of 
downstream targets of ATR such as Chk1(253-257).    
Gene Expression: TopBP1 is a transcriptional regulator, it can regulate the 
transcription of p53 as described above (331) and is a transcriptional repressor of 
E2F1 (262). The sixth BRCT domain on TopBP1 interacts with the amino terminus 
of E2F1 by recruiting Brg1/Brm chromatin-remodelling complex (263). TopBP1 
mediated repression of E2F1 is crucial in the control of E2F1 dependent 
apoptosis during normal cell growth and DNA damage (263).  
Reproductive System Disease: TopBP1 is involved in reproductive system 
disease via its involvement in both breast and ovarian cancers as described 
earlier. TopBP1 has also been shown to be an interacting partner with HPV-16 E2 
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(219) and thus may be included in this disease gene set through its potential 
involvement in the HPV infection and the pathogenesis of cervical cancer.  
Cell Death: TopBP1 is known to be involved in cell death through its interactions 
with the p53 regulated apoptotic pathway as described above. Furthermore it 
has been shown that SiTopBP1 treated cells arrest at G1(330).   
Cell Cycle: As described above, TopBP1 is known to be involved in the regulation 
of the cell cycle via its interaction with E2F1.  
3.5.9.2.2 Genes de-regulated by UVR 
UV induces dimerization of adjacent pyrimidines on DNA to form cyclobutane 
pyrimidine dimers (CPD) and 6-4 pyrimidone photoproducts (6-4PP). UVB induces 
characteristic mutations at di-pyrimidine sites (C to T transitions) and these UVB 
signature mutations have been detected in p53 genes from SCC (3). UVB induced 
DNA damage activates the DNA damage response pathway as damage is sensed 
by the phosphoinositide 3 kinase (PI3K) related proteins kinases (PIKKs) including 
ATM (ataxia telangiectasia mutated) and ATR (ATM and RAD3 related). ATM and 
ATR are the major regulators of the DNA damage response pathway and act to 
phosphorylate downstream targets that regulate the cell cycle, DNA replication, 
DNA repair and apoptosis (reviewed in (258;332)).  
Five of the top ten altered biological functions/diseases identified with this gene 
set by the IPA analysis were the main functions/diseases that we would expect 
UV to be involved in, namely cell death, cell cycle, cancer, cellular growth and 
proliferation and DNA replication, recombination and repair. 
The list of differentially expressed genes induced by UVR damage contained only 
23 genes. The relatively small gene number observed in this study may be due to 
the UV dose that was utilised to damage cells. We used a low UV dosage system, 
designed to induce DNA damage, as shown by induction of phosphorylated Chk1 
but a dose that would allow cell survival, essential to allow for the microarray 
analysis. Furthermore, cells were harvested 30 minutes following UV irradiation 
and while it is anticipated that this would be sufficient time to allow for UVR 
induced changes in gene expression, it is conceivable that a longer period of 
249 
time between UV treatment and cell harvesting may have generated a larger 
number of altered genes.  
3.5.9.2.3 Genes de-regulated by UVR in the absence of TopBP1.  
The final set of differentially expressed genes, genes de-regulated by UVR in the 
absence of TopBP1 contained only eight significantly altered genes.  
UV induced DNA damage activates the DNA damage response pathway primarily 
through activation of ATR (reviewed in (258;332)). TopBP1 interacts with the 
ATR-ATRIP complex, activating ATR and allowing phosphorylation of downstream 
targets such as Chk1 (253-257). The small number of differentially expressed 
genes in this gene set may be due to lack of TopBP1 and therefore reduced 
activation of ATR and its downstream targets.  
There were three genes up regulated by UVR both in the presence and absence 
of UVR: EGR1, FOS and NR4A1 – suggesting that these genes are regulated by 
UVR independently of TopBP1. 
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Chapter 4: Discussion 
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4.1. Conclusions, Summary and Future Prospects 
The scope of work carried out in this thesis ranges from a clinical and 
epidemiological study through two investigations utilising patient samples, 
finishing with two molecular experimental chapters. For this reason, the findings 
have been discussed in detail at the end of each results chapter.  
Chapter 3.1 describes the results of a clinical and epidemiological study of the 
West of Scotland renal transplant population. Chapters 3.2 and 3.3 describe two 
investigations utilising tissue samples from this population, firstly by HPV 
genotyping the samples and secondly examining the same samples by 
immunohistochemistry to determine expression of cell cycle biomarkers. 
The study of the epidemiology of NMSC in the West of Scotland renal transplant 
population is the largest study of this kind to be carried out in Scottish RTRs. 
The results demonstrated that the incidence of nonmelanoma skin cancer in our 
population was lower than that seen in other geographical areas with higher UV 
exposure such as Australia and interestingly was also lower than that previously 
reported in other areas of the UK. The results also demonstrate a different 
pattern of skin cancer with a change in the BCC:SCC ratio but no reversal, a 
finding that has been reported infrequently from other studies from Southern 
Europe but not from the UK (30;31).  It will be interesting to determine whether 
this pattern changes with continued follow up of this cohort over time. The data 
also demonstrate that with changing immunosuppressive regimes such as 
introduction of ciclosporin and the move from dual to triple therapy, duration of 
time between transplantation and the development of a first skin cancer has 
shortened. While this largely retrospective data must be interpreted with 
caution, the results are in keeping with what is currently known about 
immunosuppressants and skin cancer risk. With the advent of newer 
immunosuppressants such as the mTORi it may be that skin cancer incidences 
fall although other factors that tend towards increased skin cancer incidences 
such as older age at transplantation and longer duration of graft survival are 
likely to increase. In our population there were too few patients currently on 
mTORi to establish if these newer agents have led to a reduced incidence of skin 
cancer in our population and continued prospective collection of data is 
necessary to address this question.  
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A skin cancer database intrinsically linked to the renal patient electronic record 
has been established along with a vital clinical service which has achieved the 
objectives of providing rapid access to Dermatology services to RTRs in the West 
of Scotland and establishing links with renal and transplant medicine. Ongoing 
prospective data collection will facilitate future research in this population.  
From this clinical and epidemiological study an investigation was carried out 
utilising patient samples from this population. Normal skin and skin cancers 
samples were collected and examined for the presence of betaPV. This 
investigation utilised a novel technique for examining for all betaPV types and 
this technique has since been widely used for studies of betaPV prevalence in 
both IC and IS patients. Use of a single technique across studies may allow more 
accurate comparisons of betaPV prevalence between studies, an important 
factor in determining whether any single type(s) of betaPV prevails in NMSC. Our 
study identified betaPV presence in 47.1% of paraffin-embedded tissue samples 
and 18.2% of normal skin samples. This may add support to the literature that 
suggests betaPV has a role in NMSC. The detection of betaPV in our samples was 
lower than we had anticipated. Emerging studies using this technique have 
detected betaPV in 80-90% of samples. Our lower detection rates may reflect 
the use of archival material where the quality of the DNA extracted may be 
poorer quality and more difficult to amplify. A higher prevalence of betaPV was 
present in frozen tissue (84.6% of skin cancers and 57.1% of normal skin samples) 
suggesting that the use of frozen tissue would be optimal. 
BetaPV carriage is ubiquitous and detection of betaPV DNA in normal skin and 
skin cancers in both immunocompetent and immunosuppressed populations using 
many detection methods including the PCR-RHA assay has failed to establish a 
hierarchy of risk for different betaPV types and their relationship to cutaneous 
SCC. Another approach to investigate the relationship between betaPV and NMSC 
is to measure betaPV antibodies in the sera of NMSC cases and controls. 
Serological responses to betaPV may suggest a clinically significant past or 
present infection whereas detection of betaPV DNA may be a reflection of the 
ubiquitous nature of betaPV DNA and not represent active infection. Conversely, 
it is possible that development of an SCC may lead to a positive serological 
response as could a cancer related event such as severe sunburn, a concept 
known as reverse causality. The factors which predict a serological response to 
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betaPV are not known and therefore the significance of positive serology is not 
well defined. Recently a study combined both approaches; DNA detection, 
utilising the skin beta HPV prototype research assay (Diassay BV, Rijswijk, The 
Netherlands) to detect betaPV DNA in eyebrow hairs and multiplex serology to 
detect antibody responses. Using concordant DNA detection and antibodies, this 
study identified a significant association HPV-36 infection and cutaneous SCC in 
OTRs and a trend towards positive associations for HPV-5, -9 and -24(117). It 
may have been helpful to incorporate serology into the investigation described 
in this thesis. Future large epidemiological studies utilising this combined 
approach may be helpful in determining the association between betaPV and 
SCC.  
In this investigation, a wide spectrum of betaPV genotypes were isolated, the 
most common types being HPV-24,-36, -38, -15, -5 and -80 but no one type 
predominated in keeping with the current literature. The body of evidence 
suggesting that betaPV is important in cutaneous carcinogenesis is increasing but 
a causal link has not yet been established. We hypothesised that one way to 
establish a link between HPV and NMSC would be to examine the genotyped 
lesions by immunohistochemistry to determine if there were differences in 
biomarker expression between HPV positive and HPV negative lesions. Such 
differences have been observed in HPV positive and negative cervical lesions. 
The results of this part of the investigation are described in Chapter 3.3. We 
examined the expression of a number of biomarkers (Ki67, MCM2, MCM5, p53 and 
P16) and found them to be over-expressed in comparison to normal skin however 
there was no relationship between the expression of any of these markers and 
the presence or absence of HPV. It may be that the number of lesions examined 
(100) was too small to detect any differences between the two groups or it is 
possible that only infection with certain betaPV types would alter biomarkers 
expression and to determine this larger sample numbers would be required. 
Furthermore, whereas in cervical lesions, altered expression of biomarkers 
relates to disease state and HPV status, in skin lesions, biomarkerexpression, in 
particular p53 and p16, may also be altered by the effects of UVR thus making 
linking interpretation of staining patterns to HPV increasingly complex. Had 
alternative antibodies such as Bak been available they would have been a 
preferable biomarker to p53. 
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A novel marker, TopBP1 was included in the panel of biomarkers examined. 
TopBP1 expression was investigated because aberrant expression of TopBP1 
protein has been demonstrated in breast cancers and polymorphisms in the 
TopBP1 gene have been identified in a sub-set of familial breast and ovarian 
cancers. TopBP1 expression in other cancer types has not been previously 
investigated. TopBP1 is a DNA damage response protein that is essential for 
signalling DNA damage following UVR. Therefore aberrant expression of TopBP1 
in skin might compromise the cells ability to respond to UV damage thus 
contributing to carcinogenesis. Furthermore, TopBP1 is an interacting partner 
for HPV16 E2. For these reasons we wished to determine if the expression of 
TopBP1 differed between HPV positive and negative skin cancers. The results 
showed that TopBP1 expression was aberrant in a sub-set of skin cancers; 
however there was no association with presence or absence of betaPV. Aberrant 
TopBP1 expression in NMSC is a novel finding however the determining factor for 
this was not identified. A larger sample number would be required to determine 
whether it was related to infection with specific betaPV types. 
From this novel finding of aberrant TopBP1 expression in skin cancers, a 
molecular study of TopBP1 and its interaction with HPV was carried out. This 
was first performed with HPV 16 and the work extended to the betaPV HPV-8. 
The final two experimental chapters focused on TopBP1, its interaction with HPV 
and role in UVR induced DNA damage.   
HPV replication is a possible therapeutic target that could be utilised for the 
development of anti-viral therapies. TopBP1 interacts with HPV-16E2 and with 
HPV-16E1. We hypothesised that viral DNA replication occurs via direct 
recruitment of TopBP1 to the E1-E2 complex resulting in DNA polymerase loading 
and initiation of viral DNA replication.  
The amino acid at residue 90 on the E2 protein is highly conserved across HPV 
types; however previous studies have not demonstrated a phenotype associated 
with mutation at this residue. The results in Chapter 3.4 describe the generation 
of a HPV-16E2 protein mutated at residues 89 and 90 on the E2 
transcriptional/replication domain that does not bind TopBP1, HPV-
16E2N89YE90V.The results demonstrate that viral DNA replication is 
compromised when this E2 mutant is tested in replication assays. Furthermore, 
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replication is also compromised with a single mutation at residue 90 (E90V). We 
have also demonstrated that all of the proteins activate transcription suggesting 
that this altered replication phenotype is not due to mis-folding or altered 
stability of the proteins. The results then demonstrate that generation of an 
equivalent double mutant at residues 89 and 90 on the HPV-8E2 gene HPV-
8E2D89AE90V generates the same phenotype and with HPV-8E2, the single 
mutant E90V, also results in compromised replication. This is a novel finding and 
it is possible that this could be used for the development of drugs that target 
viral replication. The importance of this finding is that such drugs may work 
across virus types, which is highly relevant for skin cancer in which no single 
virus predominates. 
In the final experimental Chapter 3.5 we further examined the role of TopBP1 in 
skin cancer by conducting a microarray analysis of genes differentially expressed 
in TopBP1 knockdown cells that were damaged by UV.  TopBP1 is a protein that 
is linked to DNA metabolism more than any other; it is involved in DNA damage 
and repair responses, in DNA replication and in transcription. TopBP1 is found 
throughout the epidermis in normal skin. Aberrant TopBP1 expression and 
poymorphisms in the TopBP1 gene have previously been described in breast and 
ovarian cancers. We hypothesised that TopBP1 might be involved in mediating 
the cellular DNA damage response to UVR through it’s known role as a 
transcription factor and specifically through activation of ATR. Little is known of 
the functions of TopBP1 as a transcription factor. Whilst we confirmed that 
TopBP1 is involved in a number of cellular processes, only a small gene set were 
significantly differentially expressed following UVR both in the presence and 
absence of TopBP1 thereby the data were inconclusive. The experiment was 
designed to induce a damage response in the cells and not a death response 
which would induce alterations in a different gene set such as those involved in 
apoptosis and death signalling. A dose of 0.002J/cm2 was chosen as it had been 
shown to produce damage by induction of phosphorylated -Chk1. With hindsight 
it is likely that the dose chosen was too low and a higher dose such as 
0.008J/cm2 may have induced more DNA damage yet still permitted survival of 
the MCF7 cells. It is likely that the lower UVB dose used was insufficient thereby 
resulting in too few genes being significantly differentially expressed. An 
alternative explanation could be that the time between damaging the cells and 
harvesting was too short (30 minutes) and perhaps a longer time would have 
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yielded a greater number of altered genes. Had there been no time or financial 
constraints then it would have been desirable to repeat the experiment utilising 
a higher UVB dose. 
4.2 Future prospects 
The clinical and epidemiological parts of this work will continue in the future as 
data continues to be collected prospectively. This may facilitate the 
involvement of our patient population in future studies with particular interest 
in determining factors that influence the development and outcome of skin 
cancer in this population such as immunosuppression and betaPV.  
The data support the hypothesis that the E2-TopBP1 interaction is essential for 
viral replication and we hypothesise that this interaction will be essential for the 
viral life cycle. To confirm this, further work is being carried out in association 
with Professor Lou Laimins, Northwestern University, expert in HPV life cycle 
studies (333-335). This system involves introducing mutations into the whole HPV 
genome, e.g. HPV16E2 N89YE90V and transfecting the genomes into primary 
keratinocytes. The cells may then be “rafted” to produce living skin equivalents 
or grown in monolayer and differentiation induced by the addition of calcium. 
The genome (wild type or mutated) is established in non-differentiated cells and 
then amplifies as differentiation is induced in the cells, mimicking a natural 
infection. In this way, the effect of mutations introduced into the genome on 
the viral life cycle may be measured.  
We predicted that viral DNA containing the HPV16E2 N89YE90V mutation would 
not replicate thus confirming the results of our studies in vivo. Initial results of 
the life cycle studies have confirmed this. In monolayer wild type HPV16 E2 
genomes replicate as demonstrated by the detection of episomal DNA. In cells 
transfected with HPV-16 genomes containing either the single or double 
mutations in the E2 gene, E90V or N89Y E90V, no episomal DNA is detected 
indicating that the presence of these mutations result in failure to replicate viral 
DNA (unpublished data, not shown).  
The results of the work described in this thesis suggest that introduction of 
mutations E90V or N89YE90V on the HPV-16 E2 gene generate an E2 mutant that 
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fails to bind TopBP1 and that failure to bind TopBP1 results in compromised 
replication of viral DNA and failure to establish viral maintenance of infection. 
This discovery is potentially very important for the development of therapies 
that target viral DNA replication and may be developed for the treatment of HPV 
associated disease.  
Future studies will confirm whether a single mutation at amino acid 90 is 
sufficient to disrupt the E2/TopBP1 interaction or if a double mutation across 
residues 89 and 90 is required. Amino acid 90 is always conserved across HPV 
types whereas amino acid 89 is not which would suggest that a mutation at 
residue 90 might be sufficient to disrupt the interaction. The data from the HPV-
16 mutants show that both single and double mutants fail to bind TopBP1 in vivo 
and, result in compromised replication, however, replication is more severely 
compromised with the double mutant and can be seen at both 1ng and 10ng 
titrations. In the life cycle studies, both the E90V and N89YE90V mutants 
demonstrate the same phenotype and this is a more sensitive assay than the 
replication assays suggesting that E90V alone may be sufficient. The data 
generated by the HPV-8E2 mutants in replication assays support the hypothesis 
that a single amino acid substitution is sufficient as that both the E90V and the 
D89YE90V mutants have a severely compromised replication phenotype. Previous 
work generating a single amino acid substitution at position 90 on the E2 gene 
failed to generate a phenotype however the substitution was Glutamine to an 
Alanine (271). We have also shown that HPV-16E90A binds TopBP1 like wild type 
in vitro and also replicates like wild type in replication assays (data not shown). 
Our HPV-8 data demonstrate that the E90A mutant behaves like wild type E2 in 
replication assays.  It is interesting that the substitution of amino acid 90 to a 
Valine generates a phenotype whereas an Alanine does not. This may be due to 
the properties of Valine which is hydrophobic and may thus interfere with 
interaction at or around this site with greater efficiency than an Alanine 
substitution and this can be due to the site within the folded protein. 
Importantly, our data show that the introduction of a Valine substitution does 
not alter the folding of the protein. To further examine the interaction and to 
elucidate the reasons for this, which will be vital for the development of drugs, 
we will generate a crystal structure of the E2/TopBP1 interaction. The first step 
in this process is to make TopBP1 protein and the results are shown in Figures 57 
and 58 below (work performed by L. Mackintosh). The proteins have now gone to 
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our collaborators in (Dr Brian Smith, University of Glasgow) to generate these 
proteins on a large scale and the crystal structure of the TopBP1/E2 interaction 
will then be generated by collaborators at St Andrews University.  
Further work in this laboratory will confirm the results of TopBP1/E2 interaction 
in other virus types such as HPV-18, a pathogen in cervical cancer and HPV-6, 
(genital warts).  
The work will ultimately facilitate the development of anti-viral therapies that 
target HPV DNA replication by disrupting the E2/TopBP1 interaction.  
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Figure 57 Agarose gel of TopBP1-GST fusion proteins. 
To make the TopBP1-GST fusion proteins that will be used to generate a crystal structure of 
the TopBP1/HPV-16E2 interaction, primers were designed amplify fragments of the TopBP1 
genes from template DNA (TopBP1-myc and TopBP1BRCT1). The fragments amplified by 
PCR were TopBP1 (2-258; 2-258BRCT1, 586-700, 586-775 and 776-932). The PCR products 
were run on an Agarose gel (above) which confirmed the DNA was of the expected size. 
TopBP1 fragments were then cloned into the GST containing vector, pGEX-4T-2 between the 
BamH1 and Xho1 restriction sites. DH5 bacteria were transformed with the TopBP1-GST 
fusion plasmids, plasmid DNA was purified and the proteins prepared and purified as 
described (2.2.4.17).    
700-586 GST 2-258 776-932KDa
SeeBlue
Ladder
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62
49
38
28
14
 
Figure 58 TopBP1-GST fusion proteins stained with Coomassie Blue.  
Three TopBP1-GST proteins were chosen for induction (2-258, 700-586 and 776-932).  After 
large scale production and purification, proteins were separated by SDS-PAGE gel 
electrophoresis and visualised by Coomassie Blue staining of the gel as described 
(2.2.4.18).  
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